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2Abstract
Cortisol analogues have been used to treat skin disorders, such as psoriasis and atopic
dermatitis, for over 50 years but the ability of normal human keratinocytes to synthesise
cortisol has not been reported.  Keratinocytes are capable of de novo cholesterol
synthesis, they express P450 enzymes that are required for steroidogenesis and can
metabolise androgens and estrogens.  In addition, steroidogenic acute regulatory protein
(StAR) that controls the rate determining step of acute steroidogenesis has been
identified in the epidermis.  The aim of this thesis was to identify de novo cortisol
steroidogenesis by keratinocytes and investigate the function of cortisol in keratinocytes
in vitro.
Normal epidermis was shown to express three cholesterol transporters that are
associated with promoting steroid synthesis; StAR was identified in the basal layer,
metastatic lymph node 64 (MLN64) in the suprabasal layers and translocator protein
(TSPO) was detected throughout the epidermal layers.  In addition, the nuclear receptor
DAX1, a negative regulator of StAR, was identified in the cytoplasm of cells that form
normal epidermis.  Comparatively, the expression of these proteins was altered in
psoriasis and atopic dermatitis, where DAX1 was localised to the nucleus of most
diseased tissue and StAR was not detected.  This suggests that acute steroid synthesis is
ablated in these hyperproliferative skin conditions.
The ability of normal primary human keratinocytes to synthesise cortisol was
investigated.  Radioimmunoassay demonstrated keratinocytes were capable of de novo
pregnenolone synthesis, which was promoted with the cortisol analogue dexamethasone
(dex).  Interestingly, 25-hydroxycholesterol, which bypasses StAR, did not further
enhance steroid synthesis.  This suggests that there is an alternative rate determining
step of steroid synthesis in cultured primary keratinocytes.  Thin layer chromatography
demonstrated keratinocytes could metabolise pregnenolone to progesterone and
progesterone to cortisol.  Progesterone metabolism to cortisol was also confirmed with
liquid chromatography/mass spectroscopy.
3Dex was shown to maintain keratinocyte viability and was implicated in promoting
cellular redox potential.  Since redox potential is a critical regulator of steroidogenesis,
this observation could provide a mechanism for dex-induced pregnenolone synthesis in
cultured keratinocytes. These observations led to a hypothesis that local cortisol
synthesis functions to regulate cellular redox potential to prevent cell death as part of a
positive feedback system.  Therefore, this thesis has identified the cortisol steroidogenic
pathway in primary human keratinocytes and a potential functional mechanism for the
pathway.
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Introduction 1.1: Steroid synthesis
1.1.1 Sources of cholesterol, the precursor to steroids
Cholesterol is the precursor to all steroids.  The basic four-carbon ringed cholesterol
molecule can undergo sequential enzymatic modifications to produce thousands of
unique steroid signalling molecules (basic pathway depicted in Figure 1.1).  Most cells
are capable of synthesising cholesterol de novo from acetate.  Alternatively, cells obtain
cholesterol from circulating lipoproteins or by release of intracellular esterified
cholesterol lipid stores (Cherradi and Capponi, 1998).  Due to the high lipophilic nature
of steroids, these molecules do not accumulate within secretory cells and require
continuous synthesis to maintain steroid output.  Upon extracellular (e.g. trophic
hormone) stimulation, cholesterol esters are hydrolysed and cholesterol is mobilised to
the outer mitochondrial membrane for the first step of steroid synthesis (Cherradi and
Capponi, 1998).
23
Figure 1.1  Schematic of human steroidogenesis.  White highlights the site of
chemical modification post enzymatic metabolism.
(http://en.wikipedia.org/wiki/File:Steroidogenesis.svg).
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1.1.2 Steroidogenic acute regulatory protein
Steroidogenic acute regulatory protein (StAR, also known as STARD1) is critical for
delivering insoluble cholesterol across the aqueous inter-mitochondrial membrane space
to initiate acute de novo steroid synthesis (Stocco, 2001a).  The transport of cholesterol
to the inner mitochondrial membrane (IMM) appears to be the rate determining step of
steroid synthesis rather than the metabolism of cholesterol to pregnenolone (Iida et al.,
1989; Stocco and Clark, 1996).
Early experiments demonstrated that acute steroid synthesis, induced by ACTH in
adrenals and gonadotrophins in gonads, was blocked by chemical protein synthesis
inhibitors such as cycloheximide (Cherradi and Capponi, 1998).  This showed that acute
steroidogenesis was dependent upon protein synthesis, which led to future
investigations into protein synthesis inhibitor sensitive proteins that were associated
with the induction of steroidogenesis.  Using rat adrenal cells, a set of 30 kDa
phosphoproteins were identified to be up regulated upon ACTH stimulation (Brownie et
al., 1972).  Rapid cessation of steroidogenesis was observed in MA-10 mouse Leydig
cells treated with protein synthesis inhibitors (ortho-phenanthroline and carbonyl
cyanide m-chlorophenylhydrazone), however the 30 kDa proteins were still found to be
expressed in the mitochondria (Stocco and Sodeman, 1991).  Instead, a labile 37 kDa
precursor protein was identified.  Decreased expression of the 37 kDa precursor protein
corresponded with the reduction of steroidogenesis and the appearance of 32 and 30
kDa phosphoproteins in MA-10 Leydig cells treated with protein synthesis inhibitors
(Stocco and Sodeman, 1991).  Pulse-chase experiments identified the precursor-product
relationship between  37 kDa, 32 kDa and 30 kDa proteins (Stocco and Sodeman,
1991).  The direct link between the 37 kDa pre-protein and steroidogenesis was
established by the isolation of cDNA that encoded the protein in MA-10 mouse Leydig
cells (Clark et al., 1994).  Sequence analysis identified the 37 kDa product as a novel
protein and was called ‘steroidogenic acute regulatory protein’ (Clark et al., 1994).
Co-transfection of StAR and the P450 side chain cleavage system into non-
steroidogenic COS-1 cells demonstrated that StAR could induce over a four-fold
increase in pregnenolone synthesis (Sugawara et al., 1995).  Further analysis of StAR
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demonstrated that the 37 kDa precursor protein is expressed in the cytoplasm of cells
and only activated upon phosphorylation of Ser195, which targets the protein to the outer
mitochondrial membrane (OMM) (Arakane et al., 1996).  StAR is then processed to a
32 kDa intermediate, imported into mitochondria and cleaved to a 30 kDa inactive
protein (Arakane et al., 1996).
Shortly after the identification of StAR, mutations in StAR were found to be the only
cause of lipoid congenital adrenal hyperplasia (LCAH) (Bose et al., 1996; Sugawara et
al., 1995; Tee et al., 1995).  LCAH is a potentially fatal condition characterised by an
almost complete inhibition of steroid synthesis.  Patients with LCAH have abnormally
high levels of ACTH and low levels of cortisol in their serum and a build up of
esterified-cholesterol as lipid droplets in the adrenal glands (Bose et al., 1996; Sugawara
et al., 1995; Tee et al., 1995).  As a result, LCAH patients are unable to regulate salt or
glucose levels.  Despite the lack of steroid synthesis, LCAH patients were found to have
normal steroidogenic enzyme activity.  The discovery that cholesterol transport for
steroidogenesis was inhibited due to loss of StAR function explained the cause for the
absence of steroids in patients with LCAH (Bose et al., 1996; Sugawara et al., 1995;
Tee et al., 1995).
Genetic analysis of patients with LCAH has identified thirty common mutations in
StAR that have been used to aid mechanistic understanding of the StAR protein (Bose
et al., 2000a; Roostaee et al., 2008).  StAR is composed of two functional domains, an
N-terminal 62 amino acid domain that provides the mitochondrial target sequence and a
C-terminal StAR-related lipid transfer (START) domain (Christenson and Strauss,
2001).  The START domain is critical for the binding and transfer of cholesterol and
mutations that cause LCAH are predominantly located between exons 5 and 7 of this
domain (Bose et al., 2000a).
The mutation F267Q is located in the C-terminal α-helix 4 region that lines the interface
of the START domain cholesterol binding site (Roostaee et al., 2008).  Thermodynamic
stability analysis demonstrated that the F267Q mutation resulted in significantly
diminished cholesterol binding capacity (Roostaee et al., 2008).  This was coupled with
an inhibition of pregnenolone synthesis when the F267Q mutant was transfected in Y-1
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adrenal cells and MA-10 Leydig cells (Roostaee et al., 2008).  Hence cholesterol must
bind to StAR to initiate acute steroidogenesis.
Replacement of arginine by leucine at position 182 (R182L) is common in patients with
LCAH from the Arab population (Bose et al., 1996).  This mutation lies at the site of the
hydrophobic core of StAR which is involved in binding and transferring cholesterol.
Interestingly, the R182L mutant does not alter the binding capacity of cholesterol to
StAR but rather the conformational flexibility of the protein (Bose et al., 2009).  Wild
type StAR was found to adopt a flexible form due to the accommodation of more water
molecules whereas R182L mutant maintained a more rigid structure inhibiting its
activity (Bose et al., 2009).
The precise molecular mechanism by which StAR enables cholesterol transport across
the mitochondrial membranes is still under debate.  It was first proposed that StAR
could fuse the outer and inner mitochondrial membrane forming a bridge that
hydrophobic cholesterol could cross (Clark et al., 1994; Stocco and Clark, 1996;
Thomson, 2003).  However, this inter-membrane shuttle model was questioned when
cells that were transfected with StAR lacking the mitochondrial signalling domain were
still able to induce steroid synthesis, even though StAR had not entered the organelle
(Stocco, 2001b).
The molten globule hypothesis was proposed following the discovery that StAR
partially unfolds and transitions to a molten globule state at low pH (below pH 4) (Bose
et al., 1999).  The phospholipids on the OMM may form an acidic microenvironment,
increasing the flexibility of the StAR structure, allowing for the cholesterol binding site
to be exposed (Bose et al., 1999).  This corresponds with the data generated from
thermodynamic activity of R182L versus wild-type StAR (Bose et al., 2009).
Importantly, this hypothesis does not require StAR to contact the IMM to induce
cholesterol transport.
The molton globule hypothesis is also supported by the observation that the 37 kDa
StAR pre-protein is functionally active and exclusively resides on the OMM.  However,
mature 30 kDa StAR protein formed by cleavage of N-terminal amino acids resides in
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the IMM and is functionally inactive (Arakane et al., 1996).  Therefore import of StAR
into the mitochondrial matrix has been described as a switch-off mechanism for
terminating StAR activity (Arakane et al., 1996).  Thus StAR is thought to be rapidly
degraded once imported into the matrix compartment.  Excessive accumulation of 30
kDa StAR in the cristae of the IMM can damage the mitochondria (Granot et al.,
2007b).  As a result, StAR has a short half-life and requires continual protein synthesis
to maintain steroidogenic activity.  Pulse-chase experiments of StAR-transfected COS-1
cells showed that newly imported 30 kDa StAR is degraded with a half life of 5 hours
and that this degradation could be delayed with the protease inhibitor MG132 (Granot et
al., 2007a; Granot et al., 2007b).
In addition to protease degradation, mitochondrial membrane potential (manipulated by
changes in pH) can also regulate StAR activity (Granot et al., 2007b).  Maintenance of
the mitochondrial membrane potential is critical for steroid synthesis.  Recently StAR
was found to form a complex with voltage-dependent anion channel 1 (VDAC1) and
phosphate carrier protein (PCP) (Bose et al., 2008).  Absence of VDAC1 inhibited
StAR-mediated pregnenolone synthesis (Bose et al., 2008).  The majority of metabolites
are thought to cross the mitochondrial membrane via VDAC proteins, therefore
cholesterol could be transported into the mitochondria via VDAC1 channels upon
activation with the StAR complex (Hodge and Colombini, 1997; Liu et al., 2006).
Channel opening and closing of VDAC1 is sensitive to electron gradient, which may
account for the sensitivity of steroidogenesis to mitochondrial membrane potential
(Hodge and Colombini, 1997).
Other proteins are associated with StAR and VDAC1 to form a macromolecular
signaling complex on the OMM for steroidogenesis.  These include translocator protein
(TSPO, also known as the peripheral benzodiazepine receptor or PBR (see section 1.4)
and the PBR associated protein 7 (PAP7) which is thought to form an anchor for PBR
interaction with cAMP-dependent PKA regulatory subunit 1a (PKAR1α) (Bose et al.,
2008; Liu et al., 2006).
Therefore cholesterol transport for steroidogenesis is a complex, highly coordinated
event but the synthesis of StAR remains the critical step for initiating acute steroid
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synthesis.  Expression of StAR is initiated by trophic hormone signalling such as
ACTH, LH or hCG.  Upon binding to their respective receptors, these hormones initiate
a cAMP second messenger response, causing protein kinase A (PKA) activation (Elias
and Clark, 2000).  Even though StAR mRNA transcription rapidly increases in the
presence of cAMP, the human StAR promoter does not contain a consensus cAMP-
responsive element (CRE) (Manna et al., 2009b).  Instead, cAMP activates transcription
factors such as CREB/CREM/ATF-2, Fos and Jun, and C/EBPβ, which promote the
transcription of StAR (Manna et al., 2009b). These transcription factors contain a basic
leucine zipper motif that can bind to StAR promotor regions to facilitate RNA
polymerase II recruitment and initiate StAR transcription (Manna et al., 2009b).
Alternatively, StAR expression can be mediated by cAMP-independent mechanisms.
This is thought to be particularly important for maintaining basal levels of StAR
expression rather than acute StAR activation (Manna et al., 2006).  A number of factors
including insulin-like growth factor-I, epidermal growth factor (EGF), fibroblast growth
factor, transforming growth factor alpha, interleukin-1, and colony-stimulating factor-1,
increased the levels of StAR mRNA, StAR protein, and progesterone in mouse Leydig
tumour cells (Manna et al., 2006).  These factors promoted StAR protein to varying
degrees but did not induce StAR phosphorylation and were not associated with
fluctuations of cAMP signaling (Manna et al., 2006).
Therefore StAR is a tightly regulated protein essential for acute activation of
steroidogenesis.  However, other proteins have been implicated in contributing to
steroid synthesis.  These are metastatic lymph node 64 (MLN64) and the translocator
protein (TSPO).
1.1.3 Metastatic lymph node 64
MLN64, also known as STARD3, was first identified as a gene up regulated in highly
invasive breast cancers (Alpy et al., 2003).  The protein was found to contain a C-
terminal START domain, sharing 38% sequence homology and 60% amino acid
similarity with the START domain of StAR (Watari et al., 1997).  The START domain
is a 210 amino acid region that provides a hydrophobic pocket capable of binding lipids
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such as cholesterol oxysterols, phospholipids or ceramides depending on the specific
START domain protein (Alpy and Tomasetto, 2005).  To date, sixteen START domain
proteins have been identified and both StAR and MLN64 are specific for regulating
cholesterol transport (Alpy and Tomasetto, 2005).
The START domain of StAR is a highly flexible structure and forms aggregates at the
concentration required for crystal formation, thus the structure has yet to be resolved
(Tsujishita and Hurley, 2000).  However, X-ray crystallography analysis of MLN64’s
START domain has increased the understanding of both MLN64 and StAR function
and activity (Bose et al., 2000b).  Crystallographic analysis of the MLN64 START
domain revealed a nine-stranded twisted antiparallel β-sheet, 4 α-helices and 2-ohme
loops (Tsujishita and Hurley, 2000).  The β-sheets are arranged as a β-barrel forming a
hydrophobic tunnel optimal for accommodating one cholesterol molecule (Tsujishita
and Hurley, 2000).  The α4-helix appears to form a lid for the cavity and access to the
hydrophobic tunnel is dependent on the conformational changes of the α4-helix and
connecting loops (Reitz et al., 2008).  Photoaffinity labeling with [3H]azocholestanol
demonstrated that cholesterol preferentially interacts with one side of the START
hydrophobic cavity in StAR but that cholesterol can interact with any side of the
hydrophobic cavity in MLN64 (Reitz et al., 2008).  This suggests that there could be
differential cholesterol binding properties for StAR and MLN64 (Reitz et al., 2008).
However, mutations of inactive StAR identified from LCAH patients correlated with
conserved motifs identified in MLN64 (Watari et al., 1997).
Due to sequence homology and cholesterol binding capacity, MLN64 was investigated
to see if it possessed StAR-like activity.  MLN64 was shown to be able to induce
cholesterol transport to promote pregnenolone synthesis in COS-1 cells co-transfected
with the cytochrome P450 scc system (Watari et al., 1997).  However, MLN64 could
only increase steroid synthesis by two-fold whereas StAR induced a seven-fold increase
in pregnenolone synthesis.  Therefore, MLN64 has approximately 30% activity of StAR
(Watari et al., 1997).
This functional evidence for MLN64-mediated steroidogenic activity supported the
theory that MLN64 was responsible for steroid synthesis in the human placenta, a tissue
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capable of steroidogenesis but lacking StAR expression (Sugawara et al., 1995; Watari
et al., 1997).  In placental trophoblasts, MLN64-mediated cholesterol transport was not
regarded as the rate limiting step of steroid synthesis (Tuckey, 2005).  Unlike acutely
regulated StAR, MLN64 is constitutively active and could therefore supply a constant
amount of cholesterol to the mitochondria for steroidogenesis to maintain the
production of progesterone (Tuckey, 2005). Progesterone production by the placenta
inhibits spontaneous abortion, 83% of miscarriages are associated with serum
progesterone concentrations below a threshold level (Hahlin et al. 1990).
However, there is now substantial evidence suggesting that MLN64 is not directly
responsible for cholesterol delivery enabling pregnenolone synthesis.  This is because
the protein was found to be exclusively located to the late endosomes, an organelle
involved in the trafficking of cholesterol (Alpy et al., 2001; Holtta-Vuori et al., 2005).
The N-terminal sequence for MLN64 differs greatly from the mitochondrial targeting
sequence found in StAR, suggesting MLN64 functions in a different sub cellular
compartment (Alpy et al., 2001).  A mouse model with a targeted homozygous mutation
in the MLN64 START domain failed to show any significant phenotype since the mice
were viable, neurologically intact and fertile (Kishida et al., 2004).  However,
embryonic fibroblasts isolated from the mutant mice that were transfected with P450
scc system did show a reduction in testosterone (but not corticosterone) synthesis
(Kishida et al., 2004).  The authors concluded that MLN64 was largely dispensable for
intracellular sterol trafficking but might play an upstream role in delivering cholesterol
for steroidogenesis (Kishida et al., 2004).
Therefore the precise function of MLN64 remains elusive, however the protein does
appear to be highly expressed in numerous hormone-dependent tumours such as some
invasive breast carcinomas and high stage prostate cancer (Alpy et al., 2003; Stigliano
et al., 2007).  Both these tumours are associated with poor patient prognosis and are
resistant to hormone therapy.  Interestingly, a positive correlation for MLN64 and
CYP17 gene expression was identified in neoplastic but not normal prostate tissue,
suggesting a role for MLN64 in intraneoplastic autonomous steroidogenesis (Stigliano
et al., 2007).
31
In addition, reduction of both MLN64 and StAR expression in human macrophages has
been implicated in foam cell formation where cells are laden with cholesterol and
cholesterol ester (Borthwick et al., 2009).  Dysregulation of macrophage cholesterol
homeostasis and foam cell formation leads to the development of atherosclerosis
(Borthwick et al., 2009).  In addition, dysregulation of cholesterol transport was
associated with over-expression of hepatic MLN64 inducing liver damage in mice
(Tichauer et al., 2007).  Therefore, although the precise function of MLN64 has yet to
be determined, it is likely that the protein plays a role in cholesterol homeostasis and
could therefore influence steroid synthesis.
1.1.4 Translocator protein
The translocator protein (TSPO) functions to regulate steroid synthesis, cell
proliferation, calcium flow, mitochondrial respiration, apoptosis, cellular immunity and
malignancy (Gavish et al., 1999).  These seemingly disparate biological activities can
be accounted for due to the protein complexes formed by TSPO that interact with both
StAR and the mitochondrial permeability transition pore (MPTP) (Veenman et al.,
2007).
TSPO is a small 18 kDa protein originally described as the peripheral benzodiazepine
receptor due to its binding site for the benzodiazepine diazepam (Braestrup and Squires,
1977).  In addition to drug binding properties, TSPO also has a high affinity for
cholesterol binding and is associated with cholesterol transport (Delavoie et al., 2003).
TSPO is predominantly located on the outer mitochondrial membrane of steroidogenic
cells but can also locate to the inner mitochondrial membrane, nuclei, Golgi apparatus,
lysosomes, peroxisomes and plasma membrane in some cell types (Gavish et al., 1999).
The density of TSPO expression is particularly high in classical steroidogenic tissues
with the greatest expression in the adrenals, however, TSPO is ubiquitously expressed
throughout all tissues, including the skin (Stoebner et al., 1999).
Numerous high affinity drug ligands have been used to assess the function of TSPO.
These include the isoquinoline carboxiamide PK 11195, the PK 11195 nitrophenyl
derivative PK 14105 and the benzodiazepine Ro5-4864.  Photolabeled PK 14105
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identified that TSPO forms a complex with at least two proteins, the voltage-dependent
anion channel (VDAC, 32 kDa), and the adenine nucleotide carrier (ANT, 30
kDa)(Golani et al., 2001; McEnery et al., 1992).  VDAC and ANT form part of the
MPTP which is a critical mediator of apoptosis through regulation of cytochrome c
release (Tsujimoto and Shimizu, 2000).  TSPO is reported to regulate the opening and
closing of VDAC, where VDAC opening leads to cytochrome C release into the
cytoplasm, initiating caspase-dependent apoptosis.
In addition to mediating apoptosis, TSPO has been shown to be functionally coupled to
steroidogenesis.  Due to the high expression in steroidogenic tissue and co-localisation
to the mitochondria, TSPO was assessed for its ability to regulate steroid synthesis
(Gavish et al., 1999).  Ligands for TSPO enhanced steroid production in Y-1
adrenocortical and MA-10 Leydig immortalised cells (Papadopoulos et al., 1990), as
well as stimulating pregnenolone synthesis in brain mitochondrial preparations
(Guarneri et al., 1992; Papadopoulos et al., 1992).  Diazepam binding inhibitor (DBI, 10
kDa), a natural ligand for TSPO, is reported to be required for ACTH, hCG and
luteinising hormone-activated steroid synthesis (Boujrad et al., 1996; Papadopoulos et
al., 1991a; Papadopoulos et al., 1991b).  TSPO is also reported to be capable of
translocating cholesterol across the mitochondrial membranes in adrenocortical cells
that could be enhanced with PK 11195 (Krueger and Papadopoulos, 1990).  This
suggests that TSPO is a facilitator of the rate-determining cholesterol transport step in
steroid synthesis.
Despite the mounting evidence for TSPO regulation of steroidogenesis, it is unclear
whether TSPO and StAR interact (Figure 1.2).  Bioluminescence resonance energy
transfer analysis did not identify any direct interaction of StAR with TSPO (Bogan et
al., 2007).  However, in a separate study fluorescence energy transfer analysis suggested
co-localisation of TSPO with StAR (West et al., 2001).  Recent studies have found that
the two proteins form a complex via VDAC1 to coordinate steroidogenesis (Bose et al.,
2008; Miller, 2007).
PBR can reside as a monomer or form polymeric clusters. The monomer is thought to
bind cholesterol with greater efficacy whereas the polymers demonstrate high drug-
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ligand binding affinity (Delavoie et al., 2003).  In mouse Leydig cells, hCG induced
rapid (15-30 s) cluster formation consisting of seven or more TSPO monomers (Boujrad
et al., 1996).  The fast rate of cluster formation is associated with the rapid induction of
steroidogenesis by hCG in Leydig cells (Amri et al., 1996).  Clusters develop through
the formation of dityrosine covalent cross-linker bonds following U.V. exposure and
subsequent ROS production (Delavoie et al., 2003).  However, ROS is a by-product of
steroidogenesis and may account for rapid cluster formation with hCG stimulation in
Leydig cells (Delavoie et al., 2003).
Changes in cholesterol transport are associated with cancer progression, and increased
TSPO expression is associated with increased severity of breast cancer (Hardwick et al.,
1999).  In addition there was a direct correlation with TSPO nuclear localisation and
intensity with the severity of metastatic breast cancer cells lines (Hardwick et al., 1999).
Therefore TSPO is now generating interest as an important protein for regulating cell
viability, proliferation and apoptosis with implications in disease.
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Figure 1.2 Illustrations of cholesterol transport for steroid synthesis.
(A) StAR associates with TSPO to facilitate acute steroidogenesis.  TSPO interacts with
PAP7 and PKA to maintain the active phosphorylated state of StAR.  (B)  StAR and
TSPO do not directly interact but bind to VDAC1 to promote steroid synthesis.  AKAP
anchors StAR mRNA and PKA to the outer mitochondrial membrane, where StAR is
translated in situ and rapidly activated by PKA phosphorylation.  The precise
mechanism of cholesterol transport across the mitochondrial membranes is not known
but is currently thought to be regulated by VDAC1.  Once cholesterol enters the inner
mitochondrial membrane, the sterol is metabolised to pregnenolone by CYP11A1.
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1.1.5 DAX1, a negative regulator of StAR
Dosage-sensitive sex-reversal, adrenal hypoplasia congenita, critical region on the X-
linked chromosome, gene 1 (DAX1, gene name NR0B1) is a nuclear receptor (NR) that
acts as a negative regulator of steroidogenesis (Zazopoulos et al., 1997).  The essential
role of DAX1 during development and regulation of subsequent steroid synthesis is
exemplified by X-linked adrenal hypoplasia congenita (AHC).  Loss of function or
expression mutations of DAX1 in AHC prevents the inhibition of StAR and steroid
synthesis (Zanaria et al., 1994).  This leads to an abnormally early expression of genes
involved in steroid production, impairing proliferation and adrenal zonation in the
developing embryo (Lalli and Sassone-Corsi, 2003). Patients with AHC also have
gonadal deficits including disorganised testes cords and hypogonadic hypogonadism.
In contrast DAX1 gene duplication in males leads to dosage-sensitive male-to-female
sex reversal (Ludbrook and Harley, 2004).
Members of the NR superfamily have conserved structural domains that separate them
from other transcription factor families (Niakan and McCabe, 2005).  These are an N-
terminal DNA binding domain (DBD) and C-terminal ligand binding domain.  DAX1 is
unusual as its N-terminal domain does not resemble the canonical zinc-finger DNA
binding domain making it distinct from all other NRs (Zazopoulos et al., 1997).
Instead, in humans DAX1 has a unique 65-67 cysteine-rich amino acid sequence that
repeats three and a half times and includes an LXXLL or NR-box motif (Suzuki et al.,
2003).  Unlike the N-terminus, the C-terminus of DAX1 does share sequence homology
to other NR proteins such as the retinoid X receptor (RXR) (Niakan and McCabe,
2005).  This region contains a transcriptional activation function 2 (AF2) ligand-binding
domain, although currently there is no known ligand to induce DAX1 activity making it
an orphan receptor (Niakan and McCabe, 2005).
As an NR, DAX1 can exert its steroidogenic repressor activities by inhibiting
transcription of genes involved in the steroid response.  For example, the DAX1 N-
terminus recognises adenine-rich hairpin loop structures in the StAR promoter,
preventing StAR transcription.  DAX1 and SF-1 binding sites are close together on the
promoter, suggesting allosteric inhibition by DAX1 of SF-1-StAR interaction.  Indeed,
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the expression pattern of DAX1 overlaps with SF-1 in specialised steroidogenic and
reproductive tissue.  SF-1 knockout mice suggests that SF-1 can control the
transcription of the Dax1 gene (Kawabe et al., 1999).  Activation of the PKA and PKC
second messenger response in mouse Leydig tumour cells inhibited DAX1-DNA
binding interactions, leading to promotion of StAR expression and progesterone
synthesis (Manna et al., 2009a).  Interestingly, the DAX1 promoter site also contains an
adenine-rich hairpin loop structure suggesting a self-regulating feedback system.  In
addition, DAX1 can act as a coregulatory protein suppressing the activity of other NRs,
including NR5A1 encoding SF1, the estrogen receptor (ER), androgen receptor (AR),
progesterone receptor (PR) (Niakan and McCabe, 2005).
DAX1 can also function in the cytoplasm through protein-protein interaction.  A single
C200W mutation in the hinge region of the DAX1 was identified in a family with mild
AHC phenotype (Bernard et al., 2006), leading to prevention of nuclear localisation of
DAX1, shifting expression to the cytoplasm.  Despite this, the patients still maintained
80% of wild-type activity (Bernard et al., 2006).  Protein-protein interactions of DAX1
have been identified with SF1 and ER and DAX1 has been shown to antagonise AR and
ER receptor dimerisation, as well as retinoic acid response element interaction with
RXR (Niakan and McCabe, 2005).  DAX1 can also recruit co-repressors, such as
nuclear co-repressor and Alien, and shuttle mRNA back to the nucleus to prevent
protein synthesis (Iyer and McCabe, 2004).  Thus DAX1 acts as a master suppressor of
steroid synthesis by interacting with the steroid pathway at many different levels.
1.1.6 Enzymes of steroid synthesis
Cytochrome P450 side chain cleavage enzyme (CYP11A1) catalyses the first step in
steroid synthesis, metabolising cholesterol to pregnenolone (Storbeck et al., 2007).
CYP11A1 is tightly associated but not integrated to the IMM.  The CYP11A1
preprotein contains an N-terminal target sequence to deliver the protein to the surface of
the IMM (Storbeck et al., 2007).  This target sequence is then rapidly cleaved yielding
the mature CYP11A1 protein by specific peptidases that are only found in the
mitochondrial matrix of cells that express mitochondrial P450 enzymes (Storbeck et al.,
2007).
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CYP11A1 acts in a sequential three-step process where cholesterol undergoes 22-
hydroxylation, 20-hydroxylation and then C20-C22 bond cleavage yielding
pregnenolone and isocaproic acid (Storbeck et al., 2007).  Each hydroxylation step
requires two electrons to activate molecular oxygen that are provided by a
mitochondrial steroid electron transport system (a distinct system from respiratory
electron transport) (Lambeth et al., 1979).  Electron transfer from NADPH to CYP11A1
is mediated via two soluble enzyme components, ferredoxin reductase (FDXR, also
known as adrenodoxin reductase, a mono FAD single subunit protein) and ferredoxin
(FDX, also known as adrenodoxin, an Fe2S2* protein) (Lambeth et al., 1979).  NADPH
directly reduces FDXR which in turn reduces FDX that then acts as an electron shuttle
between FDXR and CYP11A1 (and other mitochondrial P450 enzymes).  FDXR is
specific for NADPH rather than NADH since the apparent Km values for these pyridine
nucleotides are 1.82 µM and 5.56 mM respectively (Lambeth et al., 1976).  In addition,
in vitro, 1 NADH can only reduce the FDXR FAD moiety by 70%, whereas NADPH is
100% efficient (Lambeth et al., 1976).
Once CYP11A1 synthesises pregnenolone from cholesterol, pregnenolone is converted
to progesterone by dehydrogenation of the 3β-hydroxyl group and Δ5 to Δ4 double
bond isomerisation (Davies and MacKenzie, 2003).  The enzyme 3β-hydroxysteroid
dehydrogenase (3βHSD) was identified in 1951 to be responsible for the catalysis of
this reaction (and all other steroid 3β-hydroxylations and Δ5 to Δ4 isomerisations)
(Simard et al., 2005). In humans, two 3βHSD isoenzymes account for 3βHSD activity,
where type I regulates 3βHSD activity in placenta and peripheral tissues, and type II
predominantly regulates 3βHSD activity in the adrenal gland, ovary, and testis (Simard
et al., 2005).  Located to the membrane of both the ER and mitochondria, 3βHSD is
dependent upon NAD+ (Simard et al., 2005).  A shift in 3βHSD localisation from the
ER to the mitochondria in mouse ovaries was observed during the luteal phase of
ovulation (Chapman et al., 2005).  It has been proposed that this shift in localisation
ensures high levels of progesterone production during the luteal phase, since NAD+
cofactor availability is greater in the mitochondria relative to the ER (Chapman et al.,
2005).  The difference in subcellular localisation of 3βHSD could also aid the efficiency
of steroidogenesis depending on the substrate.  For example, mitochondrial 3βHSD can
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interact with CYP11A1 to promote progesterone synthesis, whereas ER 3βHSD
promotes DHEA metabolism (Simard et al., 2005).
The Δ5 to Δ4 isomerisation step is also thought to be conducted by 3βHSD since
reduced NAD+ (NADH) has been shown to induce a conformational change in 3βHSD
that causes 3-oxo-Δ5-steroid isomerisation (Simard et al., 2005).  However recent
evidence has demonstrated that human alpha class glutathione transferase 3-3 (GSTA3-
3) may regulate the isomerase part of the reaction (Johansson and Mannervik, 2001).
GSTA3-3 was shown to be 230 times more efficient than 3βHSD at Δ5 to Δ4 steroid
isomerisation and siRNA targeted inhibition of GSTA3-3 in adrenal whole cell extracts
decreased progesterone production by 30% (Johansson and Mannervik, 2001; Raffalli-
Mathieu et al., 2008).
An alternative pathway of pregnenolone metabolism is via CYP17.  CYP17 is a 17-
hydroxylase and 17,20 lyase enzyme that is regarded as the ‘qualitative regulator’ that
determines which class of steroids are produced (Miller, 2005).  For example, in the
absence of 17,20 lyase activity, C21 17-deoxysteroids such as aldosterone are
synthesised, but with 17,20 lyase activity C19 precursors of sex steroids are produced
(Miller, 2005).  The onset of 17,20 lyase activity is predominant in controlling the
development of the adrenarche, inducing an increase of adrenal DHEA synthesis from
aged 6-8 years that reaches its pinnacle level between 25-30 years in humans.  The
increase of DHEA synthesis is independent of serum concentrations of cortisol and
ACTH (Miller, 2005).
Both 17-hydroxylase and 17,20 lyase reactions occur at the same, single active site of
the enzyme but 17,20 lyase activity is regulated by electron flow from NADPH via
P450 oxidoreductase (POR) to CYP17 (Miller, 2005).  POR is required for both
reactions however cytochrome b5 selectively augments 17,20 lyase activity (Miller,
2005).  The increase in cytochrome b5 expression in the zona reticularis of the adrenals
coordinates the onset of adrenarche.  Kinetic analysis revealed that the 17,20 lyase
activity of CYP17 is 30-fold greater for Δ5 substrates than Δ4, thus most
androstendione synthesis proceeds via DHEA from 17-hydroxypregnenolone
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metabolism rather than from 17-hydroxyprogesterone metabolism in humans (Miller,
2005).
The next step of cortisol synthesis is via CYP21 that acts as a 21-hyroxylase to
synthesis 11-deoxycortisol from 17-hydroxyprogesterone.  Similar to CYP17, this
enzyme is located to the ER membrane and is dependent upon NADPH cofactor POR
electron transport.  CYP21 also regulates the formation of mineralocorticoids (e.g.
aldosterone) by metabolising deoxycorticosterone to corticosterone as a precursor to
aldosterone synthesis (Miller, 2005).  The significance of CYP21 in glucocorticoid
(GC) and mineralocorticoid synthesis is highlighted in two disorders, Addison’s disease
and congenital adrenal hyperplasia (CAH).
Addison’s disease causes adrenocortical failure due to the production of autoimmunity
auto-antibodies that are specific for CYP21 (Bratland et al., 2009).  CAH also causes
adrenocortical insufficiency and is one of the most common autosomal recessive
inherited diseases affecting 1:5000-15000 live births (Trakakis et al., 2009).
Approximately 90% of all CAH cases are due to mutations of CYP21 (as opposed to
lipoid CAH that is due to StAR deficiency) (Trakakis et al., 2009).  Interestingly,
untreated infants with lipoid CAH may survive without treatment for several months,
whereas patients with severe salt-wasting CAH do not (Miller, 2005).  This is due to
StAR-independent steroidogenesis that is not disrupted in lipoid CAH, however both
acute (StAR-mediated) and background steroidogenesis of cortisol and aldosterone can
be inhibited CYP21 mutations in CAH (Miller, 2005).
The 11-deoxycortisol product of CYP21 metabolism can then be used to synthesise
cortisol.  This is achieved by the 11β-hydroxylase activity of CYP11B1, a member of
the same CYP11 gene family as CYP11A1.  Similar to CYP11A1, the CYP11B1
enzyme is also expressed in the mitochondria and couples with NADPH to achieve
cortisol synthesis in humans (Ishimura and Fujita, 1997).  The activity of the two P450
enzymes are interlinked since the expression of CYP11A1 can promote CYP11B1
activity in recombinant yeast models (Cauet et al., 2001).
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Another enzyme of the CYP11 family is CYP11B2, sharing 95% sequence homology to
CYP11B1.  CYP11B2 is also located at the IMM and is responsible for synthesising
corticosterone, the precursor to aldosterone.  Corticosterone rather than cortisol is the
major GC in rodents.  This is due to differences in the expression patterns where by the
qualitative regulator CYP17 is expressed in the zona glomerulosa of rat adrenals but
zona fasiculata of human adrenals (Miller, 2005).  Thus the synthesis of cortisol is a
divergent pathway from mineralocorticoid production in humans.
The concentration of cortisol in cells can be tightly regulated by 11βHSD activity,
which exists as two distinct isoforms of 11βHSD, 11βHSD1 and 11βHSD2.  Both
isoforms are expressed in the ER but have different functions.  11βHSD2 is an NAD+
dependent enzyme that rapidly deactivates cortisol to inactive cortisone.  This enzyme
is expressed in mineralocorticoid-sensitive cells, since cortisol can bind to
mineralocorticoid receptors with the same affinity as GC receptors.  In contrast,
11βHSD1 is a reversible NADPH dependent reaction that predominantly acts to oxidise
cortisone to cortisol (Sherbet et al., 2007).  Unlike most other HSD enzymes, 11βHSD1
uses NADPH cofactor generated from the intra-luminal hexose-6-phosphate
dehydrogenase (H6PD) pathway in the ER (Hewitt et al., 2005).  Disruption of
11βHSD1 due to an impairment of the H6PD activity and has recently been implicated
in the pathogenesis of metabolic syndrome, highlighting the necessity of cofactor
availability for steroid catalysis (Hewitt et al., 2005).
1.1.7 Cofactors, redox potential and cell viability
Cofactor availability is the driving force of steroid metabolism, determining the
directional preference of HSD catalysis (unlike HSD enzymes, P450 reactions are
considered mechanistically irreversible) (Sherbet et al., 2007).  HSD enzymes appear to
have unidirectional synthesis, however these enzymes are bidirectional with strong
directional preference that is governed by cofactor availability.  A pseudo-equilibrium
state is reached that gives the apparent directional preference of the enzyme (Agarwal
and Auchus, 2005).  There are two key factors that ensure cofactors regulate the
directional preference of HSD enzymes, these are cofactor concentration and binding
kinetics.  Free cofactor (NADPH and NAD+) exceeds steroid substrate by several orders
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of magnitude (mM versus nM), in addition, steroid enzyme kinetics require the cofactor
to bind prior to the substrate (Agarwal and Auchus, 2005).  Thus subtle changes in
cofactor levels that can be tolerated by cells may dramatically alter the ability of the
cells to synthesise steroids (Agarwal and Auchus, 2005).
Cofactor availability in the cell is controlled by the amount and type of metabolism
together with oxygen supply (Agarwal and Auchus, 2005).  The overall redox state of
the cell is determined by the relative abundance of reducing (NADPH) and oxidising
equivalents (NAD+).  Under optimal fuel and oxygen conditions, there is a high ratio of
NADPH relative to NADP+ and NAD+ relative to NADH (Agarwal and Auchus, 2005).
The pentose phosphate pathway (PPP) is the principle process that maintains the
cytosolic NADP+/NADPH gradient by regenerating NADPH from NADP+ during the
oxidation of hydrocarbon substrates (Agarwal and Auchus, 2005).  This provides a
source of NADPH to most HSD enzymes for steroid metabolism.  Two enzymes,
glucose-6-phosphate dehydrogenase (G6PDH) and 6-phosphogluconate dehydrogenase
(6PGDH), are key to the PPP pathway and utilise glucose-6-phosphate (G6P) from
glucose to generate NADPH (Agarwal and Auchus, 2005).  An alternative pathway for
cytosolic NADPH production is via the citric acid cycle.  All reactions for this cycle
occur in the mitochondria and reduce NAD+ to NADH, except for one step that in the
cytoplasm where isocitrate dehydrogenase uses NADP+ as an electron acceptor, creating
NADPH in the process (Agarwal and Auchus, 2005).  Another source of NADPH that is
restricted to the lumen of the ER is generated by the hexose-6-phosphate dehydrogenase
pathway (Agarwal and Auchus, 2005).  Most enzymes that require NADPH from the
ER rely on this local source of NADPH.
All NADPH is originally derived from NAD+/NADH.  NAD+ is produced by the de
novo pathway or the salvage pathway and under physiological conditions, cytosolic
NAD+ exceeds NADPH by approximately 700:1 (Ying, 2008).  In contrast to NADPH,
cells maintain the NAD+/NADH gradient to favour the NAD+ oxidised form.  This is
because electrons from NADH are constantly removed for use in the mitochondrial
electron transport chain for ATP generation (Ying, 2008).
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Interestingly, GC whose synthesis relies heavily on cofactor availability are able to
influence cellular redox potential. GC have been shown to increase G6PDH in rat
hepatocytes and adipose tissue, suggesting GC can influence cellular redox potential
(Agarwal and Auchus, 2005).  Cortisol has also been reported to promote NADPH
reduction in the predominantly oxidative environment of the ER lumen (Piccirella et al.,
2006).  The ER lumen is considered to be a uniformly oxidising environment since the
ratio of reduced to oxidised glutathione is 1-2:1 in the ER but 200:1 in the cytosol
(Piccirella et al., 2006).  This oxidising environment aids the protein folding and
secretion function of the ER, however there are many intra-luminal ER reactions that
require reducing equivalents.  This includes 11βHSD1, which predominantly exhibits
cortisone reductase activity in vivo but is also reported to oxidise cortisol in vitro
(Piccirella et al., 2006).  Addition of cortisone promoted NADP+ oxidation in liver
microsomes whereas cortisol enhanced NADPH reduction (Piccirella et al., 2006).
Therefore, cortisol can promote 11βHSD1 to favour cortisone to cortisol formation,
whereas cortisone may enhance the enzyme to favour cortisone formation (at least in an
in vitro system).  Increased NADPH levels in the ER following incubation with cortisol
occurred due to upregulation of the hexose-6-phosphate pathway that was independent
of glutathione reductase activity (Piccirella et al., 2006).  Therefore, cortisol can change
both cytosolic and ER redox potential to favour steroidogenesis and further cortisol
synthesis.
The positive feedback effect of cortisol on steroidogenesis was identified in a study on
granulosa cells.  Cortisol promoted steroidogenesis in granulosa cells independently of
StAR and steroid enzyme protein expression levels (Sasson et al., 2001).  However no
mechanism for this phenomenon was described in the paper and changes in cellular
redox potential or cofactor availability were not measured.  In addition, corticosterone
deficiency was shown to inhibit testosterone synthesis in mice Leydig cells.  Addition
of corticosterone back to the system rescued the phenotype and increased expression of
CYP11A1 and 17αHSD mRNA levels (Parthasarathy and Balasubramanian, 2008).
Therefore, whilst GC can act via a negative feedback response to suppress the HPA
access that ultimately down regulates steroidogenesis, GC also appear to be able to
promote steroidogenesis.  Indeed, GC have been described as having a biphasic
response with respect to the regulation of neuronal plasticity by protecting cells and
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preventing apoptosis at low concentration but inducing apoptosis at high concentration
(Du et al., 2009).  GC exerted these differential properties in neuronal cells by
modulating cellular redox potential, calcium flux and Bcl-2 proteins (Du et al., 2009).
Maintaining cellular redox potential is pivotal to cell viability and prevention of
apoptosis (Green and Reed, 1998).  Changes in electron transport, loss of mitochondrial
transmembrane potential, altered cellular oxidation-reduction, and participation of pro-
and anti-apoptotic Bcl-2 family proteins are all key factors in the onset of apoptosis
(Green and Reed, 1998).  In a tissue-specific manner, cortisol can either inhibit or
promote apoptosis (Viegas et al., 2008).  Recently this function of cortisol has been
attributed as an additional novel anti-inflammatory mechanism of GC.  This is because
GC predominantly induces apoptosis of haematopoietic cell such as monocytes,
macrophages and T lymphocytes whilst protecting tissues such as mammary gland
epithelial cells, endometrium, hepatocytes, ovarian follicular cells, fibroblasts and
keratinocytes (Viegas et al., 2008).  The mechanism for these opposing effects of
cortisol are yet to be elucidated, though the steroid has been shown to have differential
effects on Bcl-2 proteins that could account for the pro- and anti-apoptotic properties of
GC (Viegas et al., 2008).
The seemingly disparate function of steroidogenesis and apoptosis are also linked via
the TSPO protein (as described previously).  TSPO is a ubiquitously expressed protein
and could aid the transport of cholesterol for steroid synthesis in tissues that are not
classically regarded as steroidogenic cells.  Over the past few years, many non-classical
endocrine cells such as retinal pigment epithelium (Zmijewski et al., 2007), astrocytes
(Karri et al., 2007), the hair follicle (Ito et al., 2005), sebocytes (Chen et al., 2006) and
dermal fibroblasts (Slominski et al., 2006) have been shown to possess steroidogenic
capabilities (Table 1.1).  In addition, many more tissues such as pancreatic cells
(Morales et al., 2008) and chondrocytes (Takeuchi et al., 2007) have been shown to
express StAR, TSPO and enzymes required for steroidogenesis.  The function of local
steroidogenesis and its necessity beyond the systemic endocrine system remains to be
defined.
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Cell/tissue type and
reference
Steroid measured Concentration Method of
analysis
SEB1 sebocytes
(Thiboutot et al., 2003)
17OH
pregnenolone
~5pg/106 cells or ~2 pg 106 cells without
10µM forskolin when treated with 22-
OHcholesterol (5µM) for 48h.
RIA
P r i m a r y  h u m a n
keratinocytes
(Milewich et al., 1988)
Pregnenolone and
progesterone
No metabolism detected Radiometric
HaCaT keratinocytes
(Slominski et al.,
2002) and (Rogoff et
al., 2001)
Progesterone to
deoxycorticosterone
Not applicable Radiometric
Hair follicle
(Ito et al., 2005)
Cortisol ~10 µg/L by follicles treated with CRH
(0.1 µM) and 10 µg/ml hydrocortisone;
~5 µg/ml by follicles treated with 10
µg/ml hydrocortisone over 6 days.
RIA
Primary human dermal
fibroblasts
(Slominski et al.,
2006)
Cortisol ~1 ng/ml untreated, ~4 ng/ml with
progesterone (1 µM),~ 6 ng/ml with
progesterone (1 µM) and ACTH (1
µM), cell density 1x105 in 24 well plate,
24 h.
RIA
Mesencephalon
primary rat astrocytes
(Karri et al., 2007)
Pregnenolone ~20 pg/0.1ml extract, ~120 pg/ml with
1mM dbcAMP, 20 µM SU-10603 and 5
µM cyanoketone both over 24 h
RIA
Cerebellum primary rat
astrocytes
(Karri et al., 2007)
Pregnenolone ~10 pg/0.1ml extract, ~100 pg/ml with
1mM dbcAMP, 20 µM SU-10603 and 5
µM cyanoketone both over 24 h
RIA
Rat heart
(Silvestre et al., 1998)
Corticosterone ~500 pg/mg protein from basal levels to
1500 pg/mg protein upon 3 h ACTH (10
nM) perfusion.
RIA
ARPE-19 (human
r e t i n a l  p i g m e n t
epithelial cells)
(Zmijewski et al.,
2007)
Cortisol ~5 ng/ml untreated or ~25 ng/ml with
progesterone (10 µM) over 24 h,
500,000 cell per 10 cm Petri dish.
ELISA
Table 1.1 Summary of studies reporting pregnenolone, progesterone and/or
cortisol synthesis and metabolism by non-classical steroidogenic tissue.
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Introduction II: Steroid biology of the skin
1.2.1 The structure and function of the epidermis
The skin is an essential barrier that protects the body from the external environment.  As
such, the skin forms the primary defence from biological, chemical and U.V. radiation
assault.  In addition, this organ provides a vital role to protect the body from
dehydration as well as aiding body temperature regulation.
The skin is composed of three layers, the epidermis (epithelial layer), the dermis
(connective tissue) and the hypodermis (adipose tissue).  The epidermis forms as a
stratified layer of cells, which provides greater protection than a single monolayer
(Eckert, 1989).  Approximately 85% of the epidermis is made up of keratinocytes whilst
the remaining cell components are melanocytes, Langerhans and Merkel cells.  There
are five distinct layers of the epidermis that are formed due to morphological changes
that keratinocytes undergo as they differentiate (Figure 1.3).  These are the basal layer,
spinous layer, granular layer, transitional layer and cornified layer (Proksch et al.,
2008).
The basal layer is the site of proliferating keratinocytes containing transient-amplifying
keratinocytes and stem cells that maintain keratinocyte regeneration (Watt, 1998).  The
stem cells undergo a mitotic division to produce two daughter cells, one forms another
stem cell to maintain the stem cell pool (approximately 10%), whilst the other forms a
transient-amplifying cell that undergoes a limited number of cell divisions to generate
the main basal layer (Watt, 1998).  Approximately 80% of the basal layer comprises
transient-amplifying cells.  After completing the cell division cycles, the transient-
amplifying cell enters differentiation (forming the remaining 10% of the basal
population) and migrates through the epidermal layers starting with the spinous layer
(Watt, 1998).
The spinous layer forms above the basal layer and derives its name from the spine-like
morphology of the keratinocytes.  The spines are formed by the development of
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desmosome connections with neighbouring cells.  Above the stratum spinosum is the
granular layer.  As the name suggests, keratinocytes in the granular layer exhibit
keratohyalin granules that contain profilaggrin and lipid-filled lamellar granules (Eckert
1989).
Granular keratinocytes then transition from ‘live’ to ‘dead’ cells in the transition zone.
This is a demanding metabolic process where all organelles are destroyed and lamellar
granules fuse with the plasma membrane, releasing lipids into the extracellular space
that leads to the formation of the cornified layer (Elias, 2005).  The cornified layer is the
site of terminal keratinocyte differentiation where keratinocytes flatten and lose
approximately 70% of their dry weight.  Keratins form 80% of the corneocytes that
interlink with lipids to provide a waterproof barrier.  Over time, the corneocytes are
sloughed off as the skin regenerates. The transition from the basal layer to the stratum
corneum takes between 12-24 days (Eckert 1989).  The thickness of the epidermis is
maintained through a delicate equilibrium between cell proliferation, cell
differentiation, senescence and apoptosis (Doger et al., 2007).  Aberrant regulation of
one or all of these processes leads to barrier incompetence as seen in many skin diseases
(Doger et al., 2007).
Keratinocyte differentiation for barrier formation is a complex event that can be defined
by certain markers.  Keratins are intermediate filaments that form a ring surrounding the
nucleus and radiate out to desmosome junctions to provide a major structural network
for the keratinocyte (Proksch et al., 2008).  Keratin 5 (K5) and keratin 14 (K14) are
associated with proliferating keratinocytes and are expressed exclusively in the basal
layer of normal epidermis.  An early marker of keratinocyte differentiation is the
expression of keratin (K1) and keratin (K10) instead of K5 and K14, as detected in the
spinous layer (Leigh et al., 1993).  During conditions of hyper-proliferation such as
lesional atopic dermatitis and psoriasis, K6 and K16 are expressed instead of K1 and
K10 as well as inflammation-associated keratin (K17) (Jensen et al., 2004).
Filaggrins are filament associated-proteins that are essential for skin hydration and bind
to keratin fibres to form a dense lipid-protein matrix.  Profilaggrin is an insoluble
phosphorylated protein containing multiple filaggrin repeats that accumulate in
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keratohyalin granules (Markova et al., 1993).  In late stages of differentiation, the
protein is dephosphorylated and processed into individual filaggrin units that aligns
keratins and lipids into a parallel plane to form the cornified layer of the epidermis
(Markova et al., 1993).  Loricrin is another critical component of the hydrophobic
epidermal barrier that is linked together with disulphide bonds by the action of
transglutaminase as part of cornification.
Calcium homeostasis is an important regulator of epidermal differentiation and can
coordinate protein synthesis, including the activation of transglutaminase activity
(Proksch et al., 2008).  A healthy epidermis has a complex calcium gradient.  The
highest calcium level is in the granulosum which rapidly drops during cell transition to
the stratum corneum due to high lipid and low water content of cornified keratinocytes
(Proksch et al., 2008).  Previously it was considered that a calcium gradient existed
from basal (low calcium) to granulosum (high calcium) keratinocytes.  However,
electron probe microanalysis recently demonstrated that the calcium content of basal
layer keratinocytes was higher than that of the lowest spinous cell layer in normal
epidermis (Leinonen 2008).  The epidermal calcium gradient is disrupted with barrier
defects leading to abnormally low calcium content throughout the epidermis (Proksch et
al., 2008).
Oxygen can also regulate keratinocyte differentiation.  The skin is one of the few organs
that can absorb atmospheric (21%) oxygen and levels as high as 17% O2 have been
measured in corneocytes whilst basal keratinocytes are exposed between 2-5% O2 (Ngo
et al., 2007).  Primary keratinocytes cultured in 5% O2 do not display altered
proliferative rates but differentiation is profoundly suppressed (Ngo et al., 2007).  Cells
cultured at 2% O2 showed decreased cell proliferation and differentiation rates but
higher colony forming capacity (Ngo et al., 2007).  Thus the oxygen gradient is
proposed to act as a driving force between basal cell maintenance and keratinocyte
differentiation.
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Figure 1.3 The layers of the epidermis
(A) a schematic and (B) an hematoxylin and eosin image of the epidermis.  The diagram
depicts the stratum basale where stem cells and transient amplifying keratinocytes
reside.  Once the keratinocytes have completed transient amplification, they undergo
differentiation and migrate through the stratum spinosum, granulosum and lucidium.
The stratum corneum is the site of terminal differentiation where lipids and proteins are
released from the keratinocytes to form the skin barrier.
(modified from http://upload.wikimedia.org/wikipedia/commons/2/20/Skinlayers and
www.etsu.edu/cpah/hsci/bowersjh/skin.html).
Stratum basale
Stratum spinosum
Stratum granulosum
Stratum lucidum
(transition layer)
Stratum corneum
A. B.
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1.2.2 Atopic dermatitis
Atopic dermatitis (AD) is a common chronic inflammatory skin disease characterised
by itchy, red, papulous, severely dry skin that is prone to cutaneous infections.  The
pathogenesis of AD is not fully characterised but there are clear environmental,
immunologic and genetic contributions to the disease (Elias et al., 2008).  Most AD
patients also suffer from asthma and allergic rhinitis comorbidities, possibly due to IgE-
sensitisation or low-grade systemic inflammation (Leung et al., 2004).
The histology of AD includes premature keratinocyte apoptosis throughout the
epidermal layers, hyperproliferation, poor keratinocyte differentiation, disturbed barrier
formation with increased trans-epidermal water loss (TEWL) and immune cell invasion
(Elias et al., 2008; Leung et al., 2004). Classic hyperproliferation keratin markers are
induced in lesional AD skin, including K6 and K16, K17 and a decrease in K10
expression (Jensen et al., 2004).
There are three different immune stages of atopic dermatitis; uninvolved, acute and
chronic epidermal inflammation (Leung et al., 2004).  Even uninvolved atopic
dermatitis exhibits increased TEWL and a sparse perivascular T cell infiltrate that is not
seen in normal healthy epidermis (Leung et al., 2004).  Environmental factors such as
irritating substances, climate, emotional stress or infection can exacerbate the disease
triggering acute or chronic inflammation.  The acute response activates keratinocytes to
release proinflammatory cytokines and chemokines that facilitate immune cell
infiltration into the epidermis resulting in a Th2 immune profile (IL-4, IL-5 and IL-13)
(Leung et al., 2004).
Further irritation (e.g. by scratching the skin) stimulates IL-12 release that switches the
immune response from a Th2 to Th1 profile with IFNγ expression (Trautmann et al.,
2000). The secretion of IFNγ up regulates Fas-ligands, inducing Fas-mediated apoptosis
in primary keratinocytes (Trautmann et al., 2000).  Dysregulated apoptosis of
keratinocytes is thought to be a key event in the development, severity and exacerbation
of AD (Leung et al., 2004).  Although apoptosis is commonly regarded as a form of cell
death that does not release inflammatory mediators, apoptosis does appear to be coupled
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with inflammation.  It is thought that the inflammatory infiltrate is the cause rather than
the consequence of keratinocyte apoptosis in AD (Leung et al., 2004; Trautmann et al.,
2000).
Until recently, atopic dermatitis was primarily considered as an immunologic disorder,
however, genetic screening identified that the FLG gene, which encodes filaggrin, is
mutated in up to 20% of all Euro-American cases of AD (McGrath, 2008).  Loss of
filaggrin function in these patients may be responsible for the high TEWL loss of
uninvolved atopic dermatitis (Seguchi et al., 1996).
In addition to filaggrin, involucrin and loricrin expression is also dysregulated in AD.
Unlike filaggrin, normal involucrin levels were detected in uninvolved AD skin but
expression was decreased in lesional regions (Seguchi et al., 1996).  Loricrin was found
to be decreased in both lesional and non-lesional AD relative to healthy skin.
Involucrin and loricrin were suppressed by IL-4 and IL-13, thus the Th2 response could
exacerbate dysregulated keratinocyte differentiation in acute AD (Kim et al., 2008). In
addition, a recent mouse model with a triple knockout of involucrin, envoplakin and
periplakin exhibited infiltration of CD3+CD4+ T cells, as observed in AD patients
(Sevilla et al., 2007).  It remains inconclusive as to whether inflammation or barrier
defect is the primary cause of AD but both factors are able to influence the other to
aggravate the disease.
AD skin is also prone to infection, particularly by Staphylococcus aureus.  This is
thought be due to the lack of inducible antimicrobial peptides, particularly the
cathelicidin LL-37 and human beta-defensin 2 (HBD-2) which forms part of the innate
immune system that targets S. aureus infection (Ong et al., 2002).  In addition, defective
epidermal pH regulation in AD provides an environment nearer to pH 7.4 rather than
pH 5.5 that is optimum for most microbial growth (Elias et al., 2008).
Dry skin in AD is related to changes in epidermal lipid composition due to disturbed
epidermal differentiation.  This skin dehydration can be treated by topical application of
an emollient cream containing lipids or lipid-like substances such as hydrocarbons, long
chain alcohols, free fatty acids, cholesterol esters and triglycerides (Proksch et al.,
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2003).  Emollient treatment can reduce TEWL and in some cases even decrease mild
inflammation (Proksch et al., 2003).  Topical GC application is the mainstay anti-
inflammatory therapy and is able to treat both acute and chronic AD (Proksch et al.,
2003).  Due to the associated skin thinning side-effects of GC, this treatment is not
generally used for maintenance therapy.  However, there is some evidence showing that
once the initial disease is under control, long-term management can be achieved with
twice-weekly GC therapy to prevent relapse.  More recently, topical calcineurin
inhibitors such as tacrolimus and pimecrolimus have been used to manage AD (Leung
et al., 2004).  Calcineurin inhibitors act by inhibiting nuclear factor of activated T cell
protein (NF-ATp), providing an anti-inflammatory effect by preventing transcriptional
activation of Th1 and Th2 cytokines (Leung et al., 2004).
1.2.3 Psoriasis
Psoriasis is a highly prevalent disease occurring worldwide and affecting approximately
2% population in the U.S. and Europe (Langley et al., 2005).  This skin disorder can
present at any stage of life, from birth to advanced age, however it is more likely to
occur from the age of 15 to 20 years and then from 55 to 60 years (Langley et al., 2005).
Psoriasis is described as a papulasquamous disease with scaling papules (raised lesions
less than 1 cm in diameter) and plaques (raised lesions greater than 1 cm in diameter)
(Langley et al., 2005).  The distribution, morphology and severity can vary on a daily
basis but the papules and plaques are generally distributed on the scalp, elbows, knees,
lumbosacral area and in body folds (Langley et al., 2005).  Histological features of
psoriatic plaques include hyperproliferative keratinocytes with improper differentiation,
immune cell infiltration and increased angiogenesis (Yu et al., 2007).
The underlying cause of psoriasis is unknown but it is regarded as a complex condition
involving genetic, immunologic and environmental factors.  Psoriasis is characterised
by epidermal hyperplasia, increased keratin expression, recruitment of T cells and
changes in the endothelial vascular system (Yu et al., 2007).  Th1 cells secrete TNFα as
part of the inflammatory response and inhibiting this process with anti-TNFα therapy
offers a highly effective treatment for psoriasis (Albanesi et al., 2007).
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However, it is clear that the disease also emanates from the skin itself and keratinocytes
can release factors that initiate, propagate and exacerbate the disease (Albanesi et al.,
2007).  This is most elegantly described by the severe combined immunodeficiency
(SCID) mouse xenograft model (Wrone-Smith and Nickoloff, 1996).  Autologous
immunocytes injected into the SCID mouse only produced psoriasis in xenograft skin
from uninvolved psoriatic patients but not normal healthy human skin (Wrone-Smith
and Nickoloff, 1996).
One of the hallmarks of psoriasis is hyperproliferation that corresponds with K6 and
K16 expression in psoriatic lesions but not normal keratinocytes in vivo (Iizuka et al.,
2004).  Furthermore, high levels of the phosphorylated mitogen-activated protein
kinases (MAPKs) ERK1/2 and p38, which are potent inducers of cell proliferation, are
also upregulated in lesional psoriatic keratinocytes (Yu et al., 2007).  Hyperproliferation
also corresponded with poor differentiation and defective barrier formation in lesional
psoriasis since K1, K10, loricrin and filaggrin were absent in the psoriatic lesion (Iizuka
et al., 2004).
Cytokines released by infiltrating Th1 cells have been shown to promote keratinocyte
hyperproliferation (Albanesi et al., 2007).  The inflammatory cytokines TNFα, IL-1, IL-
6 and IFNγ are released by Th1 cells and are elevated in lesional psoriatic skin
(Albanesi et al., 2007).  Interestingly, only IFNγ has been demonstrated to influence
psoriatic stem cell proliferation and induce plaque development in pre-lesional psoriatic
skin (Albanesi et al., 2007).  However, the role of IFNγ in modulating epidermal
hyperproliferation has recently been challenged since transgenic overexpression of IL-
22 but not IFNγ was shown to induce a psoriatic skin phenotype in mice (Wolk et al.,
2009).  In addition, Th17 cells that secrete IL-22 and IL-17 are highly expressed in
psoriatic lesions compared to AD where the Th17 response is absent (Guttman-Yassky
et al., 2008).  Psoriatic skin also demonstrated an upregulation of inducible
antimicrobial peptides, which are absent in AD, accounting for the low prevalence of
skin infections of psoriatic patients despite having a compromised immune barrier (Kim
et al., 2005).  Recently psoriasis has also been associated with comorbidities including
arthritis, diabetes, atherosclerosis and coronary heart disease (Christophers, 2007).
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These conditions have so far been attributed to persistent low-grade inflammation
influencing other tissues in the body (Christophers, 2007).
High levels of apoptosis have also been detected by TUNEL assay in the epidermis of
lesional psoriatic skin (Doger et al., 2007).  This is partly thought to be an attempt to
regulate the balance between cell proliferation and poor differentiation in lesional
psoriatic skin (Doger et al., 2007).  An aberrant patterning of apoptotic regulators was
detected in psoriatic skin, where Fas, Bcl-xL, Bax and ICAD (inhibitor of caspase 3-
related DNase) of the psoriatic involved epidermis were increased by 4.2-, 2.8-, 2.6- and
5.6-fold (Takahashi et al., 2002).  In contrast Bcl-2 was down regulated by one third
(Takahashi et al., 2002).
Consistent with observations of increased apoptosis, research has shown a disruption of
NADPH levels, a compound intimately linked to apoptosis, in psoriatic skin.  Analysis
of NADPH and NADP+ content of healthy versus psoriatic skin demonstrated an
increase in NADP+ content by approximately 75% in non-involved and involved areas
of psoriatic skin compared to normal (Hammar, 1975).  Since NADPH is a cofactor for
many enzymes in steroid synthesis, this observation suggests that steroid synthesis
could be dysregulated in psoriasis.
There is genetic evidence that links psoriatic susceptibility and poor steroid regulation.
The Coiled-Coil alpha-Helical Rod protein 1 (CCHCR1) lies within the locus of the
major psoriasis susceptibility locus PSORS1 and is regarded as a plausible candidate
gene for risk effect (Tiala et al., 2007).  CCHCR1 has been shown to regulate the
expression of StAR and is linked to the potential aberrant regulation of steroid synthesis
within psoriatic skin (Tiala et al., 2007).  The expression pattern of CCHCR1 coincides
with StAR in the basal layer of normal healthy epidermis and the CCHCR1 protein is
able to promote steroid synthesis (Tiala et al., 2007).  CCHCR1 mRNA was
downregulated two fold in non-lesional psoriatic skin with an accompanying altered
protein expression pattern lesional areas (Tiala et al., 2007).  This suggests that StAR-
mediated steroid synthesis could be dysregulated in psoriasis.
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Other research has also implicated dysregulated localised HPA axis activity in psoriasis
and AD.  A localised HPA axis has been identified in hair follicles, and both CRH and
the CRH-receptor have been identified in the epidermis (Ito et al., 2005; Kono et al.,
2001; Slominski et al., 2001).  As the end-point of the HPA axis, cortisol is able to
negatively regulate CRH expression.  If local cortisol synthesis is present in normal skin
and ablated in psoriasis, then one would predict an increase in CRH and ACTH levels
consistent with a block in HPA feedback response, as observed in congenital adrenal
hyperplasia.  Interestingly, CRH and CRH-R have been shown to be upregulated in
psoriatic and atopic dermatitis skin (Kono et al., 2001; O'Kane et al., 2006).  Synthetic
cortisol analogues are able to rescue some of the abnormal phenotype of the psoriatic
plaques and are one of the most widely prescribed drugs used to manage psoriasis.
1.2.4 Biological effects of GC on skin biology
The use of topical cortisol therapy was introduced in 1952 by Sulzberger and Witten to
treat dermatological diseases such as psoriasis, atopic and seborrheic dermatitis,
intertigo and eczema (Stojadinovic et al., 2007).  Synthetic analogues of cortisol are still
the treatment of choice for multiple skin disorders including psoriasis and atopic
dermatitis.  This powerful therapy is due to the profound effects that cortisol has on the
epidermis since this steroid can influence keratinocyte cell fate, tissue remodelling, cell
motility, differentiation and metabolism (Stojadinovic et al., 2007).
Cortisol is a potent inducer of keratinocyte differentiation.  Microarray analysis of
primary human keratinocytes demonstrated that dexamethasone (dex) induced
transcription of TGM1 (transglutaminase 1), FLG (filaggrin), CDSN (corneodesmosin),
SULT2B1 (sulfotransferase type 2 isoform B1) and KLF4 (Kruppel-like factor 4)
(Stojadinovic et al., 2007).  All these genes contribute to driving late and terminal
stages of keratinocyte differentiation.  Interestingly this study found that dex inhibited
involucrin expression while promoting filaggrin, suggesting that dex could inhibit early
stages of differentiation in preference for late and terminal differentiation (Stojadinovic
et al., 2007).  Whilst there have been studies to show that dex can induce profilaggrin
expression, other studies have shown that dex can induce rather than inhibit involucrin
expression in immortalised keratinocytes (Monzon et al., 1996).
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The role of cortisol-regulated keratinocyte differentiation was further supported by
incomplete epidermal stratification of an embryonic GR knock out mouse model (GR-/-)
(Bayo et al., 2008).  The GR-/- mouse displayed decreased filaggrin, loricrin and
involucrin protein expression which was associated with poor granulosa and squamous
cell differentiation (Bayo et al., 2008).  The down regulated expression of filaggrin was
due to decreased profilaggrin expression (Bayo et al., 2008).  In addition, fewer
desmosome connections were present and K10 and involucrin gene expression was
decreased in GR-/- mouse skin (Bayo et al., 2008).
Concomitant with the induction of differentiation, cortisol appears to inhibit
keratinocyte proliferation.  Although some genes that promote the basal keratinocyte
phenotype were induced by dex, activation of DUSP1 was observed after 1 h treatment
(Stojadinovic et al., 2007).  DUSP1 dephosphorylates MAPKs, inhibiting MAPK-
mediated induction of cell proliferation.  Furthermore, cell counting assays showed that
dex inhibited cell proliferation after 48 h (Stojadinovic et al., 2007).  In addition, dex
can inhibit the expression of K6 and K16 that are markers of hyperproliferating
keratinocytes (Stojadinovic et al., 2007).  Increased cell proliferation was also observed
in the GR-/- mouse, where BrdU incorporation was increased in the basal and uniquely
the suprabasal layers of the epidermis of the GR-/- but not GR+/+ mouse (Bayo et al.,
2008).  Cultured keratinocytes from the GR-/- mouse also had constitutively active
MAPK ERK1/2 activity (Bayo et al., 2008).
GC can also protect keratinocytes from apoptosis, whilst promoting differentiation and
inhibiting proliferation.  Primary neonatal foreskin keratinocytes co-cultured with T-
cells to mimic an eczematous state were protected from Fas-induced apoptosis
(Trautmann et al., 2000; Trautmann et al., 2001).  In addition, skin from atopic
dermatitis patients treated with prednicarbate (a synthetic cortisol analogue) exhibited
significantly reduced keratinocyte apoptosis (Trautmann et al., 2001).  Furthermore
normal primary human keratinocytes were protected from U.V. induced apoptosis when
treated with dex (Stojadinovic et al., 2007).  Microarray analysis detected the induction
of 12 anti-apoptotic genes such as IkB, BCL6, SFP1, PTK2B and BAG whereas pro-
apoptotic genes such as CASP1 and –4, BAK1, TNSF10, TSSC3, MX1 and TRADD were
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suppressed by dex (Stojadinovic et al., 2007).  In addition, the IFNγ response was
blocked by dex in primary keratinocytes predominantly by inhibiting STAT-1 activity
(Stojadinovic et al., 2007).  IFNγ released by infiltrating T-cells in chronic AD, triggers
Fas-mediated apoptosis of primary keratinocytes leading to further barrier disruption
(Leung et al., 2004).  The GR-/- mouse displayed high levels of apoptosis throughout all
the epidermis layers, whereas no apoptosis was observed in GR+/+ mouse as detected by
TUNEL assay (Bayo et al., 2008).
GC are also regarded as major anti-inflammatory agents as they suppress inflammation
and regulate innate immunity.  One of the key inducers of the inflammatory response is
NFkB.  Although GC are able to inhibit the NFkB pathway, microarray analysis did not
detect down regulation of NFkB in primary human keratinocytes (Stojadinovic et al.,
2007).  Instead dex rapidly induced the negative NFkB regulator IkB, providing a
mechanism for suppressing NFkB activity (Stojadinovic et al., 2007).  Pro-
inflammatory interleukin signalling was also down regulated as IL-1β, IL-4 receptor
and IL-11 genes were inhibited (Stojadinovic et al., 2007).
Dex also affected keratinocyte lipid metabolism by suppressing fatty acid Δ-6-
desaturase (FADS2) (Stojadinovic et al., 2007).  This is the rate-limiting enzyme in the
synthesis of long-chain polyunsaturated fatty acids such as arachidonic acid that plays a
central role in regulating inflammation.  In addition, dex has been reported to inhibit the
synthesis of some lipids that form the epidermal barrier (Elias, 2005).  Interestingly, dex
upregulated 11βHSD2 transcription by 8-14-fold in keratinocytes (Stojadinovic et al.,
2007).  Unlike 11βHSD1, this enzyme acts irreversibly to inactivate cortisol to
cortisone.  Since dex is a potent steroid that cannot be deactivated by 11βHSD1 or
11βHSD2 activity, induction of 11βHSD2 could occur in response to hyper-GC
stimulation.
Overall, dex appeared to predominantly act by suppressing gene activity rather than
inducing transcription (Stojadinovic et al., 2007).  This suggests that ligand-associated
GR functions as a monomer rather than a dimer in keratinocytes since generally GR-
monomer suppresses and GR-dimer activates gene transcription (Bayo et al., 2008).
This also compliments findings observed in GRdim/dim mouse, where GR was mutated so
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that it was unable to form a dimer (Bayo et al., 2008).  Unlike the GR-/- mouse,
keratinocyte differentiation was not impaired in the GRdim/dim mouse and the epidermis
appeared normal (Bayo et al., 2008).
The affect of cortisol on skin is most apparent in patients with Cushing’s syndrome.
Cushing’s syndrome can be caused by a pituitary adenoma that hyper secretes ACTH
inducing elevated synthesis of cortisol by the adrenals.  Alternatively, ACTH-
independent Cushing’s syndrome is caused by adrenal gland tumours, hyperplastic
adrenal glands, or adrenal glands with nodular adrenal hyperplasia that secrete high
levels of cortisol.  This disease has a profound effect on the skin, causing skin thinning,
dryness, fragility, facial acne and hirsutism.  Milder forms of skin thinning/atrophy are
observed in people suffering from psychological stress that increases cortisol circulatory
levels.  Studies in mice found that psychological stress and dex decreased lamellar body
secretion and anti-microbial peptide synthesis, accounting for increased infection-
related skin disorders of patients suffering from psychological stress.  These Cushing’s-
like effects are also observed with prolonged cortisol therapy in patients suffering hyper
proliferative skin diseases.  Thus the correct balance of cortisol level in the skin is
critical to regulating an effective epidermal barrier.
1.2.5 Steroid synthesis in the skin
Despite the effects that cortisol has on keratinocytes, local de novo synthesis of cortisol
by these cells has not been reported.  However, many regulators and enzymes required
for steroidogenesis have been detected in the epidermis.  In addition, some metabolic
studies have identified androgen and oestrogen steroid metabolism by primary human
keratinocytes (Figure 1.4).
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Figure 1.4 Steroidogenesis previously reported in keratinocytes.
Green box corresponds to androgen and oestrogen synthesis and metabolism identified
in primary human keratinocytes (Milewich et al., 1988).  Blue box corresponds to
progesterone to deoxycorticosterone metabolism identified in HaCaT immortalised
keratinocytes (Rogoff et al., 2001).  Bold font and arrows depict de novo cortisol
synthesis pathway of interest.
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There is an abundant source of cholesterol in skin as keratinocytes are capable of
synthesising cholesterol de novo (Menon et al., 1985).  Cholesterol transporters
associated with steroid synthesis have been identified in the skin.
Immunohistochemistry detected StAR protein in the epidermis, sebocytes (more
strongly in undifferentiated sebocytes), outer root sheath of hair follicles, eccrine sweat
ducts but not eccrine sweat glands and vascular tissue in whole skin sections (Chen et
al., 2006).  MLN64 protein was serendipitously detected in whole skin extracts by
western blotting when assessing for StAR expression, which was not detected in the
study (Slominski et al., 2004).  TSPO was also ubiquitously expressed throughout the
epidermis with increasing intensity as keratinocytes differentiate (Stoebner et al., 1999).
TSPO protein was distributed throughout the cytoplasm with selective expression on the
mitochondrial membranes of epidermal cells (Stoebner et al., 1999).
Co-repressors and co-activators of StAR have also been identified in skin.  DAX1, the
negative regulator of StAR, was detected by immunohistochemistry in the epidermis,
sebaceous glands, sweat glands and outer root sheath of the hair follicle with weaker
expression in the inner root sheath, matrix cells, and dermal papilla cells (Patel et al.,
2001).  Immunohistochemistry discovered the presence of the StAR transcription
activator SF-1/Ad4BP distributed with a scattered nuclear pattern throughout all
epidermal layers (Patel et al., 2001; Thiboutot et al., 2003).
There have been several studies of steroid synthesis on skin and its appendages
(Slominski et al., 2007) (Figure 1.5).  For example, the hair follicle has been reported to
express elements of the hypothalamic-pituitary-adrenal (HPA) axis and can synthesise
cortisol (Ito et al., 2005).  CYP11A1 and FDXR have been identified in  the epidermis,
hair follicles, sebaceous ducts and sebaceous glands of human facial skin, human
sebocytes, and SEB-1 sebocytes (Thiboutot et al., 2003).  The production of 17-
hydroxypregnenolone from 22-hydroxycholesterol was detected at very low levels
(0.008 pmol) in SEB-1 cells compared to normal theca cells (60-300 pmol) per 1x106
cells over 72 h (Thiboutot et al., 2003).  Melanocytes and  dermal fibroblasts have also
been shown to produce corticosterone and cortisol (Slominski et al., 2005a; Slominski
et al., 2005b; Slominski et al., 2006).
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Figure 1.5 Schematic representation of steroid enzymes and synthesis identified in
the skin.  Modified from Tobin (2006).
BV: blood vessel, D: dermis, E: epidermis, FNe: free nerve ending, HF: hair follicle
HS: hair shaft, MC: meissner’s corpuscle, NF: nerve fibre, P: pore, PC: pacinian
corpuscle, SCFL: subcutaneous fat layer, ESG: eccrine sweat gland, SC: sebaceous
gland.
HaCaT (immortalised
keratinocytes): m R N A  f o r
CYP11A1, CYP17 and CYP21,
progesterone to corticosterone
metabolism (Rogoff et al., 2001)
Primary human keratinocytes:
Androgen and oestrogen synthesis
and metabolism  (Milewich et al.,
1988).
SZ95 (immortalised sebocytes):
mRNA for CYP11A1, CYP17 and
CYP21, 17OH progesterone
synthesis (Thioboutot et al., 2003).
Total skin: mRNA for CYP11A1, CYP17 and CYP21, MLN64 (Slominski et al., 2004)
Hair follicle: responds to CRH to synthesise
POMC, ACTH and cortisol. (Ito et al., 2005).
Primary human dermal fibroblasts
stimulated with CRH produce
POMC, ACTH and can synthesise
cortisol and corticosterone (Slominski
et al., 2005a; Slominski et al., 2006)
Epidermal melanocytes stimulated
with CRH produce POMC, ACTH to
synthesise cortisol (Slominski et al.,
2005b)
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There has also been extensive research into keratinocyte steroid synthesis, although de
novo steroid synthesis was not detected, androgens and oestrogens were effectively
synthesised by the cells (Gingras et al., 2003; Milewich et al., 1988). Radiometric
analysis of steroid metabolism in cultured primary keratinocytes revealed DHEA could
be metabolised via androstenediol and testosterone to dihydrotestosterone (DHT). DHT
could be further metabolised to 5α-androstane-3β, 17β-diol or 5α-androstane-3α,17β-
diol by 3βHSD or 3αHSD respectively.  Thus demonstrating 17βHSD, 3αHSD and
3βHSD activity in keratinocytes (Milewich et al., 1988).  The synthesis of DHT is
significant because it is at least five times more potent than testosterone due to higher
affinity binding to androgen receptors (Hoffmann, 2001).
Oestrogen metabolism was also demonstrated in primary human keratinocytes.  In skin,
oestrogens can improve collagen content and quality, increase skin thickness, enhance
vascularisation, increase the rate and quality of wound healing and protect the skin from
photoaging in rats (Thornton, 2002).  Oestrone (E1) to oestradiol (E2) metabolism by
17βHSD was demonstrated by radiometric assay.  Similar to 11βHSD1, 17βHSD
catalyses a reversible reaction, regulating the amount of active E2 relative to inactive
E1.  In vitro 17βHSD preferentially converts E2 to E1 by a factor of ten relative to the
reverse reaction (Milewich et al., 1988).  It has been postulated that E1 is
unconventionally the biologically active oestrogen in skin, however it is possible that
the preference for synthesising E1 over E2 is an in vitro phenomenon (Hughes et al.,
1997).
Evidence of CYP19 aromatase activity, linking the DHEA pathway with E1/E2
metabolism is controversial, where some studies have not been able to identify the
conversion of androstenedione to E1 (Milewich et al., 1988) but others have observed
some CYP19 metabolic activity (Hughes et al., 1997).
The study by Milewich included radiometric analysis of pregnenolone and progesterone
metabolism by primary human keratinocytes.  Neither pregnenolone nor progesterone
metabolism was detected (Milewich et al., 1988).  However progesterone (but not
pregnenolone) metabolism was demonstrated in HaCaT keratinocyte immortalised cells
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but the metabolites were derivatives of deoxycorticosterone (DOC) (Slominski et al.,
2002).  Progesterone metabolism to DOC is a divergent pathway from the formation of
cortisol from progesterone, where the latter proceeds via the synthesis of 17α-
hydroxyprogesterone.  Surprisingly, the synthesis of cortisol has yet to be functionally
characterised in primary human keratinocytes.
Aims and Objectives:
To identify the expression of cholesterol transporters (StAR, TSPO and MLN64) and
the negative regulator of steroidogenesis (DAX1) in normal human epidermis.
To determine whether the expression pattern of StAR, MLN64 and DAX1 is aberrant in
skin disorders such as atopic dermatitis and psoriasis that are commonly treated with
glucocorticoids.
To examine the expression of StAR, TSPO, MLN64 and DAX1 in cultured primary
human keratinocytes.
To determine whether cultured normal primary human keratinocytes can synthesise
cortisol.
To examine the affect of dexamethasone (a glucocorticoid analogue) on cell viability,
proliferation and redox potential of cultured primary human keratinocytes.
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Chapter 2. Materials and methods
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2.1 Cell culture methods
All cell culture was performed in a laminar flow hood under aseptic conditions in
accordance with standard tissue culture technique.  All sterile disposable tissue culture
flasks, plates and dishes were purchased from Nunc (Roskilde, Denmark).  For tissue
culture all centrifuge steps were using an IEC Centra-3C Centrifuge (International
Equipment company, Dunstable, U.K.), for sample analysis a SciQuip 1 – 15 K (Sigma-
Aldrich, Poole, U.K.) centrifuge was used unless otherwise stated.
All primary human keratinocytes were used for experiments at passage 2 or less.  RM+
culture medium was modified DMEM:Ham’s F12, 3:1 (custom made, 3 parts DMEM to
1 part Ham’s F12 containing 3.8 g/L D-glucose, 3.7 g/L sodium bicarbonate and 0.082
g/L sodium pyruvate; PAA laboratories GmbH, Pasching, Austria) supplemented with
10 % foetal bovine serum (FBS, Biowest, East Sussex, U.K.), 2 mM L-glutamine (PAA
Laboratories GmbH, Pasching, Austria), 1X penicillin streptomycin (PAA laboratories
GmbH, Pasching, Austria), 5 µg/ml apo-transferrin, 0.4 µg/ml hydrocortisone, 100 pM
cholera toxin, 5 µg/ml insulin, 20 pM liothyronine, 10 ng/ml epidermal growth factor
(EGF) (all from Sigma Aldrich, Poole, U.K.).
2.1.1 Immortalised mouse 3T3 fibroblasts
NIH/3T3 mouse fibroblast cells were purchased from ATCC (Manassas, VA, U.S.A.).
This cell line was established from Swiss 3T3 cells that were originally isolated from
disaggregated embryos of Swiss mouse and deposited by G. Todaro and H. Green in
1962.  The cells were cultured in T75 or T175 cm2 polystyrene culture flasks with
Dulbecco’s Modified Eagle’s medium (DMEM) (PAA laboratories GmbH, Pasching,
Austria) with 10% bovine calf serum (CS) (ATCC, Manassas, VA, U.S.A.), 2 mM L-
glutamine (PAA Laboratories GmbH, Pasching, Austria) and 1x penicillin/streptomycin
(PAA Laboratories GmbH, Pasching, Austria) at 37°C in an humidified chamber at 5%
CO2/95% atmospheric air.  The culture medium was changed every two to three days
and the cells were passaged (section 2.1.4) before reaching 70% confluency to prevent
transformation.
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2.1.2 Mitomycin C treatment of 3T3 mouse fibroblasts
Mouse 3T3 fibroblasts were used to support the growth of primary human
keratinocytes.  This is because 3T3 fibroblasts release nutrients that encourage
keratinocyte proliferation and adhesion.  In addition, the use of mouse 3T3 fibroblasts
prevents the growth of potentially contaminating dermal fibroblasts.  However, the 3T3
fibroblasts must first be treated with mitomcyin C (Sigma-Aldrich, Poole, U.K.) which
intercalates with DNA to inhibit proliferation.  This prevents the NIH/3T3 cells from
outgrowing the keratinocytes but still allows the cells to support primary keratinocyte
growth.
When mouse fibroblast NIH/3T3 cells were 60% confluent, they were treated with
mitomycin C in the flask by removing spent media and adding 10 ml fresh media
containing 10 µg/ml mitomycin C.  The cells were incubated for 2 h at 37°C in an
humidified chamber at 5% CO2/95% atmospheric air.  The cells were then washed three
times in sterile PBS (PAA Laboratories GmbH, Pasching, Austria) to remove excess
mitomycin C and trypsinised (as described in section 2.1.10).
Mitomycin C treated NIH/3T3 cells (2x106) were seeded per T75 cm2 flask with 10 ml
complete RM+ culture medium 24 h prior to adding primary keratinocytes.  Seeding the
fibroblasts 24 h in advance of the keratinocytes greatly increased keratinocyte growth
and adhesion efficiency.  If required, 5x105 extra mitomycin C-treated 3T3 cells were
added to top-up fibroblasts in existing primary keratinocyte culture.
2.1.3 Isolation of primary human keratinocytes
Human fronto-temporal scalp skin specimens were obtained with informed consent
during routine face-lift surgery (Caucasian females over 40 years), approved by the East
London and City Health Authority Research Ethics Committee for use of human
redundant skin (T/01/034).  The skin specimens were couriered from the theatre
immediately after the operation in moist gauze.  Upon arrival, the sample was
transferred to a 100 mm cell culture dish containing complete RM+ culture medium and
stored overnight at 4°C.
66
The keratinocytes were isolated based on the Rheinwald and Green method (Rheinwald
and Green, 1975).  The dermis and connective tissue was removed from the sample by
scissors and a scalpel.  This step is crucial for efficient isolation of primary
keratinocytes since the keratinocytes can stick to fatty tissue, thus decreasing yield.  The
skin was washed twice in 1x versene (PAA Laboratories GmbH, Pasching, Austria)
then chopped into small (approximately 4 mm by 4 mm) pieces in versene using a
scalpel.  Versene is an isotonic solution containing 0.53 mM ethylenediaminetetraacetic
acid (EDTA) that chelates cationic ions which would otherwise inhibit trypsin
enzymatic activity.
The tissue was then transferred into two 50 ml centrifuge tubes containing 30 ml 0.25%
(v/v) trypsin (PAA laboratories GmbH, Pasching, Austria) and incubated at 37°C for 1
to 2 h and mixed well every 20 min.  Trypsin acts by cleaving extracellular adhesion
proteins that are responsible for cell to cell adhesion.  Keratinocytes were among the
cells that were shed into the trypsin during this process.  Trypsinisation was deemed to
be complete when the solution turned cloudy, the epidermis began to lift from the
basement membrane and the tissue pieces floated to the surface of the liquid.
The solid material was transferred to a 100 mm cell culture dish and the cloudy trypsin
solution was transferred to 50 ml centrifuge tubes and neutralised in complete RM+
culture medium in a 1:1 ratio.  Using two needles, the epidermis was then separated
from the basement membrane to release basal keratinocytes.  The tissue clumps and
cells were transferred to the centrifuge tubes containing the rest of the cells, the plate
was rinsed with RM+ culture medium which was also then transferred to the centrifuge
tubes.  The samples were shaken vigorously to release any remaining cells.  Excess skin
clumps were removed by sieving the sample and retained for fibroblast isolation (see
section 2.1.5).  Equal volumes of complete RM+ culture medium was added to the
filtrate (containing the keratinocytes) and centrifuged at 1,000 rpm for 5 min.
The supernatant was aspirated and the cell pellet was resuspended in 10 ml complete
RM+ culture medium, 10 µl of this suspension was mixed with 10 µl 0.4% (w/v) trypan
blue (Invitrogen, Paisley, UK) and the viable cells were counted using a
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haemocytometer (Weber Scientific International Ltd, Middlesex, U.K.).  Trypan blue is
selective for membrane-damaged, non-viable cells.  This is because Trypan blue has a
negatively charged chromophore, which cannot penetrate an intact cell membrane.
Therefore viable cells appeared bright and not stained when viewed under the
microscope, whereas non-viable cells were dark blue.  Cells were then washed again by
centrifugation (1,000 rpm, 5 min at room temperature) and resuspended in 10 ml
complete RM+ culture medium.  Two million freshly isolated keratinocyte cells were
seeded with 2 million mitomycin C treated 3T3 fibroblasts that had been seeded the
previous day (as described in section 2.1.2).  The cells were incubated at 37°C in a
humid environment of 90% air, 10%CO2 (RM+ culture medium sodium bicarbonate
concentration buffers to pH 7.4 at 10% CO2 rather than 5% CO2).  The culture medium
was refreshed two days later.  The cells were monitored daily with further addition of
mitomycin C treated 3T3 cells if required.
2.1.4 Passaging primary human keratinocytes
Once keratinocytes were 60 to 70% confluent, the 3T3 fibroblast layer was removed by
washing the cells twice with 5 ml PBS followed by incubating cells for 5 min in 5 ml 1x
versene (Gibco, Paisley, U.K.) at 37°C, 90% air, 10% CO2.  The progress of 3T3
detachment was monitored every few minutes by checking the cells under a Leica
DMIRB light microscope (Leica Microsystems, Germany); the flask was also tapped to
encourage detachment.  After all the fibroblasts had detached, the versene containing
3T3 fibroblasts was aspirated and the keratinocytes were washed twice with 5 ml PBS.
The keratinocytes were then incubated overnight at 37°C, 90% air, 10% CO2 in
complete RM+ culture medium.
The next morning, keratinocytes were washed twice in 5 ml PBS, once in 5 ml 1x
versene then incubated at 37°C, 90% air, 10%CO2 in 5 ml pre-warmed 0.05% (v/v)
trypsin/ 0.02% (v/v) versene (PAA laboratories GmbH, Pasching, Austria).  The
detachment process was encouraged by tapping the flasks every few minutes and was
monitored using a light microscope.  To prevent cell death of detached keratinocytes,
cells that had lifted off the flask after 5 min were transferred to a 50 ml centrifuge tube
containing 20 ml complete RM+ culture medium (containing 10% (v/v) FBS, to stop the
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trypsinisation) and 5 ml fresh pre-warmed 0.05% (v/v) trypsin/ 0.02% (v/v) versene was
added to the remaining keratinocytes in the flask.  This process was repeated several
times until all the keratinocytes were removed from the flask.
Once all the keratinocytes had been trypsinised, they were centrifuged at 1,000 rpm for
5 min at room temperature.  The supernatant was discarded and the cell pellet was
resuspended in 10 ml complete RM+ culture media and centrifuged again at 1,000 rpm
for 5 min.  The supernatant was aspirated and the cell pellet was resuspended in 10ml
complete RM+ culture medium.  Cells were counted using a haemocytometer and then
plated out for experiments, transferred to new flasks for propagation (at 2x106 per T75
cm2 flask) or cryopreserved for storage (see section 2.1.12).
2.1.5 Isolation of human dermal fibroblasts
Human dermal fibroblasts were segregated from the solid material remaining after
keratinocyte isolation.  The material was incubated overnight in a 100 mm cell culture
dish with 15 ml 0.5 mg/ml collagenase D (Roche Diagnostics GmbH, Mannheim,
Germany) in a humid environment with 90% air, 10% CO2 at 37°C.
The next day, any remaining solid material was removed by sieving the sample.  The
filtrate (containing dermal fibroblasts) was then centrifuged, 1,000 rpm, 5 min at room
temperature.  The cell pellet was resuspended in 10 ml DMEM medium and the cells
were counted using a haemocytometer. The fibroblasts were then transferred to a T75
cm2 flask and incubated overnight in 20 ml DMEM medium, 37°C, 90% air, 10% CO2..
The culture medium was refreshed every 2 – 3 days and cells were passaged according
to section 2.1.10.
2.1.6 N/TERT immortalised keratinocytes
N/TERTs are telomerase immortalised human keratinocytes first deposited by J.
Rheinwald and were obtained from the Centre for Cutaneous Research, (Institute of
Cell and Molecular Science, London, U.K.).  The cells are cultured in complete RM+
culture medium at 37°C  in a humidified environment of 90% air, 10% CO2. The culture
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medium was refreshed every 2 – 3 days and cells were passaged according to section
2.1.10.
2.1.7 HaCaT immortalised keratinocytes
HaCaT cells are spontaneously immortalised human keratinocytes that were established
by Boukamp (Boukamp et al., 1988) and obtained from the Centre for Cutaneous
Research, (Institute of Cell and Molecular Science, London, U. K.).  HaCaTs were
cultured in DMEM with 10% (v/v) FCS (Biosera Ltd., East Sussex, U.K.), 2 mM L-
glutamine, 1x penicillin/ streptomycin (both PAA Laboratories GmbH, Pasching,
Austria) and incubated at 37°C  in a humidified environment of 95% air, 5% CO2. The
culture medium was refreshed every 2 – 3 days and cells were passaged according to
section 2.1.10.
2.1.8 H295R immortalised adrenocortical cells
H295R cells (ATCC, Manassas, U.S.A.) were adapted from the H295 pluripotent
adrenal carcinoma cell line that was established by A.F. Gazdar from an adrenal
carcinoma.  Whereas H295 cells grow in suspension, H295R cells are an adherent cell
line.  Both cell lines have retained the ability to synthesise androgens.  H295R cells
were cultured in 35 ml DMEM:F12 medium supplemented with 2.5% (v/v) Nu-Serum I
and 1x ITS+ premix (BD Biosciences, Belgium) which contains 0.00625 mg/ml insulin;
0.00625 mg/ml transferrin; 6.25 ng/ml selenium; 1.25 mg/ml bovine serum albumin;
0.00535 mg/ml linoleic acid.  The cells were incubated in a humidity chamber at 5 %
CO2, 95% air, 37°C.  Culture medium was refreshed every 2 – 3 days and cells were
passaged according to section 2.1.10.
2.1.9 JEG-3 human choriocarcinoma cells
JEG-3 human choriocarcinoma cells were obtained from Professor V.K Chatterjee,
(Department of Medicine, University of Cambridge, Cambridge, U.K.).  The cells were
cultured in DMEM (Sigma-Aldrich, Poole, U.K.) supplemented with 10% (v/v) FBS
70
(Biosera, East Sussex, U.K.) and 1% (v/v) L-glutamine at 37°C, 95% air, 5% CO2 in a
humidity chamber. The culture medium was refreshed every 2 – 3 days and cells were
passaged according to section 2.1.10.
2.1.10 Passaging cells
Cells that were not grown on a feeder layer were passaged when they were 70%
confluent by washing once in 5 ml PBS, once in 5 ml versene and incubating for
approximately 5 min in 5 ml 0.05% (v/v) trypsin/ 0.02% (v/v) versene until all the cells
had detached.  The trypsinisation process was monitored under a Leica DMIRB light
microscope and stopped by adding 5 ml culture medium containing 10% (v/v) serum
(FBS or CS depending on cell type).  The cells were centrifuged at 1,000 rpm, for 5 min
at room temperature.  The supernatant was aspirated, the cell pellet resuspended in 10
ml culture medium and the cells counted using a haemocytometer (see section 2.1.11).
Cells were then seeded for experiments, propagated at 10-20% of their original density
or cryopreserved.
2.1.11 Cell counting
After trypsinisation, cells (10µ l of cell suspension) were counted using a
haemocytometer (Weber Scientific International Ltd, Middlesex, UK).  To count live
cells, a 10 µl aliquot of cells was diluted 1:2 with trypan blue (Sigma-Aldrich, Poole,
U.K.) and 10 µ l of this solution was deposited on the haemocytometer.  The
haemocytometer grid arrangement had four primary squares, each containing sixteen
squares.  The cells in one of the major squares were counted, those that lay inside the
square or touched the top or left boundary were included; those that lay outside the
square, or touched the lower or right boundary were excluded.  Cells in another major
grid were counted and an average of the two counts was taken.  The average count was
then multiplied by 1x104 to give the value of cells per ml.  If the cells had been counted
in trypan blue for cell viability (section 2.3), then the average count was multiplied by
two to allow for the 1 in 2 trypan blue to cell dilution factor.
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2.1.12 Cryopreservation
Trypsinised cells were centrifuged at 1,000 rpm at room temperature and resuspended
in freezing medium (10% (v/v) diethyl sulphoxide (DMSO) (Fisher, Leicestershire,
U.K.), 90% (v/v) complete culture medium containing serum) to a concentration of
2x106 cells per ml.  DMSO was included in the freezing medium to prevent the
formation of crystals during the freezing process that would otherwise lyse the cells.
The cell suspension (1ml) was transferred into each cryovial and frozen slowly to
–80°C.  After 1 – 3 days, the cell vials were transferred and stored in liquid nitrogen
until required.
When cryopresereved cells were required, the vial was removed from liquid nitrogen
storage and thawed rapidly at 37°C in a waterbath.  As soon as the cell aliquot had
thawed, the cells were transferred to a 50 ml centrifuge tube containing 10 ml complete
culture medium (relevant to the cell type) and centrifuged at 1,000 rpm for 5 min to
remove the DMSO.  The supernatant was aspirated and the cell pellet was resuspended
in complete culture medium and cells were seeded in T75 cm2 flasks at 2 million per
flask.
2.1.13 NEB-1 organotypic raft preparation
Frozen sections of NEB-1 organotypic rafts were kindly donated by Dr. Anna Thomas
(Institute of Cell and Molecular Science, London, U.K.) and prepared as follows:
Glycerol preserved skin was obtained from the European skin bank in Denmark. The
skin was washed three times in PBS and incubated in PBS containing an antibiotic mix
(600units/ml penicillin-G, 600 µg/ml streptomycin sulphate, 250 µg/ml gentamycin and
2.5 Mg/ml of fungizone; all from Sigma-Aldrich, Poole, U.K.) at 37ºC for 10 days.
Following incubation, the epidermis was removed from the dermis with a pair of sterile
forceps.  The dermis was cut into 1.5 x 1.5 cm squares and placed into a well of a 6 well
dish with a sterilised stainless steel ring placed on the reticular side of the dermis.
Human dermal fibroblasts (2x105)  were seeded on to the DED in the ring in RM+
culture medium.  Additional RM+ culture medium was added around the ring to keep
the DED moist.  The preparation was incubated overnight in a humidity chamber at
10% CO2, 90% atmospheric air, 37°C.
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Following incubation, the medium and ring was removed from the DED, the DED was
inverted and the ring was placed on the papillary surface of the DED.  NEB-1
immortalised keratinocytes (2x105)  were seeded on to the DED within the ring in RM+
culture medium. Additional RM+ culture medium was added around the ring to keep
the DED moist.  The preparation was incubated overnight in a humidity chamber at
10% CO2, 90% atmospheric air, 37°C. The ring was removed and the preparation was
incubated for a further 2 days submerged in RM+ culture medium in a humidity
chamber at 10% CO2, 90% atmospheric air, 37°C.
Following this incubation, the DED was raised and placed on steel grids with medium
underneath so that the keratinoycte cultures were at an air-liquid interface.  The raft
preparation was incubated in a humidity chamber at 10% CO2, 90% atmospheric air,
37°C for a further 14 days with the media changed every 2 – 3 days. After this time, the
organotypic raft preparation was cryopreserved and cut into sections for histological
analysis.
2.2  Immunofluorescence histochemistry and immunofluorescence cytochemistry
Immunofluorescence histochemistry (tissue) and cytochemistry (cells) is a technique
using a fluorescent secondary antibody to detect a primary antibody bound to an antigen
(i.e. protein of interest) within a tissue or cell sample.  This identifies the expression
pattern of a specific protein within the sample.
All primary and secondary antibodies were diluted in 1% (w/v) BSA TBS-T (50 mM
Tris base, 140 mM NaCl, 0.1% (v/v) Tween-20, pH 7.6) and all incubations were
carried out in a humidified chamber at room temperature.
2.2.1 Sample preparation and method for immunofluorescence histochemistry
Immunofluorescence histochemistry was used to determine the protein expression
pattern of MLN64, DAX1, TSPO and StAR in human skin sections.  Skin from normal
facelift and breast reduction patients were cut into 1 cm x 1 cm pieces, transferred into
cryovials and snap frozen in liquid nitrogen for 1 h.  Psoriatic skin sections were a kind
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gift from Dr. Paul Bowden (Cardiff University, Cardiff, U.K.) and Dr. Catherine
Harwood (Institute of Cell and Molecular Science, London, U.K), atopic dermatitis skin
sections were donated from Dr. Wei-Li Di (Institute of Child Health, London, U.K.) and
Professor Arne Akbar (UCL, London, U.K.).  Professor David Kelsell (Institute of Cell
and Molecular Science, London, U.K) generously gave sections from harlequin
ichthyosis biopsies.
Samples were stored at –80°C prior to being cut into sections by Alex Brown (ICMS
Pathology, London, U.K.).  Skin biopsies were cut by cryostat into 6 µm sections and
mounted onto Superfrost ® Plus microscope slides (Knittel Glaser, Germany) and
stored at –80°C.  When required, skin sections were removed from –80°C storage and
allowed to thaw for 20 min at room temperature.  The tissue sections were then fixed by
submerging in ice-cold methanol: acetone 1:1 (v/v) for 10 min.
Tissue sections were washed three times in TBS-T for 5 min per wash before incubating
in blocking solution, 1% (w/v) bovine serum albumin (BSA) (Sigma-Aldrich, Poole,
U.K.)  TBS-T, for 30 min.  The blocking solution was removed and 20 µl of primary
antibody (either rabbit polyclonal StAR (10 µg/ml), rabbit polyclonal MLN64 (10
µg/ml), chicken polyclonal PBR (5 µg/ml) all from Abcam, Cambridge, U.K. or rabbit
polyclonal DAX1 (K-17) (2 µg/ml) (Santa Cruz, California, U.S.A) was added to the
sections for 1 h.
Samples were washed three times for 5 min per wash in TBS-T and then incubated for 1
h in the dark with 200 µ l Alexa Fluor ® 488 goat anti-rabbit IgG (H+L) 2 µg/ml
(Molecular Probes, Invitrogen, Paisley, UK) with the exception of samples treated with
PBR antibody, which were incubated with 200 µl Alexa Fluor ® 594 goat anti-chicken
IgG (H+L) 2µg/ml (Molecular Probes, Invitrogen, Paisley, UK).  The sections were
washed once in TBS-T and then once in TBS (without Tween-20, since Tween-20 can
auto-fluoresce) for 5 min per wash.  Samples were then washed in TBS containing 2
µg/ml 4’,6-diamidion-2-phenylindole dihydrochloride (DAPI)  (Sigma-Aldrich, Poole,
UK).
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The skin sections were sealed with a drop of fluorescent mounting medium
(DakoCytomation, Glostrup, Denmark) and a 22 mm x 22 mm coverslip (VWR,
Leicestershire, U.K.) and allowed to set overnight in the dark at 4°C. The fluorescent
signal was observed using a Carl Zeiss Laser Scanning Microscope LSM 510 META
(Carl Zeiss Ltd., Hertfordshire, U.K.) and analysed using Zeiss LSM Image Browser
software (Carl Zeiss Ltd., Hertfordshire, U.K.).
2.2.2 Sample preparation and method for immunofluorescence cytochemistry
Primary keratinocytes (5x104) were seeded onto sterile 19 cm diameter coverslips
(VWR, Leicestershire, U.K.) that had been pre-seeded with mitomcycin C-treated 3T3
mouse fibroblasts (5x104) 24 h earlier in complete RM+ culture medium.  Keratinocytes
were incubated for a period of time as indicated in the figure legend of the specific
experiment, 24 h prior to analysis the fibroblasts were removed with 1x versene
(described in section 2.1.4) and the keratinocytes were incubated overnight in complete
RM+ culture medium.  Cells were then washed twice in PBS and fixed and
permeabilised in ice-cold methanol:acetone (1:1 (v/v); Fisher, Leicestershire, U.K) for 2
min.
Cells were washed three times in TBS-T for 5 min per wash before incubating in
blocking solution, 1% (w/v) BSA (Sigma-Aldrich, Poole, U.K.)  TBS-T, for 30 min.
The blocking solution was removed and 20 µl of primary antibody either rabbit
polyclonal StAR (10 µg/ml), rabbit polyclonal MLN64 (10 µg/ml), chicken polyclonal
PBR (5 µg/ml) (all Abcam, Cambridge, U.K.) or rabbit polyclonal DAX1 (K-17) (2
µg/ml; Santa Cruz, California, U.S.A) was added to the sections for 1 h.
Cells were washed three times for 5 min per wash in TBS-T and then incubated for 1 h
in the dark with 200 µl Alexa Fluor ® 488 goat anti-rabbit IgG (H+L) 2 µg/ml
(Molecular Probes, Invitrogen, Paisley, UK), with the exception of samples treated with
PBR antibody, which were incubated with 200 µl Alexa Fluor ® 594 goat anti-chicken
IgG (H+L) 2µg/ml (Molecular Probes, Invitrogen, Paisley, UK).  Cells were washed
once in TBS-T and then once in TBS (without tween, since tween can auto-fluoresce)
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for 5 min per wash.  Samples were then washed in TBS containing 2 µg/ml 4’,6-
diamidion-2-phenylindole dihydrochloride (DAPI)  (Sigma-Aldrich, Poole, UK).
The coverslips (that the cells were seeded on) were inverted and mounted with a drop of
fluorescent mounting medium (DakoCytomation, Glostrup, Denmark) onto Superfrost
® Plus microscope slides (Knittel Glaser, Germany) and allowed to set overnight in the
dark at 4°C.  The fluorescent signal was observed using a Carl Zeiss Laser Scanning
Microscope LSM 510 META (Carl Zeiss Ltd., Hertfordshire, U.K.) and analysed using
Zeiss LSM Image Browser software (Carl Zeiss Ltd., Hertfordshire, U.K.).
2.3 Protein isolation
Protein was isolated from cells and whole skin to be used for western analysis.  Two
methods, one using a RIPA buffer and the other a urea buffer, were used to isolate
protein as outlined below.
2.3.1 Total protein isolation
Cells seeded in 6 well plates were washed twice in ice-cold 1 ml PBS (PAA laboratories
GmbH, Pasching, Austria) and then incubated in ice-cold 300 µl RIPA buffer (Tris 50
mM, pH 7.3, NaCl 150 mM, SDS 0.1% (w/v), NP-40 0.1% (v/v) (all from Sigma-
Aldrich, Poole, U.K.) and 1X Complete Protease Cocktail Inhibitor (Roche Diagnostics
GmbH, Mannheim, Germany) for 20 min.  The protein was harvested in 1.5 ml
microfuge tubes and pulse sonicated twice for 3 sec (Vibra Cell, Sonic and Material
Incs, Danbury, CT, USA).  The samples were then centrifuged for 5 min, 4°C, 10,000 x
g to remove cell debris.  The protein concentration of the supernatant was determined
using a Bradford assay (section 2.4) and samples were stored at –80°C.
Alternatively, cells seeded in 6 well plates were washed twice in ice-cold 1 ml PBS and
then incubated in 300 µl of 8 M urea buffer (8 M urea, 1 M thiourea, 0.5% (w/v) 3-[(3-
cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS), 50 mM
dithiothreitol (DTT), 24 mM spermine) for 5 min at room temperature.  This is a strong
buffer which rapidly lyses the cells and denatures all protein.  The sample suspension
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was harvested in 1.5 ml microfuge tubes and centrifuged at 10,000 x g for 5 min at 4°C.
The supernatant (containing protein isolate) was transferred to fresh microfuge tubes
and protein concentration was determined by Bradford assay (section 2.4) and samples
were stored at –80°C if they were not used immediately.
2.3.2 Total protein isolation from human skin
Human fronto-temporal scalp skin specimens were obtained with informed consent
during routine face-lift surgery (all Caucasian females over 40 years).  The skin was cut
into 10 x 5 mm pieces, individually transferred to cryovials and snap frozen in liquid
nitrogen.  A frozen skin section was then smashed to a powder using a metal pestle and
mortar pre-chilled with liquid nitrogen.  The skin powder was scraped up and
transferred to a 5 ml bijoux tube (Fisher, Leicestershire, U.K.) containing 1 ml of RIPA
buffer.  The sample was homogenised on ice for 1 min at speed 5 using an Ultra-Turrax,
x120 Status homogeniser.  The sample was left in RIPA buffer for 20 min on ice, then
sonicated for 3 x 3 sec pulses and centrifuged for 10 min at 10,000 x g at 4°C.  The
supernatant, containing the protein was transferred to a fresh 1 ml microfuge tube and
stored at –80°C before being analysed for the protein concentration and used for
western blot analysis (see Section 2.5).
2.3.3 Mitochondrial protein enrichment
Cells (JEG3, dermal fibroblasts, HaCaTs, primary human keratinocytes) were seeded at
1.5x106 in 10 ml of their respective culture medium in 100 mm diameter cell culture
dishes and incubated overnight in a humidity chamber, 37°C, 90% air, 10% CO2.  The
media was refreshed and cells were treated with or without 1 mM dibutyryl cAMP
(D0260, Sigma, Poole, UK) for 4 h 30 min.
Cells in 100 mm diameter Petri dishes were washed twice in ice cold 5 ml PBS and then
harvested in 300 µl mitochondrial enrichment buffer pH 7.4 (20 mM HEPES-KOH, 10
mM KCl, 1.5 mM MgCl2, 0.5 mM EGTA, 0.5 mM EDTA, 1M DTT) supplemented
with 250 mM sucrose and 1X complete protease cocktail inhibitor (Roche Diagnostics
GmbH, Mannheim, Germany).  Cells were homogenised with approximately 60 stokes
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of a 1 ml Dounce glass homogeniser with a tight pestle (Wheaton, Fisher Scientific,
Leicestershire, UK).  To remove the nuclear fraction and unlysed cells, the homogenate
was centrifuged at 600 x g at 4°C for 5 min.  The supernatant was transferred to a fresh
tube and re-centrifuged at 600 x g at 4°C for 5 min.  The supernatant was transferred to
a fresh tube and centrifuged at 10,000 x g for 30 min at 4°C.  The pellet, containing
enriched mitochondrial  protein, was resuspended in 50 µl mitochondrial enrichment
buffer supplemented with 1X complete protease cocktail inhibitors but not sucrose.  The
protein concentration was determined using a BCA kit and stored at –80°C.
2.4 Protein quantification
The concentration of isolated protein was estimated using a Bio-Rad protein assay kit
(Bio-Rad Laboratories, Hertfordshire, UK) based on the Bradford assay (Bradford,
1976).  A protein standard curve was generated using 0.1 to 0.8 mg/ml BSA that had
been reconstituted in the same buffer as the samples to be analysed.   Protein standard
or sample (10 µl) was pipetted in triplicate into well of a clear, flat bottomed 96-well
plate (Fisher, Leicestershire, U.K.).  To this, 200 µl of Bio-Rad protein assay solution
was added and mixed well.  The intensity of the solution colour in each well, which was
proportional to the amount of protein, was measured using a spectrophotometer plate
reader measuring absorbance at 600 nm (Victor 1420 Multi-Label Counter, Wallac,
PerkinElmer, MA, USA).  A standard curve was plotted (intersecting the y-axis at 0
since the value of the blank was subtracted from all readings) and the protein
concentration of each sample was calculated according the equation of the straight line
from the standard graph (Figure 2.1).
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Figure 2.1 Example of a Bio-Rad Bradford assay protein standard curve.
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2.5 Western blotting
Western blotting can be used to estimate the expression of a specific protein in cell
lysates.  Protein isolated from the cell is first denatured and then separated according to
size by sodium dodecyl sulphate (SDS) gel electrophoresis.  SDS applies a negative
charge to any positive ion on the protein, thus allowing the protein to be transferred to a
nitrocellulose membrane by electrophoresis.  A specific protein is then detected on the
membrane using a primary antibody, which a secondary antibody that is coupled to
horseradish peroxidase (HRP) binds to.  Bound secondary antibody can be detected by
luminescence due to a chemical reaction with HRP upon the addition of ECL plus (GE
Healthcare, Buckinghamshire, U.K.).  The resulting light emission is detected using an
autoradiography film.
2.5.1 Sodium dodecyl sulphate - polyacrylamide gel electrophoresis
Protein samples were adjusted to 1 mg/ml protein according to the outcome of the
Bradford assay.  Protein was reduced and denatured by adding 1:4 Laemmli buffer
(Invitrogen Ltd, Paisley, U.K.), 2% (v/v) β-mercaptoethanol (VWR, Leicestershire,
U.K.) and heating for 5 min at 95°C.  A NuPAGE 10% Bis-Tris gel (Invitrogen,
Paisley, U.K.) was assembled into a Novex Mini-cell gel electrophoresis tank
(Invitrogen, Paisley, U.K.) according to manufacturers instructions and the tank was
filled with 1X MOPS Running buffer (Invitrogen, Paisley, U.K.).  Equal protein
concentration and volume of each sample was loaded into the wells of the gel.  In
addition 10 µl of SeeBlue Plus Two protein standard molecular weight marker
(Inivtrogen, Paisley, U.K.) was loaded into one well of the gel.  The proteins were
separated at 200 V for 50 min until the dye front reached the base of the gel.
2.5.2 Western blotting
Proteins were transferred from the polyacrylamide gel to a 45 micron Hybond C Extra
nitrocellulose membrane (GE Healthcare, Buckinghamshire, U.K.) in 1X NuPAGE
transfer buffer (Invitrogen, Paisley, U.K.) including 10% (v/v) methanol (Fisher,
Leicestershire, U.K.) at 150 V, 250 mA for 90 min at 4°C.  The membrane was
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removed and immediately immersed in blocking solution and incubated according to
table 2.1.  The success of the transfer was estimated by checking the protein marker was
present on the membrane.  The membrane was then incubated in 10 ml of primary
antibody (see Table 2.1 for the conditions of each antibody) on a rocking platform.
The membrane was washed three times for 5 min in TBS-T and then transferred into 10
ml 0.05 mM swine anti-rabbit HRP secondary antibody (DakoCytomation, Glostrup,
Denmark) (Table 2.1), unless the primary antibody was mouse anti-β-actin, for which
10 ml 0.05 mM goat anti-mouse HRP secondary antibody (DakoCytomation, Glostrup,
Denmark), or chicken anti-PBR (peripheral benzodiazepine receptor also known as
TSPO), for which 10 ml 2 µg/ml goat anti-chicken IgY HRP secondary antibody
(Abcam, Cambridge, U.K.) was used.  All secondary antibodies were diluted 1:1000 in
the same buffer as the primary antibody and incubated on a rocking platform for 1 h at
room temperature.  After 1 h the membrane was washed three times for 5 min in TBS-
T.  The protein of interest was detected by covering the membrane in 1 ml ECL-Plus
chemiluminesence solution (GE Healthcare, Buckinghamshire, U.K.).  The blot was
wrapped in cling film.  The resulting luminescence was observed by exposing the blot
to light-sensitive Hyperfilm (GE Healthcare, Buckinghamshire, U.K.) for 1 – 30 min,
depending on signal intensity, in a dark room and the film was developed using a
Hyperprocessor automatic Autoradiography Film Processor (GE Healthcare,
Buckinghamshire, U.K.).
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Protein Blocking
conditions
Primary antibody supplier
and concentration or
dilution
Primary antibody dilution
buffer and incubation
StAR 5% milk TBS-T,
overnight, 4°C
StAR (ab3433, Abcam,
Cambridge, UK) 1 µg/ml
1% milk TBS-T, overnight,
4°C
DAX1 5% milk TBS-T,
overnight 4°C
DAX1 (sc-841, Santa Cruz)
1 µg/ml
1% milk TBS-T, 1 h, RT
MLN64 5% milk TBS-T,
overnight 4°C
MLN64 (ab3478, Abcam,
Cambridge, UK) 1 µg/ml
1% milk TBS-T, 1 h, RT
TSPO 5% milk TBS-T,
overnight 4°C
PBR (ab37884, Abcam,
Cambridge, UK) 5 µg/ml
1% milk TBS-T, 1 h, RT
DUSP1 5% milk TBS-T,
overnight 4°C
MKP1 (sc-1102, Santa
Cruz) 1 µg/ml
1% milk TBS-T, 1 h, RT
ERK 1/2 5% BSA TBS-
T, 1 h, RT
p44/42 MAP kinase 1:1,000
(Cell Signalling, Danvers,
MA. U.S.A.)
5% BSA TBS-T, overnight,
4°C
pERK
1/2
5% BSA TBS-
T, 1 h, RT
phospho- p44/42 MAP
kinase, 1:2,000 (Cell
Signalling, Danvers, MA.
U.S.A.)
5% BSA TBS-T, overnight,
4°C
pMEK 5% BSA TBS-
T, 1 h, RT
phospho MEK 1:1,000 (Cell
Signalling, Danvers, MA.
U.S.A.)
5% BSA TBS-T, overnight,
4°C
β-Actin 5% milk TBS-T,
1 h RT
β-Actin, 1:10,000 (Sigma-
Aldrich, Poole, UK)
1% milk TBS-T, 1 h RT
Table 2.1 Antibodies and conditions for western blotting.
All primary antibodies listed are rabbit polyclonal antibodies, except for β-actin which
is a mouse monoclonal antibody and TSPO which is a chicken polyclonal antibody.
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2.5.3 Western blot membrane stripping and reprobing
Western blots can be reprobed for another protein of interest by stripping the membrane
of primary and secondary antibodies and repeating the detection step with different
antibodies.  Thus a housekeeping gene, such as β-actin, can be detected to check equal
loading between samples or, in the case of mitogen activated protein kinases (MAPK),
phosphorylated versus total protein levels can be compared.
Membranes were stripped by incubation with stripping buffer (62.5 mM Tris pH 6.8,
2% (w/v) SDS, 100 mM β-mercaptoethanol, all from Sigma-Aldrich, Poole, U.K.) for
30 min at 60°C in an oven on a rocking platform.  The blot was then washed three times
in TBS-T for 5 min at room temperature and then blocked and re-probed with primary
and secondary antibody according to Section 2.5.2 and Table 2.1.
2.6 Reverse transcriptase - polymerase chain reaction
Reverse transcriptase-polymerase chain reaction (RT-PCR) is a method to detect genes
that are synthesised into RNA in cells or tissue.  Extracted RNA is converted into DNA
by reverse transcriptase.  The presence of a specific DNA sequence is then targeted and
amplified by PCR with the aid of oligonucleotide primers that are complementary to the
flanking DNA regions of interest.  The PCR product is separated by size by running the
sample on an ethidium bromide-agarose gel that can be visualised with ultra violet
(U.V.) light.  If the size of the PCR product correlates with the expected size, the
product can be extracted and authenticated with DNA sequencing.
2.6.1 Total RNA extraction from cultured cells
Cells were trypsinised as described in section 2.1.4 or 2.1.10 (depending on whether
cells were cultured with 3T3 feeders) and centrifuged for 5 min at 1,000 rpm at room
temperature.  The cells were then washed twice in ice cold PBS and centrifuged for 5
min at 1,000 rpm.  The work surface and pipettes were prepared with RNase Zap
(Ambion, Cambridgeshire, U.K.) to remove enzymes that digest RNA.  RNA extraction
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was carried out using an RNeasy Mini Kit (Qiagen, West Sussex, U.K.).  All
centrifugation steps were at 13,000 rpm for 15 sec at room temperature unless stated
otherwise.  All flow-throughs were also discarded unless stated otherwise.
The supernatant was aspirated and the cell pellet was resuspended in 600 µl RLT buffer.
The RLT buffer acts to lyse the cells and contains guanidine isothiocyanate, which
deactivates RNase enzymes.
The cell lysate was transferred and passed through a QIAshredder Mini Spin column by
centrifugation at 13,000 rpm for 2 min.  The flow through solution was retained and
mixed with 600 µl of 70% (v/v) ethanol.  The sample was then transferred into an
RNeasy Mini Spin column and RNA (and DNA) within the sample was adhered to the
column by centrifugation.
RW1 wash buffer (350 µl) was added and the column was centrifuged.  Genomic DNA
was digested by adding 80 µl 1:5 (v/v) DNase: RDD buffer (RNase Free DNase Set,
Qiagen, Crawley, West Sussex, U.K.) to the column and incubating for 15 min at room
temperature.
The digested DNA was washed from the column with 350 µ l RW1 following
centrifugation.  The column was then washed with 700 µl RPE buffer (part of RNeasy
Mini kit) and centrifuged.  The column was washed again with 500 µl RPE buffer and
centrifuged for 2 min at 13,000 rpm.  Finally, the column was transferred to a fresh
RNase-free microfuge tube and the RNA was eluted by addition of 30 µl RNase free
water to the column followed by centrifugation at 10,000 rpm for 1 min.  The RNA was
stored at -80°C until required.
2.6.2 RNA quantification
Isolated RNA was quantified using a NanoDrop ND-1000 Spectrophotometer (Labtech
International Ltd, East Sussex, U.K.).  The instrument was blanked against 1.5 µl
diethyl-pyrocarbonate (DEPC)-treated water (Sigma-Aldrich, Dorset, U.K.).  The
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sample RNA content and quality was estimated from a 1.5 µ l aliquot on the
spectrophotometer measured at 260 to 280 nm.
2.6.3 Reverse transcriptase complementary DNA synthesis
Reverse transcriptase is an enzyme that transcribes single-stranded RNA into double-
stranded DNA.  Reverse transcriptases were first identified from tumour viruses by
Temin and Baltimore in 1970 (Baltimore, 1970; Temin and Mizutani, 1970).
Complimentary DNA synthesis from the RNA sample was achieved using SuperScript
III First-Strand Synthesis SuperMix (Invitrogen, Paisley, U.K.).  Firstly, the following
reagents (10 µl 2x RT Reaction Mix, 2 µl RT Enzyme Mix, DEPC-treated water (all
from Invitrogen, Paisley, U.K.) and 1 µg of sample RNA (final volume 20 µl) were
mixed together and incubated for 10 min at 25°C.  The tube was then incubated for 30
min at 50°C.  The cDNA synthesis reaction was terminated by heating the sample to
85°C for 5 min, followed by chilling on ice.  Finally, 1 µl (2 units) of E. coli RNase H
was added to the mix and incubated for 20 min at 37°C to remove the RNA template.
The cDNA sample was stored at –20°C until required.
To generate two negative controls for PCR, the reverse transcriptase reaction was
carried out as described above but with the omission of (a) sample RNA or (b) RT
Enzyme Mix.
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2.6.4 Primer selection and sequences
Sense and anti-sense oligonucleotide primer sequences for StAR were designed using
Primer 3 using the StAR gene sequence from the ensembl database
(http://www.ensembl.org/index.html).  Primer sequences for GAPDH were chosen from
a previously published paper (Alexander and Klibanski, 1994).  All primers were
checked for non-specific binding using NCBI genebank BLAST analysis
(http://blast.ncbi.nlm.nih.gov/Blast.cgi).
StAR Primer sequences:
Sense strand: 5’- GCATCCTTAGCAACCAAGAG-3’
Anti-sense strand: 5’- CCAGCTCGTGAGTAATGAATG-3’
Predicted PCR product size: 333 bp
GAPDH Primer sequences:
Sense strand: 5’-GAGCCACATCGCTCAGAC-3’
Anti-sense strand: 5’-TTCTCCATGGTGGTGAAG-3’
Predicted PCR product size: 340 bp
2.6.5 Polymerase chain reaction
Polymerase chain reaction (PCR) was conducted by combining 2 µl of cDNA with 0.5
µl of sense primer, 0.5 µl of anti-sense primer, 44 µl 1.1X ReddyMix PCR Master Mix
(ABgene, Epsom, Surrey, U.K.) and 3 µl DEPC-treated water in a PCR tube and
subjecting the sample to thermal cycling conditions as described in Table 2.2 and 2.3.
The 1.1x ReddyMix PCR Master Mix contained 1.25 units of Taq DNA polymerase, 75
mM Tris HCl (pH 8.8 at 25°C), 20 mM (NH4)2SO4, 1.5 mM MgCl2, 0.01% Tween 20,
0.2 mM deoxyadenosine 5’-triphosphate (dATP), 0.2 mM deoxycytosine 5’-
triphosphate (dCTP), 0.2 mM deoxyguanine 5’-triphosphate (dGTP), 0.2 mM
deoxythymine 5’-triphosphate (dTTP), an inert red dye and gel loading precipitant.
Thus the 1.1x ReddyMix was a simple one-step master mix for PCR and also allowed
the PCR product to be loaded directly onto an agarose gel without further addition of a
loading dye.
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Two negative controls (RNA-free and reverse transcriptase enzyme-free) generated
from the reverse transcriptase reaction (see Section 2.6.3) were concurrently subjected
to the PCR.  cDNA from H295R immortalised adrenal cells was used as a positive
control for StAR. Equal loading was confirmed by GAPDH.
Stage Function Temperature (°C) Time Number of cycles
1 Initial denaturation 95 60 sec 1
Denaturation 95 15 sec
Annealing 56 30 sec
2
Extension 72 30 sec
30
Final extension 72 5 min3
Hold 4 Indefinite
1
Table 2.2 Conditions used during thermal cycling for StAR PCR.
Stage Function Temperature (°C) Time Number of cycles
1 Initial denaturation 94 60 sec 1
Denaturation 94 60 sec
Annealing 55 60 sec
2
Extension 72 60 sec
35
Final extension 72 5 min3
Hold 4 Indefinite
1
Table 2.3 Conditions used during thermal cycling for GAPDH PCR.
2.6.6 Agarose gel electrophoresis
PCR products (10 µl) were loaded on to a 1% (w/v) agarose-tris-acetate ethylediamine-
tetra-acetic acid (TAE) gel containing 1 mg/ml ethidium bromide (Sigma-Aldrich,
Poole, U.K.) in a gel tank with TAE running buffer.  Ethidium bromide intercalates with
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DNA, the intercalation causes the ethidium bromide molecule to strongly fluoresce
when exposed to U.V. light.  This allows for the location of DNA to be visualised on
the gel under U.V. light.  The samples were run against 10 µl Trackit 1 kB DNA ladder
(Invitrogen, Paisley, U.K.), to estimate the product size, and separated by
electrophoresis for 30 min at 120 V.  Finally the PCR products were visualised by U.V.
light and the gel was photographed using a Multi Image Light Cabinet (Alpha Innotech
Corporation, San Leandro, CA, U.S.A.).
2.6.7 DNA sequencing
If the PCR product matched the predicted size, the remaining PCR sample (100 ng
minimum) and StAR primers (10 pmol of each) were sent to the Genome Centre (Barts
and The London, Charterhouse Square, London, U.K.) for PCR purification and
sequencing to determine the authenticity of the product.
2.7 Pregnenolone radioimmunoassay
Radioimmunoassay (RIA) is an extremely sensitive method for detecting the
concentration of a specific substance such as a peptide or non-peptide hormone, drug,
vitamin, cyclic nucleotide, virus or protein.  The assay was developed by Rosalyn
Yalow, who observed that intravenously administered 131I-labelled insulin radioactivity
disappeared more slowing from plasma of patients that had received insulin treatment
compared to those that had not (Yalow and Berson, 1959).  Yalow suspected that this
was due to increased binding of 131I-labelled insulin to antibodies which had been
produced in response to exogenous insulin treatment (Yalow, 1977).  Yalow developed
the observation into an assay that allowed concentrations of plasma insulin and other
molecules to be quantified, even at low (pmole) concentrations, and later was awarded
the Nobel Prize for her efforts (Yalow, 1977).  The technique was then developed to
measure steroid molecules.  This revolutionised endocrinology because of its increased
specificity and sensitivity over previous analytical methods (Hillier, 2007).
RIA quantitatively analyses pregnenolone synthesis by assessing competitive binding of
cold pregnenolone (endogenous steroids released by cells) against radiolabeled
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pregnenolone to a pregnenolone antibody.  Any non-bound steroid is removed with
dextran-coated charcoal.  Thus the detected radioactive signal correlates inversely to the
amount of pregnenolone synthesised by the cells.  The concentration of pregnenolone
released by the cells is quantified against a standard curve generated using known
concentrations of cold pregnenolone.
2.7.1 Cell preparation for RIA
For RIA, primary keratinocytes (passage 1) were plated at 2x105 cells per well in 24-
well plates, grown in 3:1 DMEM:Hams F12 complete media and incubated in a humid
atmosphere with 10% CO2, 90% air at 37°C for 24 h in the absence of 3T3 fibroblasts.
Keratinocytes were washed twice with serum free DMEM supplemented with 1% (v/v)
glutamine and then incubated in serum free DMEM supplemented with 1% (v/v)
glutamine, 100 µM trilostane (an 3βHSD inhibitor) and 10 µM ketoconazole (a CYP17
inhibitor) for 2 h in a humidity chamber with 95% air/5% CO2 at 37°C.  Control cells
were incubated for 2 h as described above but without the 3βHSD/CYP17 inhibitors.
Following incubation, fresh serum free DMEM supplemented with 1% (v/v) glutamine,
100 µM trilostane and 10 µM ketoconazole was added to all cells, except control cells
which had medium without the 3βHSD/CYP17 inhibitors.  In addition, some cells were
treated in triplicate with 5 µM 25R-OH cholesterol and/or EGF 60 ng/ml (Sigma-
Aldrich, Poole, U.K.), 50 ng/ml TNFα, 1 µM dex and/or 50 ng/ml TNFα combined
with 1 µM dex (all from Sigma-Aldrich, Poole, U.K.) in the presence of 3βHSD/CYP17
inhibitors.  All cells were incubated in a humid atmosphere with 95% air/ 5% CO2 for
24 h.
2.7.2 Pregnenolone RIA
Culture medium from cells treated as described above was collected in borosilicate
glass tubes (Jencons-Pls, Leighton Buzzard, U.K.) and stored at –20°C prior to assay.
Borosilicate glass was chosen since steroids can adhere to plastic and soda lime glass.
Culture samples were thawed and centrifuged at 250 x g, 4°C for 5 min and 100 µl of
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the supernatants were transferred in triplicate to clean glass tubes.  An anti-
pregnenolone antibody (diluted 1:3000) and 1.50 pmol [7-3H]-pregnenolone (specific
activity = 11.5 Ci/mmol; PerkinElmer, Boston, MA) were added to each sample.  Non-
bound pregnenolone was removed with a charcoal-dextran (T500 buffer Dextran T500
0.025% (w/v), charcoal 0.25% (w/v), 40mM NaH2PO4.2H2O, 70 mM NaHPO4, 75 mM
NaCl, 0.1% (w/v) Gelatin pH 7.2; all compounds from Sigma Aldrich, Poole, U.K.).
Unknown samples were compared to concurrently run standards and adjusted for non-
specific binding (determined in the presence of an excess of non-radioactive
pregnenolone) to calculate pregnenolone concentrations.  All measured pregnenolone
levels were standardised per ml culture medium.  The working range of this RIA was
15.6 – 250 nmol/L with an assay sensitivity of  3.91 nmol/L.
2.8 Radiometric steroid metabolism assays
Primary keratinocytes (passage 2) were plated at 2x105 cells per well in 24-well plates
and incubated for 2 days in keratinocyte defined media (KDM) (Invitrogen, Paisley,
U.K.) supplemented with 1.2 mM CaCl2.  All cells were washed twice in serum free
DMEM supplemented with 1% (v/v) glutamine prior to treatment.  Cells used to assess
pregnenolone metabolism were pre-treated with 100 µM trilostane and 10 µM
ketoconazole for 2 h in a humidity chamber with 5% CO2 in air at 37°C.  Triplicate
wells of cells were incubated at 37°C for 24 h in a humid atmosphere of 5% (v/v) CO2
in air with 0.037 MBq of  [3H]-steroid. This equated to 90.0 pmol [7-3H]-pregnenolone
(with or without 100 µM trilostane and 10 µM ketoconazole), 11.0 pmol [1,2,6,7-3H]-
progesterone or 13.7 pmol [1,2,6,7-3H]-cortisol per ml of culture medium.  Assay
blanks were set up and incubated as described above but in the absence of cells.
Steroids released into the culture medium by keratinocytes were extracted by vigorous
mixing with two volumes of chloroform (HPLC grade, Fisher, Leicestershire, U.K.).
After centrifugation at 1,000 x g for 30 min at 4°C the aqueous phase was removed and
the remaining chloroform was evaporated under nitrogen gas at 45°C.  Steroid extracts
were reconstituted in up to 50 µl ethyl acetate, from which 20 µl was transferred onto a
thin layer chromatography (TLC) plate (Merck, Damstadt, Germany).  The remaining
30 µ l was reserved to be run with authentic standards (10 mM pregnenolone,
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progesterone or cortisol, all purchased from Sigma-Aldrich, Poole, U.K.).  Migration of
reference steroids was monitored by spiking aliquots of each sample with 0.037 MBq
[3H] cortisol, [3H] progesterone or [3H] pregnenolone.  TLC plates were developed in a
tank in a pre-equilibrated atmosphere of 92:8 (v/v) chloroform: 95% (v/v) ethanol.
Resolution of [3H]-steroid metabolites was quantified using an AR2000 Bioscan
radiochromatogramme scanner (Lablogic Ltd, Sheffield, U.K.) and Laura Lite software
(version 3.0; Lablogic Ltd, U.K.).
2.9 Liquid chromatography-mass spectrometry
Liquid chromatography-mass spectrometry (LC-MS) was used to confirm the results
generated from TLC analysis and to authenticate the formation of cortisol by primary
keratinocytes.
Primary human keratinocytes were seeded at 1x106 cells in a total volume of 3 ml 3:1
DMEM:Hams F12 complete media into a 12-well plate and allowed to adhere to the
plate by incubating in a humidity chamber at 37°C, 10% CO2, 90% atmospheric air
overnight.  The primary keratinocytes were treated for 24 h in serum-free DMEM
supplemented with 1% (v/v) glutamine with or without 1 µM progesterone (Sigma-
Aldrich, Poole, U.K.) in a humidified chamber at 37°C in 5% (v/v) CO2 in air.  Assay
blanks were set up and incubated as described above but in the absence of cells.
10 ng of each internal standard (see below) were added to 2.5 ml culture medium.
Steroids were then extracted from the culture medium by vigorously mixing  the sample
with 1.5 ml diethylether.  The organic phase was transferred to a fresh borosilicate glass
tube and evaporated under nitrogen gas, then reconstituted by vortexing in 100 µl of
50% (v/v) methanol and filtered through 0.45 µm.  An ultra pressure liquid
chromatography system (Waters, Milford, MA, USA) was used for sample separation
with an Acquity BEH Phenyl reverse phase column, 100 mm length x 2.1 mm bore with
1.7 µm pore size.  Mobile phase A was 0.1% (v/v) formic acid in water and mobile
phase B was 0.1% (v/v) formic acid in acetonitrile.  Separation was performed  at the
following gradients: 22% (v/v) B (0 – 5 min), 22%-52% (v/v) B (5 – 15 min, linear
gradient), 52%-100% (v/v) B (15 – 16 min), 100% (v/v) B (16 – 20 min), 100%-22%
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(v/v) B (20 – 21 min), 22% (v/v) B (21 – 25 min), while maintaining the flow rate at 0.4
ml/min.  A Micromass quadruple Q-TOF Premier mass spectrometer (Waters, Milford,
MA, USA) was used for detection.  The instrument was set to ESP+ ionization mode,
V-mode for 250 – 500 Da range. Cortisone [4-Pregnen-17α,21-diol-3,11,20-trione]
(MW 360.44, m/z 361.20), Cortisol [4-Pregnene-11β,17α,21-triol-3,20-dione] (MW
362.46, m/z 363.22), Progesterone [4-Pregnene-3,20-dione] (MW 314.46, m/z 315.23)
and Pregnenolone [5-Pregnen-3β-ol-20-one] (MW 316.48, m/z 299.24 + 317.25);
(Sigma-Aldrich, Poole, U.K.) were used for calibration. Cortisone D2 (MW 362.46, m/z
363.21), Cortisol D4 (MW 366.49, m/z 367.24), Progesterone D9 (MW 323.52, m/z
324.28) and Pregnenolone D4 (MW 320.51, m/z 303.26 + 321.27); (C/D/N Isotopes
Inc., Quebec, Canada) were used as internal standards.  All steroid concentrations were
standardised to 1x106 cells.
2.10 Cortisol enzyme-linked immunosorbent assay
Primary human keratinocytes were seeded at 2x105 cell/ml in 12-well plates in DMEM,
RM+ culture medium, Keratinocyte defined medium (Gibco, Invitrogen Coporation,
Paisley, U.K.) or EpiLife complete culture medium (Gibco, Invitrogen Coporation,
Paisley, U.K.) (1ml/well) with supplements and allowed to adhere overnight in a
humidified chamber, 37°C, 95% air, 5% CO2.  The cells were then washed three times
in basal culture medium (respective culture medium with no supplemental additions)
before being incubated for 24 h at 37°C in respective basal culture medium (with the
exception of RM+(+sup) that contained 2 mM L-glutamine, 1X penicillin streptomycin,
5 µg/ml apo-transferrin, 100 pM cholera toxin, 5 µg/ml insulin, 20 pM liothyronine and
10 ng/ml EGF) in a humidified chamber, 37°C, 95% air, 5% CO2.  An assay blank was
set up and incubated as described above but in the absence of cells.
The supernatant was analysed for cortisol using an enzyme-linked immunosorbent assay
(ELISA) kit purchased from R&D Systems (Minneapolis, U.S.A.).  The ELISA was
conducted according to the manufacturer’s instructions with the exception that the
supernatants were not diluted.  Standards and non-specific binding controls for the
ELISA were therefore prepared in respective basal medium to account for this alteration
to the assay.
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2.11 MTT assay
The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay is a
rapid colorimetric analysis of mitochondrial reductase activity in metabolically active
cells.  Therefore the MTT assay generally corresponds to the number of proliferating
cells.  The soluble yellow tetrazolium salt (MTT) is reduced to purple insoluble
formazan crystals by mitochondrial dehydrogenases that normally act to reduce
nicotinamide adenine dinucleotide (NAD+) and nicotinamide adenine dinucleotide
phosphate (NADP+) to NADH and NADPH respectively in active cells.  The purple
formazan crystals are solublised by DMSO/isopropanol and quantified using
spectrophotometry by measuring the absorbance at 570 nm.
Primary keratinocytes were seeded at 5 x 104 cells per well of a 24-well plate in
modified RM+ culture medium (without cortisol and 1% FCS) and incubated overnight
at 37°C, 10%CO2, 90% air in a humidified chamber.  The following day, the
keratinocytes were washed twice in PBS then incubated in triplicate with treatments as
described in Chapter 5.  After three days, the culture media was aspirated from the wells
and the cells were washed twice in PBS.  MTT (500 µl of 0.5 mg/ml in PBS) (Sigma-
Aldrich, Dorset, U.K.) was added to each well and incubated for 1 h at 37°C.  The MTT
solution was then aspirated and the cells were washed once in PBS before 300 µl of
10% (v/v) DMSO in propan-2-ol was added to each well to dissolve the formazan
crystals.  After 10 min the plate was agitated to ensure complete solubilisation of the
crystals and 200 µl of the solution from each well was transferred to a well of a clear,
flat bottomed 96-well plate.  The optical density was measured at 570 nm using a 96-
well plate reader (Victor 1420 Multi-Label Counter, Wallac, PerkinElmer, MA, USA).
2.12 Flow cytometry
Flow cytometry utilises cell size, granularity and fluorescent markers to sort discrete
populations of cell types.  Thus early apoptotic cells were detected by an annexin V
antibody conjugated with fluorescein isothiocyanate (FITC) and propidium iodide (PI).
Dead cells were detected as they were labelled with PI but did not bind the annexin V
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antibody.  Cell debris was also positively labelled for PI but was sorted by size,
proliferating cells were negative for both markers.  Basal keratinocytes were FACS
sorted using a β1 integrin allophycocyanin (APC)-conjugated antibody.
2.12.1 Cell proliferation and apoptosis by flow cytometry
Primary keratinocytes were seeded at 1x106 cells per 60 mm cell culture dish without
3T3 mouse fibroblasts in RM+ culture medium and incubated overnight at 37°C in a
humidified chamber at 10% CO2, 90% air.  The next day the cells were washed three
times in PBS and treated with one of the following conditions all made in modified
RM+ culture medium (1% FCS, without cortisol):  vehicle control (ethanol/methanol), 1
µM dex, 1 µM RU486 or 1 µM dex and 1 µM RU486.  Alternatively, cells were
exposed to 20 mJ U.V.B. at 0.2 mV/cm2 for a negative control of apoptosis.  The U.V.
irradiation was carried out on cells that were in PBS with the cell culture dish lid
removed (to ensure complete U.V. exposure).  After U.V. exposure, the PBS was
aspirated and the cells were bathed in modified RM+ (1% FCS, without cortisol).  The
cells were incubated for 72 h in a humidified chamber at 90% air, 10% CO2.
After 72 h, the culture media was aspirated and the cells were washed once in PBS,
once in versene and trypsinised until all the cells had detached.  The trypsin reaction
was inhibited by transferring the trypsinised cells to centrifuge tubes containing RM+
with 10% FCS at a ratio of 1:1 (v/v) cells to culture medium.  The cells were washed
twice in ice cold PBS with a series of centrifugation steps (1,300 rpm, 5 min at room
temperature) in between each wash.  The final cell pellet was resuspended in 500 µl
annexin V binding buffer solution (BD Pharmingen, Franklin Lakes, NJ, U.S.A.) and
transferred to a 5 ml round-bottomed polystyrene tube (BD Bioscience Discovery
Labware, Bedford, MA, U.S.A.).  To each sample, except the compensation control, 4
µl of annexin V-FITC antibody (BD Pharmingen, Franklin Lakes, NJ, U.S.A.) was
added and the tubes were tapped gently to mix the solution.  The samples were
incubated in the dark for 15 min at room temperature.  Finally, PI (5 µg/ml, Molecular
Probes), was added per sample (except the compensation control) before the cells were
analysed using a BD LSRII flow cytometer (BD Biosciences, San Jose, CA, U.S.A.)
and data analysed using BD FACSDiva Software.  Annexin V was excited by a red
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HeNe laser of 633 nm, emission collected at 660 nm and the machine was fitted with a
660 nm/20 nm differential filter (DF).  PI was excited by an argon laser of 488 nm,
emission collected at 575 nm and the machine fitted with a 575 nm/26 nm DF.
2.12.2 β-Integrin cell sorting by flow cytometry
Primary keratinocytes (at least 4 million) were trypsinised as described in section 2.1.4
and resuspended in 6 ml 1% BSA in PBS.  Cell suspension (1 ml) was transferred to a
fresh tube to provide a negative control for flow cytometry analysis and both tubes were
centrifuged and resuspended in 500 µl 1% BSA PBS.  To the sample (but not negative
control), 10 µl of APC anti-human CD29 (BD Pharmingen, Franklin Lakes, NJ, U.S.A.)
was added and the tubes were incubated for 15 min on ice in the dark.  The cells were
washed twice in PBS with centrifugation at 1300 rpm and resuspended in 500 µl 1%
BSA/PBS.
After the final wash, the cells were transferred to fresh, sterile 5 ml round-bottomed
polystyrene tube (BD Bioscience Discovery Labware, Bedford, MA, U.S.A.).  Using a
BD FACS Aria I (BD Biosciences, San Jose, CA, U.S.A.) fitted with a 130 µm nozzle
at 20 psi, cells were sorted according to emission spectra analysed by FlowJo version
7.2 Software.  APC was excited by a red HeNe laser of 633 nm, emission collected at
660 nm and the machine was fitted with a 660 nm/20 nm differential filter (DF).  The
sorted enriched basal cells (APC conjugated CD29 positive) and suprabasal cells (APC
conjugated CD29 negative) were immediately seeded for experiments or used for
protein extraction.
2.13 Cell counting assay
Primary keratinocytes were seeded in T75 flask at 1x106 cells per flask which were
seeded with 1x106 mitomycin C-treated NIH/3T3 fibroblasts the previous day.  The
keratinocytes were grown in complete RM+ culture media until 40% confluent.  To
remove the 3T3 fibroblasts cells were washed twice in PBS and then incubated with 1x
versene for 2 – 5 min at 37°C.  When all the fibroblasts were detached, the
keratinocytes were washed three times in PBS and incubated for a further three days in
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modified RM+ culture medium (1% serum but without cortisol) with either 1x10-6 M
dex, 1:50,000 (v/v) methanol (as a vehicle control) or no further addition.
After 72 h, the culture medium was removed and the keratinocytes were trypsinised as
described in Section 2.1.4.  All washes, culture medium and trypsin solutions were kept
and combined in a 50 ml centrifuge tube.  The cell suspension was centrifuged at 1,000
rpm for 5 min at room temperature.  Viable cells were then counted using trypan blue as
described in section 2.1.11.
2.14 NADP+/NADPH quantification assay
Primary keratinocytes were seeded and treated with dex as described in the MTT assay
in section 2.10.  After 72 h treatment (with or without dex), cells were washed twice in
ice-cold PBS.  NADP+/NADPH was measured using an NADP+/NADPH Quantification
kit (BioVision, Mountain View, CA, U.S.A.) as described in the following passage.
Cells were lysed by adding 1 ml NADP+/NADPH extraction buffer to each flask and
subjecting the flasks to two freeze-thaw cycles (20 min on dry ice, 10 min at room
temperature).  The samples were then vortexed for 10 s.  A 10 µl aliquot of the cell
suspension was set aside for protein analysis.  The remaining cell debris was removed
by centrifuging at 13,000 rpm at 4°C for 5 min.  To remove NADPH digesting
enzymes, cell lysates were filtered by centrifugation through 10 kDa molecular weight
cut off filters (BioVision, Mountain View, CA, U.S.A) at 14,000 rpm for 15 min at 4°C.
The total NADP+/NADPH cell extraction sample (50 µl) was seeded in duplicate in a
flat-bottomed 96-well plate.  Another 150 µl aliquot of the sample was heated to 60°C
for 30 min to degrade NADP+.  This provided the NADPH only reading of each sample.
The samples were then cooled on ice and 50 µl was transferred in duplicate to a 96-well
plate.
A standard curve was generated by diluting 10 µl of stock NADPH (1 nmol/µl) in 990
µl NADP+/NADPH extraction buffer.  In duplicate, 0, 2, 4, 6, 8, 10 µl of the diluted
NADPH standard was added to wells of a 96-well plate so that the final concentration
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of the standards was 0, 20, 40, 60, 80 and 100 pmol/well.  The final volume of each
standard was made up to 50 µl with NADP+/NADPH extraction buffer and mixed
vigorously.
An NADP+ cycling mix was made by combining NADP+ cycling enzyme mix with
NADP+ cycling buffer mix, 1:50 (v/v) and 100 µl was added and mixed well with each
sample and standard.  The plate was incubated at room temperature for 5 min to convert
NADP+ to NADPH, then 10 µl NADPH developer was added to each well.  The
reaction was incubated  at room temperature allowed to develop for 1 h, then stopped
with 10 µl stop solution and analysed at OD 450 nm using a spectrophotometer (Victor2
1420 Multilabel counter, Wallac, Perkin Elmer Life Sciences, Wellesley, MA, U.S.A.).
2.15 Statistical analysis
Statistical analysis was determined using an unpaired-t test or one-way analysis of
variance (ANOVA) followed by a Tukey post-hoc test where appropriate.  All statistical
evaluations were performed using GraphPad Prism 4.0 software (San Diego, CA,
U.S.A.).  Significance was assessed in all experiments as a probability value of *P <
0.05, **P < 0.01, ***P< 0.001.
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Chapter 3. Expression Analysis of Steroidogenic
Regulatory Proteins in Skin
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3.1 Introduction
Cholesterol transporters are crucial for steroid synthesis, as the transport of cholesterol
is reported as the first and  rate limiting step of steroid synthesis (Stocco and Sodeman,
1991).  The ability of a cell or tissue to synthesise steroids is partly classified by the
expression of mitochondrial cholesterol transporters and their regulators.  Therefore, if
the epidermis is capable of synthesising steroids, it is expected that the tissue would
express critical cholesterol transporters associated with steroid synthesis.
StAR was the first protein identified as a cholesterol transporter for steroidogenesis.
Pulse-chase experiments and the use of protein synthesis inhibitors identified the
relationship between StAR phosphoprotein isoforms (37-, 32- and 30kDa) and steroid
synthesis (Stocco and Sodeman, 1991).  StAR is initially transcribed as a 37 kDa pre-
protein associated with the outer mitochondrial membrane.   The pre-protein is then
modified to 32 kDa before being cleaved into the mature 30 kDa isoform expressed in
the inner mitochondrial membrane (Stocco and Sodeman, 1991).
Protein synthesis inhibitors demonstrated the short half-life (less than 15 min) of 37
kDa StAR, which corresponded to a reduction in steroidogenesis and the appearance of
32 and 30 kDa phosphoproteins (Stocco and Sodeman, 1991).  Therefore continual de
novo synthesis of StAR is required to maintain acute steroidogenesis.  StAR protein
synthesis is tightly regulated and a potent inhibitor of StAR transcription is DAX1.
DAX1 is a nuclear receptor that primarily acts by inhibiting StAR transcription
(Zazopoulos et al., 1997).  Therefore, for DAX1 to directly inhibit StAR transcription, it
must reside in the nucleus of the cell.
The exact mechanism adopted by StAR to transport cholesterol has not been fully
elucidated.  Since StAR does not form a complete channel across both mitochondrial
membranes, it is likely that StAR functions with a complex of proteins to transport
cholesterol.  For example, there is a close functional interaction with TSPO and StAR to
facilitate cholesterol transport into the mitochondria (Liu et al., 2006).
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MLN64 is another putative cholesterol transporter able to promote steroid synthesis
(Watari et al., 1997).  MLN64 shares a homologous START domain with StAR that is
capable of accommodating one cholesterol molecule (Bose et al., 2000b; Watari et al.,
1997).  However, MLN64 has also been shown to localise to late endosomes rather than
mitochondria, so the exact function of MLN64 in steroid synthesis remains
controversial (Alpy et al., 2001).
The primary aim of this chapter was to identify the expression of steroid cholesterol
transporters in the epidermis and cultured primary human keratinocytes.  The presence
of StAR, MLN64 and/or TSPO and the absence or non-nuclear localisation of DAX1
would suggest that keratinocytes could be steroidogenic cells.  The secondary aim was
to identify whether these proteins were aberrantly expressed in skin disorders that are
commonly managed with GC, including psoriasis, atopic dermatitis and harlequin
ichthyosis.
To characterise the expression pattern of StAR, DAX1, TSPO and MLN64 in
epidermis, immunofluorescence histochemistry was carried out on normal human skin
sections. Immunofluorescence cytochemistry, western blotting (and RT-PCR for StAR)
were used to assess the protein expression in normal primary human keratinocytes.  In
addition, since many skin disorders are treated with analogues of cortisol, biopsies from
atopic dermatitis, psoriasis and harlequin ichthyosis were analysed for the expression
pattern of steroid synthesis regulators and compared to normal skin.
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3.2 Results
3.2.1 StAR, MLN64, TSPO and DAX1 expression in normal human skin
StAR, the cholesterol transporter required for steroid synthesis in most steroidogenic
tissues, was expressed in the basal layer of normal human epidermis (Figure 3.1).
However, StAR was not detected in suprabasal layers of the epidermis.  In some
instances, a signal was observed in the cornified layer, although this is more likely to be
attributed to non-specific antibody interactions as this patterning was also observed in
negative (no primary antibody) controls.  Non-specific antibody interactions are a
common problem in the stratum corneum of the epidermis since it is highly rich in
lipids to which antibodies can adhere.
In contrast to StAR, the StAR homologue MLN64 was completely absent in basal
epidermal keratinocytes but present in suprabasal layers where keratinocytes
differentiate (Figure 3.1).  The signal for MLN64 appeared to intensify with
differentiation.  Of the cells that expressed either StAR or MLN64, protein was
localised to the cytoplasm or an organelle within the cytoplasm since, as expected, there
was no signal in nucleus of the cells.
DAX1, a nuclear receptor that acts as a suppressor of StAR was expressed throughout
all epidermal layers but only in the cytoplasm of the cells rather than the nucleus.  The
expression appeared to be consistent throughout the layers since the intensity of the
signal did not vary from the basal to cornified layer.  TSPO was also detected
throughout the layers of the epidermis with a particularly strong expression signal in the
granular layer just prior to cornification.  TSPO showed punctate nuclear or peri nuclear
expression in the basal, spinous and granular layer that could be considered to
colocalise with the nucleus or surround the nucleus of the cells.  Both DAX1 and TSPO
were also detected in fibroblasts of the dermis whereas StAR and MLN64 were absent
from the dermis.
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Figure 3.1 StAR, MLN64 DAX1 and TSPO expression in normal human skin.
Immunofluorescence histochemistry of whole skin facelift sections from Caucasian
females (over 40 years) probed with DAPI (blue nuclear stain) and rabbit polyclonal
antibody  to (A) StAR, (B) MLN64, (C) DAX1 and (D) TSPO and detected with (A-C)
Alexafluor 488 secondary antibody (green) or (D) Alexafluor 594 secondary antibody
(red).  Each panel depicts a representative image of at least fifteen observations, each
made in skin samples from a different individual, scale bar 50 µm.
D
A B
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3.2.2 StAR, MLN64 and DAX1 expression pattern in psoriatic skin
StAR was not detected in non-lesional psoriatic skin biopsies.  This was in complete
contrast to normal human skin where StAR was present in the basal epidermal layer.
Low levels of StAR were observed in basal regions of the epidermis of lesional
psoriatic skin but the signal did not appear to be as intense compared to normal skin
(Figure 3.2).  In contrast to cytoplasmic expression of DAX1 in normal human skin,
DAX1 was localised to the nucleus in all layers of non-lesional psoriatic epidermis.
However, in lesional psoriatic skin, DAX1 was localised to the cytoplasm in a similar
manner to that seen in normal epidermis (Figure 3.2).  The pattern of MLN64
expression was the same as normal skin in non-lesional psoriatic samples (Figure 3.2).
However, MLN64 expression was detected several cell layers above the basal layer in
lesional areas of psoriatic skin as opposed to the observed expression one layer above
basal cells in normal skin.  In addition the intensity of the signal appeared less in the
involved regions of the skin diseases compared to normal epidermis (Figure 3.2).
3.2.3 StAR, MLN64 and DAX1 expression pattern in atopic dermatitis skin
Similar to non-lesional psoriatic skin, StAR was not detected in uninvolved atopic
dermatitis biopsies (Figure 3.3).  Unlike lesional psoriatic or normal skin, StAR was
also not detected in involved epidermal regions of atopic dermatitis.
Similar to non-lesional psoriatic skin, DAX1 expression was identified in the nucleus of
uninvolved atopic dermatitis skin.  However, DAX1 also localised to the nucleus of all
epidermal layers in involved regions of atopic dermatitis skin (Figure 3.3).  The
presence of DAX1 in the nucleus may account for maintained down-regulation of StAR
expression in both involved and non-involved atopic dermatitis skin.
The MLN64 expression pattern was the same in uninvolved atopic dermatitis skin
compared to normal skin (Figure 3.3).  However, the expression pattern of MLN64 was
comparable to psoriatic skin in involved regions of atopic dermatitis since MLN64
signal was detected several cell layers above the basal layer in lesional areas of atopic
dermatitis  and appeared to be less intense in atopic dermatitis biopsies compared to
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normal skin.  The intensity of MLN64 signal did not appear to increase as keratinocytes
differentiated to the uppermost layer of the epidermis.  This was in contrast to normal
and lesional psoriatic epidermis where MLN64 signal intensified with differentiation.
3.2.4 StAR and MLN64 expression pattern in harlequin ichthyosis skin
Similar to lesional psoriatic skin, StAR expression was observed in the basal layer of
the epidermis in harlequin ichthyosis but the signal appeared to be less intense
compared to normal and lesional psoriatic epidermis (Figure 3.4).  MLN64 expression
was also observed in suprabasal regions of the epidermis, although it is difficult to
determine the expression pattern since the section was unfortunately folded on the slide
(Figure 3.4).  Due to the rarity of harlequin ichthyosis and scarcity of sections, it was
not possible to repeat the experiment.
3.2.5 StAR, MLN64 and DAX1 expression in NEB1 organotypic rafts
An epidermal raft model using NEB1 immortalised keratinocyte cells demonstrated an
expression pattern of DAX1 and MLN64  similar to that of normal skin.  DAX1 signal
was observed in the cytoplasm throughout the layers but was completely absent from
cell nuclei.  MLN64 was also present in all suprabasal layers but again, MLN64 signal
was completely absent within the basal layer of the system (Figure 3.5).  However,
unlike normal skin, StAR was not detected in any layer of the raft including the basal
layer (Figure 3.5).  This is in contrast with psoriatic and atopic dermatitis biopsies
where the absence of StAR signal was associated with nuclear localisation of DAX1.
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Figure 3.2 StAR, MLN64 and DAX1 expression in psoriatic skin.
Immunofluorescence histochemistry of matched non-lesional (A, C and E) and lesional
(B, D and F) whole skin biopsies from psoriatic patients probed with DAPI (blue
nuclear stain) and rabbit polyclonal antibody  to (A and B) StAR, (C and D) MLN64 or
(E and F) DAX1 that was detected with Alexafluor 488 secondary antibody (green).
Each panel depicts a representative image of four observations, each made in paired
lesional and non-lesional skin samples from a different individual scale bar 50 µm.
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Figure 3.3 StAR, MLN64 and DAX1 expression in atopic dermatitis skin.
Immunofluorescence histochemistry of matched lesional (A, C and E) and non-lesional
(B, D and F) whole skin biopsies from atopic dermatitis patients probed with DAPI
(blue nuclear stain) and rabbit polyclonal antibody  to (A and B) StAR, (C and D)
MLN64 or (E and F) DAX1 that was detected with Alexafluor 488 secondary antibody
(green).  Each panel depicts a representative image of three observations, each made in
paired involved and non-involved skin samples from a different individual, scale bar 50
µm.
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Figure 3.4 StAR and MLN64 expression in harlequin ichthyosis skin.
Immunofluorescence histochemistry of a whole skin biopsy from a harlequin ichthyosis
patient probed with DAPI (blue nuclear stain) and rabbit polyclonal antibody  to (A)
StAR or (B) MLN64 that was detected with Alexafluor 488 secondary antibody (green).
Due to the rarity of the disease and scarcity of skin sections, each panel is only from one
observation, scale bar 50 µm.
A B
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Figure 3.5 StAR, MLN64 and DAX1 expression in NEB1 organotypic rafts.
Immunofluorescence histochemistry of organotypic NEB1 rafts probed with DAPI
(blue nuclear stain) and rabbit polyclonal antibody  to (A) StAR, (B) MLN64 or (C)
DAX1 that was detected with Alexafluor 488 secondary antibody (green).  Each panel
depicts a representative image of three observations, each made in different individual
rafts, scale bar 50 µm.
A
B
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3.2.6 Western blot analysis of StAR, MLN64, TSPO and DAX1 in skin cells
Cholesterol transport regulating proteins were identified in normal human skin by
immunofluorescence histochemistry.  To complement this data, expression of StAR,
DAX1, TSPO and MLN64 was measured in protein isolates of cultured skin cells using
western blotting (Figure 3.6).  Despite detecting StAR in the basal layer of the normal
epidermis (Figure 3.1), StAR was not detected by western blotting in primary
keratinocytes, immortalised keratinocytes (HaCaTs and N/TERTS), primary dermal
fibroblasts or immortalised sebocytes (SZ95).  However, the StAR antibody was
effective since a strong, single band was detected at approximately 30kDa in the H295R
(positive control) protein isolate lane corresponding to the predicted size of StAR
protein.
DAX1 was detected by western blotting in all cell samples tested, including
keratinocytes and fibroblasts, supporting the data generated from previous
immunohistochemistry analysis.  MLN64 was also identified in all cells except dermal
fibroblasts, in agreement with previous data showing MLN64 was absent from dermal
fibroblasts in immunohistochemical analysis.
Multiple bands for TSPO were detected in all cell samples tested, consistent with the
TSPO phenomenon of denaturation resistant dityrosine cluster formation (Delavoie et
al., 2003).  TSPO did not reside as an 18 kDa monomer in the cells since no band was
detected below 39 kDa.  The predominant band was approximately 64 kDa in N/TERT,
HaCaT, H295R and JEG3 cells, whereas two bands (at 97 kDa and above 97 kDa) were
the predominant TSPO clusters in primary keratinocytes.
In other cell systems, StAR protein has been shown to increase after 4 h with dbcAMP
stimulation (Stocco and Sodeman, 1991).  Therefore skin cells were incubated with 1
mM dbcAMP to determine whether this could induce StAR protein expression.  In
addition, since StAR is reported to be located to the outer mitochondrial membrane,
mitochondrial protein enrichment was used in an attempt to enhance StAR protein
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concentration.  Figure 3.7 demonstrates by western analysis that dbcAMP did not
promote StAR protein expression in the skin cells tested at the chosen time point.
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Figure 3.6 Western blot analysis of StAR, MLN64, DAX1 and TSPO in skin-
derived cells.
(1) Primary human keratinocytes, (2) primary human dermal fibroblasts, (3) N/TERTS,
(4) HaCaTs, (5) H295R immortalised adrenal cells (positive control for StAR), (6)
JEG3 immortalised placenta cells (positive control for MLN64), (7) SZ95 immortalised
sebocytes.  Protein was loaded at 10 µg per lane for DAX1, MLN64, TSPO and 20 µg
per lane for StAR.  β-Actin was used to determine protein loading.
MLN64
51 kDa DAX1
β-Actin
TSPO
97 kDa
64 kDa
51 kDa
39 kDa
30 kDa
50 kDa
75 kDa
StAR
1 2 3 4 5 6 7
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Figure 3.7  Western blot analysis of StAR in skin cells treated with dbcAMP.
Cells (JEG3, dermal fibroblasts, HaCaTs, primary human keratinocytes) were treated
with or without 1 mM dbcAMP for 4 h 30 min.  Protein was isolated with mitochondrial
encrichment.  Protein was loaded at 20 µg per lane with the exception of H295R cells
(used to provide a positive control for StAR protein expression) where 10 µg of protein
was loaded.
H295R JEG3 HaCaT Keratinocytes
Dermal
fibroblasts
+ -+ -+ -+ - dbcAMP
30 kDa
50 kDa
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3.2.7 RT-PCR of StAR in primary human keratinocytes and skin extracts
Since StAR protein was not detected in protein isolates from skin cells, RT-PCR was
used to check for StAR mRNA in the cells.  Figure 3.8 demonstrates that StAR mRNA
was present in primary human keratinocytes as well as in extracts from normal facelift
skin.  However, the level of StAR mRNA was lower in primary keratinocytes and skin
compared to the H295R adrenal positive control.  There was also a variation of StAR
intensity between different whole skin biopsies even though equal amounts of cDNA
were used for the PCR reaction and PCR products were loaded equally on the gel, as
demonstrated by the GAPDH controls.  The RT-PCR product was sequenced and
confirmed as StAR in each of the samples tested.  This shows that the mRNA transcript
was present in the cells  despite the absence of StAR protein by western analysis and
low level expression identified by immunofluorescence histochemistry.
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A. StAR mRNA
B. GAPDH mRNA
Figure 3.8 RT-PCR analysis of StAR in primary human keratinocytes and skin.
RT-PCR result using primers specific for (A) StAR or (B) GAPDH.  (1) 1 kb DNA
ladder, (2) H295R positive control, (3) primary human keratinocytes, (4) facelift skin
donor 1, (5) facelift skin donor 2.  Lanes 6 – 9 negative controls generated from RNA
sample extracts lacking the enzyme for cDNA synthesis for (6) H295R, (7) primary
human keratinocytes, (8) facelift skin donor 1, (9) facelift skin donor 2.  A single PCR
product was detected in each lane matching the predicted product size for StAR (333
bp) or GAPDH (340 bp).  Authenticity of the StAR product was confirmed by DNA
sequencing.  The figure is a representative of three separate experiments.
1 2 3 4 5 6 7 8 9
300 bp
300 bp
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3.2.8 Influence of oxygen and dermal fibroblasts on StAR and MLN64 expression
in keratinocytes
Keratinocyte culture conditions were manipulated to promote a basal cell keratinocyte
environment.  An oxygen gradient of 2 – 17% spans the epidermis from 2% O2 in the
basal layer to 17% in the stratum corneum (Ngo et al., 2007).  Basal keratinocytes
(particularly stem cells) isolated from mouse epidermis have been shown to apoptose
more readily when cultured at atmospheric oxygen.  In contrast, when cultured at 2% O2
less apoptosis was observed (Fozia Chaudry, personal communication).  Therefore
primary human keratinocytes were cultured at 2% O2 to investigate if this promoted the
maintenance of a basal cell population and StAR expression.  In addition keratinocytes
were cultured with either human dermal fibroblasts or conventional 3T3 mouse
fibroblasts.  This is because the factors released by dermal fibroblasts are essential for
keratinocyte function and growth and can vary between species.  The use of human
dermal fibroblasts was an attempt to replicate the human system to investigate whether
this would encourage StAR expression in keratinocyte culture.  Primary keratinocytes
were also FACS sorted to enrich for the basal cell population using a β-integrin (CD29)
antibody (Figure 3.9), since StAR was identified in the basal layer of the epidermis by
immunofluorescence histochemistry.  Figure 3.10 shows that StAR was not detected by
western analysis in CD29+ or CD29- keratinocytes cultured at 2% O2 or atmospheric
oxygen, with either human dermal fibroblasts or mouse 3T3 fibroblasts.  However,
MLN64 was present in basal enriched (CD29+) cells and the expression of MLN64
increased in suprabasal cells (CD29-) cells.
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Figure 3.9 Example of gating plots used for β1 integrin (CD29) cell sorting by flow
cytometry.
Basal cell keratinocyte enrichment was achieved with a FITC conjugated antibody to β1
integrin.  The cells were separated for CD29 positive and negative labeling.  A dot plot
of the total cell population (A) is shown with gating for CD29 positive cell, P1 in (B),
and CD29 negative cells, P2 in (B).
A B
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A. Ambient O2
B. 2% O2
Figure 3.10 Western blot analysis of StAR and MLN64 in primary human
keratinocytes grown in modified oxygen and fibroblast conditions.
Protein was isolated from primary human keratinocytes (PHK) that were FACS sorted
for CD29+ (basal) and CD29- (suprabasal) cell enrichment or unsorted  total population
(T) and cultured for 24 h at (A) atmospheric oxygen or (B) 2% oxygen.  PHK cultured
with 3T3 mouse fibroblasts (3T3) or primary human dermal fibroblasts (DF).  Protein
was loaded at 25 µg per lane except for H295R cells where 10 µg protein was loaded.
β-Actin was used to determine equal protein loading.
H295R
StAR
MLN64
β-Actin
β-Actin
MLN64
StAR
CD29+ CD29+CD29- CD29-T T
PHK (DF) PHK (3T3)
H295R CD29+ CD29+CD29- CD29-T T
PHK (DF) PHK (3T3)
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3.2.9 Immunofluorescence cytochemistry of StAR, DAX1 and MLN64 in primary
human keratinocytes
The cellular expression pattern of StAR, DAX1 and MLN64 was assessed by
immunofluorescence cytochemistry in keratinocytes that were cultured for five days
(Figure 3.11).  In tissue culture, DAX1 had a cytosolic expression pattern in every cell
and was absent from the nucleus, matching the DAX1 expression pattern observed in
normal human skin.  MLN64 was detected with punctate patterning surrounding cell
nuclei.  It is likely that this patterning corresponds with endosome localisation since
MLN64 has been associated with this organelle in other cell types (Alpy et al., 2001).
MLN64 was not detected in every cell, suggesting differential expression in the cell
population.  This could correspond to differentiating keratinocyte versus stem/transit
amplifying keratinocyte populations as observed by immunohistochemistry.
StAR expression was not detected in the majority of cells after five days of tissue
culture (Figure 3.11), which corresponded with the absence of StAR signal in protein
isolates from cultured keratinocytes (Figure 3.6).  StAR expression was then measured
in primary human keratinocytes over a five day time course (Figure 3.12).  StAR was
detected in all the primary keratinocytes after one day in tissue culture.  The proportion
of cells that expressed StAR decreased with time so that by day 5,  StAR signal was
absent in the majority of the cell population (Figure 3.12).  In StAR positive cells, the
protein was observed to form a ring-like mesh surrounding cell nuclei, which
corresponds to patterning expected for mitochondrial localisation.
In summary, regulators of steroid synthesis were identified in normal human epidermis
and the localisation of these proteins were aberrant in diseased skin (summary Table
3.1).  StAR was present in the basal layer of normal epidermis but expression was
reduced or not detected in hyperproliferative skin conditions.  In culture, MLN64,
TSPO and DAX1 were detected by western blotting and/or immunofluorescence
cytochemistry, however StAR expression diminished with time in culture even though
StAR message could still be detected.
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Figure 3.11 Immunofluorescence cytochemistry of StAR, MLN64 and DAX1 in
primary human keratinocytes.
Expression pattern of (A) StAR, (B) MLN64 and (C) DAX1 after 5 d in tissue culture.
The white arrow in (A) indicates a positive signal for StAR.  Images are representative
of three separate experiments.
A B
C
119
  
  
Figure 3.12 Immunofluorescence cytochemistry of StAR expression over time in
cultured primary human keratinocytes.
Primary keratinocytes were cultured for (A) 1 day, (B) 2 days (C) 3 days or (D) 5 days
prior to being subjected to immunofluorescence cytochemistry to detect StAR
expression (green).  The cell nuclei were detected with DAPI (blue).  The white arrow
in (D) indicates a StAR positive cell in a keratinocyte colony after 5 days in culture.
Images are representative of three separate experiments, scale bar 50 µm.
A B
C D
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StAR MLN64 DAX1
Normal epidermis Basal layer Suprabasal layers All layers,
cytoplasm
Non-lesional psoriatic
epidermis
Not detected in basal
layer
Suprabasal layers All layers,
nucleus
Lesional psoriatic
epidermis
Low level in basal
layer
Upper suprabasal
layers
All layers,
cytoplasm
Non-lesional atopic
dermatitis epidermis
Not detected in basal
layer
Suprabasal layers All layers,
nucleus
Lesional atopic
dermatitis epidermis
Not detected in basal
layer
Upper suprabasal
layers
All layers,
nucleus
NEB-1 organotypic rafts Not detected Suprabasal layers All layers,
cytoplasm
Normal cultured primary
human keratinocytes
Low level of
expression
decreasing with time
in culture
Most cells,
putative late
endosome
expression
All cells,
cytoplasm
Table 3.1 Summary of StAR, MLN64 and DAX1 expression in human epidermis
and keratinocyte culture detected by immunofluorescence histochemistry and
cytochemistry respectively.
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3.3 Discussion
The expression pattern of the cholesterol transporters StAR, MLN64 and TSPO together
with a negative regulator of StAR, DAX1 was examined in normal human skin by
immunofluorescence histochemistry.  StAR, the cholesterol transporter required for
acute steroid synthesis in most steroidogenic tissues, was exclusively expressed in the
basal layer of normal epidermis.  This StAR expression pattern concurs with previously
published research that identified StAR protein in skin by immunocytochemistry (Chen
et al., 2006; Tiala et al., 2007).  The presence of StAR in the tissue suggests that the
epidermis could have steroidogenic potential since StAR expression is regarded as an
indicator of steroid synthesis.  The expression of StAR was restricted to the basal layer
suggesting that acute regulation of steroid synthesis is only present in stem or
proliferating keratinocytes and is absent in differentiating keratinocytes.  Analysis of
StAR expression in sebocytes also found the most intense StAR signal in
undifferentiated sebocytes (Chen et al., 2006).
Previous reports detected MLN64, a protein that has also been implicated in cholesterol
transport for steroidogenesis, in whole skin extracts by western blot analysis (Slominski
et al., 2004).  In this chapter, MLN64 was detected only in the suprabasal layers of the
epidermis where keratinocytes differentiate and, in contrast to StAR, was absent from
the basal layer.  This is consistent with MLN64 analysis in the brain that identified the
protein in glia and neurones but did not co-localised with steroidogenic cells of the
brain (King et al., 2006).  Unfortunately it was not possible to perform co-localisation
studies since at the time of the experiments, only rabbit polyclonal antibodies for StAR
and MLN64 were commercially available.
MLN64 is also present in the placenta, a steroidogenic tissue which is not thought to
express StAR, where MLN64 has been linked to steroid synthesis (Tuckey, 2005).  The
protein is also highly expressed in human breast carcinomas with expression being
linked to the Her 2 receptor and the relative aggressiveness of the cancer (Alpy et al.,
2003; Vinatzer et al., 2005).   In addition, MLN64 has been identified in the prostate,
where upregulation of MLN64 expression was significantly associated with CYP17
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expression and late stages of prostate cancer (Stigliano et al., 2007).  Progression of
breast and prostate carcinoma is a hormone dependent process and it has been suggested
that there is a role for MLN64 with intra-neoplastic autonomous steroidogenesis
(Stigliano et al., 2007).  Future studies to determine MLN64 changes in skin cancer
would be beneficial.
TSPO  is reported to act synergistically with StAR to promote steroid synthesis when
associated with the mitochondria (Liu et al., 2006).  Similar to previous studies, TSPO
was expressed throughout the tissue but was particularly intense in the granulosa layer
just prior to keratinocyte stratification (Stoebner et al., 1999).  However, in this chapter
the TSPO expression pattern was predominantly perinuclear rather than mitochondrial
as described previously (Stoebner et al., 1999).  TSPO has also been detected in cell
nuclei of breast cancers and this localisation was associated with increased cell
proliferation (Hardwick et al., 1999).  Therefore, the localisation of TSPO identified by
this research suggests that the protein may be involved in regulating cell proliferation.
However, localisation according Stoebner et al. (1999) suggests that TSPO maybe
coordinating StAR-mediated cholesterol transport in the basal layer of the epidermis.  In
suprabasal layers where StAR is absent, TSPO could be functioning to coordinate
StAR-independent steroidogenesis or regulating apoptosis as reported in other systems
(Veenman et al., 2007).
In agreement with previous studies, DAX1, a negative regulator of StAR, was detected
in the cytoplasm of all epidermal layers in normal skin (Patel et al., 2001).  The absence
of DAX1 from epidermal cell nuclei implies that DAX1 is not directly repressing StAR
transcription at the point of analysis.  In addition, the expression of DAX1 throughout
all epidermal layers but absence of StAR in suprabasal layers, implies that there is an
alternative mechanism for inhibiting StAR protein expression in suprabasal
keratinocytes.  Cytoplasmic DAX1 can also inhibit StAR expression by acting as an
antagonist to SF1, preventing SF1 from initiating StAR transcription (Iyer and McCabe,
2004).  The balance of DAX1 to SF1 has been shown to mediate steroidogenesis by
regulating StAR expression (Iyer and McCabe, 2004).  SF1 has been identified
throughout the epidermis (Patel et al., 2001) therefore changes in StAR expression
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pattern from basal to suprabasal layers could be mediated via DAX1:SF1 interactions,
however this remains to be clarified.
Following the identification of StAR, DAX1, MLN64 and TSPO in normal skin, the
expression of these proteins was investigated in cultured skin cells using western
blotting and immunofluorescence cytochemistry.  Western blot analysis revealed that
DAX1 and MLN64 were expressed in all the cells tested (primary keratinocytes,
primary dermal fibroblasts, HaCaTs and N/TERTS immortalised keratinocyte cell lines,
SZ95 immortalised sebocytes, JEG3 immortalised placenta cells, H295R immortalised
adrenal cells).
Whilst TSPO monomer (18 kDa) was not identified, a series of higher molecular weight
bands were detected in all cells suggesting that TSPO was arranged in polymeric
clusters (Delavoie et al., 2003).  These clusters are formed by ROS-mediated dityrosine
bond formation and cannot be broken back down to monomers by heat, urea buffer,
SDS or reducing agents (Delavoie et al., 2003).  The role of TSPO cluster formation
remains to be defined but the TSPO monomer has been reported to promote cholesterol
binding for steroid synthesis (Delavoie et al., 2003).   Upon induction of steroidogenesis
by hCG a concomitant rapid (30 sec) formation of cluster topography is observed in
Leydig cells (Boujrad et al., 1996).  In addition, large cluster formation is associated
with cell proliferation, consistent with the environment of cell culture that is designed to
promote cell growth (Delavoie et al., 2003).
In contrast, StAR was not detected by western blot in any of the cells tested except
H295R adrenal cells that were used for a positive control.  Even the addition of
dbcAMP that has been shown to enhance StAR protein expression in MA-10 mouse
Leydig cells did not  lead to the detection of StAR protein in the skin cells tested.  Due
to the basal localisation of StAR and that the basal layer oxygen levels are
physiologically closer to 2% O2 rather than atmospheric O2, keratinocytes were FACS
sorted for basal cell enrichment (β1-integrin) and cultured at 2% O2 (Ngo et al., 2007;
Watt, 1998).  Western blot analysis still failed to identify StAR protein under these
culture conditions.
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However, StAR mRNA was identified by RT-PCR in keratinocytes that had been
cultured for 5 days, demonstrating that StAR transcription was present in the cells.  This
is consistent with the finding that the nuclear receptor DAX1 was localised to the
cytoplasm of cultured cells rather than nucleus, suggesting that DAX1 is not directly
repressing StAR transcription.
In addition, a time course of StAR expression in cultured keratinocytes showed that
after 24 h, most keratinocytes were detected as expressing StAR.  However, by day 5,
the expression of StAR was virtually absent in all primary keratinocytes.  This suggests
that StAR protein was unstable and degraded in cultured keratinocytes or that StAR
mRNA translation to protein was inhibited.
Recently, A-kinase anchoring protein (AKAP) 121 has been implicated in anchoring
StAR mRNA and PKA to the outer mitochondrial membrane in mouse Leydig cells
(Dyson et al., 2008).  The research demonstrated that AKAP121 could provide a site for
StAR mRNA translation coupled with rapid activation of the newly synthesised StAR
protein (Dyson et al., 2008).  Interestingly, knockdown of AKAP121 had no effect on
StAR transcript levels but dramatically decreased StAR protein levels and prevented
acute steroidogenesis.  Due to the high turnover of StAR, proteosome inhibitors
(MG132 and clasto-lactacystin β-lactone) have also been shown to increase StAR signal
by preventing protein degradation in rat adrenal cortex, COS cells and primary
granulosa cells (Granot et al., 2007b; Rucinski et al., 2008).  Further analysis of
AKAP149 (the human orthologue of AKAP121) and use of proteosome inhibitors is
required to confirm the above findings.
MLN64 was expressed in the majority of cultured keratinocytes and detected both by
western blotting and immunofluorescence cytochemistry. The MLN64 patterning that
was displayed would be more similar to endosomal rather than mitochondrial
localisation.  This corresponds with other reports that have localised MLN64 to the late
endosomes of neurones, glia MCF7 human breast cancer cell lines and SK-OV-3 human
ovarian cancer cell lines (Alpy et al., 2001; King et al., 2006).  The precise role of
MLN64 remains to be defined, however current theory suggests that MLN64 functions
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to supply cholesterol to StAR and/or TSPO for steroidogenesis, rather than delivering
cholesterol across mitochondrial membranes to CYP11A1 (Rone et al., 2009).
The expression pattern of StAR, DAX1 and MLN64 were also investigated in psoriasis,
harlequin ichthyosis and atopic dermatitis.  This was to assess whether regulators of
steroid synthesis were disrupted in these diseases since cortisol therapy is still the
treatment of choice for psoriasis and atopic dermatitis (Stojadinovic et al., 2007).
Low level StAR expression was detected in the basal layer of the epidermis of harlequin
ichthyosis skin.  The intensity of StAR protein expression was less than normal skin
consistent with the hypothesis that acute steroidogenesis is limited in hyperproliferative
skin conditions.  It is inconclusive as to whether MLN64 expression was moderated in
the harlequin ichthyosis epidermis.
StAR was not detected in both non-lesional psoriatic and atopic dermatitis biopsies.
However, low levels of StAR were observed in basal regions of the epidermis of
lesional psoriatic and harlequin ichthyosis skin.  Previously published research also
demonstrated that StAR was absent or down regulated in non-lesional psoriasis (Tiala et
al., 2007).  In this study, lower StAR expression was associated with decreased levels of
coiled-coil alpha helical rod protein 1 (CCHCR1); a gene that is located in the major
psoriasis susceptibility locus PSORS1 and has been shown to regulate StAR expression
(Tiala et al., 2007).
DAX1 was expressed in the cell nuclei of uninvolved atopic dermatitis, involved atopic
dermatitis and non-lesional psoriatic skin but was in the cytoplasm of lesional psoriasis.
The nuclear localisation of DAX1 could account for decreased StAR expression in
uninvolved atopic dermatitis, involved atopic dermatitis and non-lesional psoriatic
biopsies (Zazopoulos et al., 1997).  Conversely, cytoplasmic expression of DAX1 in
lesional regions of psoriasis could partly account for the slight increase in StAR
expression observed in lesional versus non-lesional regions of the skin disease.
The MLN64 expression pattern was unchanged between non-lesional psoriatic, atopic
dermatitis and normal skin.  However, MLN64 was only expressed in upper suprabasal
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layers and appeared to be less intense in lesional areas of psoriatic and atopic dermatitis
biopsies when compared to normal skin.  This could be because keratinocytes in
involved regions of psoriasis and atopic dermatitis skin display hyperproliferation and
poor differentiation.  Markers of differentiation such as involucrin and filaggrin are
downregulated in psoriasis, possibly due to increased rate of early apoptosis (Iizuka et
al., 2004).  Atopic dermatitis is also associated with loss of function mutations in the
FLG gene, which encodes filaggrin (Palmer et al., 2006).  Therefore the expression
pattern of MLN64 could be related to poor regulation of keratinocyte differentiation in
these skin diseases.
Reduced StAR expression patterning in involved and non-involved regions of psoriasis,
atopic dermatitis and harlequin ichthyosis suggests that acute steroid synthesis is
disrupted in diseased tissue.  The MLN64 expression pattern also corresponds with the
poor differentiation characteristic of psoriasis and atopic dermatitis.  The altered
expression pattern of StAR, DAX1 and MLN64 in both uninvolved and involved
regions of the skin disorders is indicative of suppressed steroidogenic cholesterol
transport.  It also demonstrates that uninvolved regions of psoriatic and atopic
dermatitis skin are not equivalent to normal skin.
In summary, the data presented here shows that normal human epidermis express the
cholesterol transporters StAR, MLN64 and TSPO that are associated with steroid
synthesis.  The expression pattern of these proteins are aberrant in hyperporliferative
skin disorders that are commonly managed with cortisol-based treatments.  This
suggests that normal epidermis could be capable of acute steroid synthesis and that this
process is disrupted in the diseased skin tested.  Although StAR expression was not
stable in cultured keratinocytes, the cells did express MLN64 and TSPO and
demonstrated cytoplasmic patterning of DAX1.  Taken together, the evidence suggests
that normal keratinocytes might be capable of de novo steroid synthesis.
127
Chapter 4. Investigating Cortisol Synthesis by
Primary Human Keratinocytes
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4.1 Introduction
Cortisol has a profound effect on the epidermis.  This steroid can induce keratinocyte
differentiation, as well as decrease keratinocyte lipid formation, apoptosis and
inflammation (Elias, 2005).  Cortisol is therefore used as a potent anti-inflammatory
agent and cortisol derivatives are the treatment of choice for multiple skin disorders
including psoriasis and atopic dermatitis.  Despite the broad clinical benefit of cortisol
analogues, the ability of normal human keratinocytes to endogenously synthesise
cortisol has not been reported.
There have been several studies of steroid synthesis within the skin (Slominski et al.,
2007).  For example, in humans the hair follicle has been reported to express a
functional hypothalamic pituitary adrenal (HPA) axis to synthesise cortisol (Ito et al.,
2005; Kauser et al., 2005).  Sebocytes can convert 22R-hydroxycholesterol to 17-
hydroxypregnenolone (Thiboutot et al., 2003), whilst melanocytes and fibroblasts have
also been shown to produce corticosterone and cortisol through localised HPA axis
stimulation (Slominski et al., 2005a; Slominski et al., 2005b; Slominski et al., 2006).
There has also been extensive research into androgen and oestrogen metabolism by
primary keratinocytes (Gingras et al., 2003; Milewich et al., 1988).  Keratinocytes have
also been shown to process POMC proteins including ACTH (Rousseau et al., 2007).
In addition, progesterone metabolism was demonstrated in HaCaT keratinocyte cell
lines but the metabolites were derivatives of deoxycorticosterone (Slominski et al.,
2002).  Progesterone metabolism to deoxycorticosterone is a divergent pathway from
the formation of cortisol from progesterone, which proceeds via the synthesis of 17α-
hydroxyprogesterone.  Despite these advances, synthesis of cortisol from cholesterol
has not previously been functionally characterised in primary keratinocytes.
Chapter 3 demonstrated that the epidermis expresses cholesterol transporters that are
associated with the first step of steroid synthesis, including StAR, TSPO and MLN64.
In addition, published research has shown that keratinocytes are capable of de novo
synthesis of cholesterol, the precursor of all steroids (Menon et al., 1985).  Finally, the
complete P450 scc system, including CYP11A1, FDXR and FDX, is present in human
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skin (Slominski et al., 2004; Thiboutot et al., 2003), although the functional capacity of
these elements has not been determined in primary human keratinocytes.
The first step of steroidogenesis involves the conversion of cholesterol to pregnenolone,
which is then metabolised to progesterone.  Progesterone influences keratinocyte
biology by enhancing keratinocyte cell proliferation and aiding moisture retention in the
dermis (Kanda and Watanabe, 2005).  The effect of progesterone on skin health is most
apparent during menopause, where skin rapidly ages as the systemic progesterone
concentration deceases (Kanda and Watanabe, 2005).
The epidermis responds rapidly to environmental stressors and can be profoundly
modulated by steroids.  Therefore, the aim of this chapter was to identify whether
normal primary human keratinocytes are able to synthesise pregnenolone, progesterone
and cortisol.  Radioimmunoassay (RIA) was used to investigate endogenous
pregnenolone synthesis by primary human keratinocytes.  Radiometric was employed to
assess the ability of keratinocytes to metabolise pregnenolone, progesterone and cortisol
and liquid chromatography-mass spectrometry (LC-MS) was used to verify the
synthesis of cortisol from progesterone by the cells.  Finally ELISA was used to
quantify cortisol synthesis by primary human keratinocytes.
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4.2 Results
4.2.1 Optimising the pregnenolone RIA
The principle of RIA is based on tritiated labelled pregnenolone of known concentration
competing for the binding of a pregnenolone antibody against endogenous (non-
labelled) pregnenolone.  The relative displacement of tritiated pregnenolone can be
measured and thus the concentration of endogenous pregnenolone can be calculated
comparatively against a standard curve.  The concentration of both labelled
pregnenolone and pregnenolone antibody must be optimised to provide sensitive
displacement when cold (sample) pregnenolone is added to the system.
Figure 4.1 shows the optimisation process for generating a standard curve that lies
within range for accurate pregnenolone displacement and therefore quantification.
Figures 4.1 A and B show that at these antibody concentrations the assay is too sensitive
since [3H] pregnenolone is completely displaced even at the lowest concentration of
cold pregnenolone in 4.1 A.  Although the assay is still too sensitive in 4.1 B, the lowest
concentration of cold pregnenolone (3.91 nM) did not completely displace [3H]
pregnenolone.  In Figure 4.1 C the assay is not sensitive enough since effective
displacement of [3H] pregnenolone only occurred beyond 31.5 nM cold pregnenolone.
Figure 4.1 D is an example of the optimised standard curve where [3H] pregnenolone is
effectively displaced from 3.91 nM to 1000 nM so that measurements of unknown
pregnenolone could be calculated at any point within this range of pregnenolone
concentrations.
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Figure 4.1 Optimisation of the pregnenolone RIA.
Concentrations of pregnenolone antibody and tritiated pregnenolone were optimised so
that known concentrations of unlabelled pregnenolone would displace tritiated
pregnenolone to generate a standard curve between 3.91 and 1000 nM pregnenolone.
(A) antibody dilution 1:3000, [3H]pregnenolone 1:8000 (B) antibody dilution 1:4000,
[3H]pregnenolone 1:8000 (C) antibody dilution 1:8000, [3H]pregnenolone 1:4000 (D)
antibody dilution 1:3000, [3H]pregnenolone 1:6000.
A.
B.
C.
D.
Pregnenolone (nM)
Pregnenolone (nM)
Pregnenolone (nM)
Pregnenolone (nM)
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4.2.2 Pregnenolone synthesis detected by RIA
RIA was used to quantify pregnenolone concentration in primary human keratinocyte
culture media.  Since pregnenolone was not detected in cell-free culture medium, it is
assumed that any pregnenolone detected was due to endogenous synthesis by the cells.
It was also predicted that the level of pregnenolone synthesis would be low, therefore
two compounds, trilostane (T) and ketokonazole (K), were used to inhibit further
metabolism of pregnenolone (Figure 4.2 B).  T is an inhibitor of 3βHSD, the enzyme
which metabolises pregnenolone to progesterone.  K is an inhibitor of CYP17, the
enzyme which converts pregnenolone to 17-OH pregnenolone.
Keratinocytes treated with T and K displayed a significant (3.7 ± 0.4 fold) increase of
pregnenolone detection relative to untreated cells (Figure 4.2A).  This demonstrated that
primary human keratinocytes are able to synthesise pregnenolone.  In addition to T and
K, 25-OH cholesterol and EGF were incubated with the cells (Figure 4.3). 25-OH
cholesterol was predicted to promote steroid synthesis by bypassing StAR, which is
considered as the rate determining step of steroid synthesis, and providing abundant
substrate to the system.  EGF was predicted to upregulate pregnenolone synthesis since
it has been shown to increase StAR promoter activity more effectively than dbcAMP in
keratinocytes (MV Patel, 2002).  Neither compound alone was able to promote
pregnenolone synthesis above basal T and K levels (T and K: 24.42 ± 3.8 nM, EGF with
T and K: 22.8 ±  11.7 nM, 25-OH cholesterol with T and K: 24.9 ±  9.0 nM
pregnenolone, Figure 4.3). Only the combination of all four compounds, 25-OH
cholesterol, EGF with T and K, produced a significant increase in pregnenolone above
the untreated baseline (untreated: 5.0 ± 5.0, 25-OH cholesterol, EGF with T and K
44.6±18.0 nM pregnenolone, P<0.001), but this increase was not significantly greater
than that achieved with T and K alone.
The only treatment tested that independently promoted pregnenolone synthesis above T
and K levels was dex (T and K: 24.4 ± 3.8 nM, dex with T and K: 52.2 ± 7.8 nM
pregnenolone, P<0.05, Figure 4.4).  The addition of 25-OH cholesterol to dex with T
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and K did not further promote pregnenolone synthesis (60.7 ± 12.7 nM), as would be
predicted of this compound that can bypass StAR.
Primary keratinocytes were incubated with TNFα to measure the input of stress
response on pregnenolone synthesis.  TNFα with T and K did not significantly promote
pregnenolone synthesis compared to T and K only treated cells (32.8 ± 12.5 nM versus
24.4 ±  3.8 nM respectively, Figure 4.4).  However, when TNFα  was added in
combination with dex, 25-OH cholesterol, T and K pregnenolone synthesis was
significantly increased compared to T and K levels (75.5 ±  19.7 nM).  This
demonstrated that dex was critical for the promotion of pregnenolone steroidogenesis.
Overall the results indicate that primary human keratinocytes are able to synthesise
pregnenolone.  In addition, since T and K can enhance the level of pregnenolone
detected, it is likely that 3βHSD and CYP17 are able to actively metabolise
pregnenolone. The addition of 25-OH cholesterol did not further promote
steroidogenesis, suggesting there could be a different rate determining step for steroid
synthesis in cultured primary human keratinocytes compared to most steroidogenic
cells.  Only the addition of dex appeared to significantly increase pregnenolone
steroidogenesis.
134
A.
Untreated T+K
0
5
10
15
20
25
**
B.
Figure 4.2 Pregnenolone synthesis by primary human keratinocytes with T and K.
(A) Pregnenolone was detected by RIA from 1ml culture media of primary human
keratinocytes (seeded at a density of 2.5x105 in 12 well plates) after 24 h.  T: 100 µM
trilostane, K: 10 µM ketoconazole. The data are from three separate experiments,
statistical differences were determine using an unpaired T-test (n=3, mean ± SEM,
**P<0.01). (B) Illustration of 3βHSD inhibition by trilostane and CYP17 inhibition by
ketoconazole.
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Figure 4.3 Pregnenolone synthesis by primary human keratinocytes with EGF and
25OH cholesterol.
Pregnenolone was detected by RIA from 1ml culture media of primary human
keratinocytes (seeded at a density of 2.5x105 in 12 well plates) after 24 h.  T: 100 µM
trilostane, K: 10 µM ketoconazole, EGF: 60 ng/ml epidermal growth factor, 25-OH: 5
µM 25-OH cholesterol.  The data was normalised against cell density, statistical
differences were determine using one-way ANOVA followed by a post-hoc Tukey test
where appropriate (200,000 cell/ml, mean ±S.D., **P<0.01 relative to untreated cells,
NS not significant relative to T+K).
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Figure 4.4 Pregnenolone synthesis by primary human keratinocytes with dex and
TNFα.
Pregnenolone was detected by RIA from 1ml culture media of primary human
keratinocytes (seeded at a density of 2.5x105 in 12 well plates) after 24 h.  T: 100 µM
trilostane, K: 10 µM ketoconazole, dex: 1 µM dex, 25-OH: 5 µM 25-
hydroxycholesterol, TNF: 60 ng/ml tumour necrosis factor-α.  The data was normalised
against total protein concentration, statistical differences were determine using one-way
ANOVA followed by a post-hoc Tukey test where appropriate (mean ±S.D., *P <0.05,
**P<0.01, ***P<0.001 relative to T+K).
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4.2.3 Pregnenolone metabolism by radiometric assay
The ability of primary human keratinocytes to metabolise pregnenolone was then
analysed by thin layer chromatography (TLC). The products of [3H] pregnenolone
metabolism by cultured keratinocytes after 24 h incubation is illustrated in Figure 4.5.
The products of [3H] pregnenolone metabolism co-migrated with progesterone, 17-OH
progesterone and 17-OH pregnenolone, cortisol, cortisone, 11 desoxycortisol, and
corticosterone together with some undetermined steroid metabolites.  This therefore
demonstrates that primary human keratinocytes are capable of synthesising cortisol
from pregnenolone.  [3H] Pregnenolone metabolism was also analysed in the presence
or absence of T and/or K (Figure 4.6).  This was for two reasons; to demonstrate
whether pregnenolone metabolism was mediated via 3βHSD and CYP17, and to
identify the relative efficiency of the 3βHSD and CYP17 inhibitors.  Therefore, if T
were 100% effective, the expected TLC pattern would include peaks that co-migrate
with pregnenolone and 17-OH pregnenolone but peaks co-migrating with progesterone
and 17-OH progesterone would be absent.  If K were 100% efficient, the predicted TLC
pattern would include peaks co-migrating with pregnenolone and progesterone but no
17-OH pregnenolone and 17-OH progesterone peaks.  Figure 4.6 demonstrates that T
was efficient at inhibiting 3βHSD activity since upon its addition, the majority of
pregnenolone was not further metabolised.
Likewise, K acts to inhibit CYP17, therefore with K treatment, the product of [3H]
pregnenolone metabolism was expected to be progesterone with little or no 17-OH
derivatives of pregnenolone and progesterone.  Figure 4.6 shows that, there was an
efficient block of keratinocyte CYP17 [3H] pregnenolone metabolism since no 17-OH
derivatives were detected by radiometric assay in the presence of K.  These data
enhance the confidence that the metabolites of [3H] pregnenolone are likely to be
progesterone, 17-OH pregnenolone and 17-OH progesterone since their synthesis can
be partially blocked by the 3βHSD and CYP17 inhibitors T and K.
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Figure 4.5 Pregnenolone metabolism by primary human keratinocytes.
(A) Cells (at a density of 2.5x105 in 12 well plates) were incubated for 24 h with fresh
serum free medium containing 0.037 MBq (90.0 pmol) of [3H] pregnenolone in a
volume of 1ml/well.  Steroid metabolites were chloroform-extracted from culture
medium and resolved by thin layer chromatography.  (B) Authentic cortisol standard,
(C) authentic pregnenolone standard demonstrate the hallmark migration of these
metabolites.  Chromatogram is a representative of three separate assays, each performed
in triplicate (one triplicate depicted in each panel) using keratinocytes isolated from two
different individuals. P5 = pregnenolone, P4 = progesterone, 17OHP5 = 17-
hydroxypregnenolone, 17OHP4 = 17-hydroxyprogesterone. E = cortisone, F = cortisol,
B = corticosterone, 11 desoxy F = 11 desoxycortisol.
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Figure 4.6 Inhibition of pregnenolone metabolism by T and K in primary human
keratinocytes.
Cells (at a density of 2.5x105 in 12 well plates) were incubated for 24 h with 0.037MBq
(90.0 pmol) of [3H] pregnenolone and trilostane (T, 100 µM) or ketoconazole (K, 10
µM) in a volume of 1 ml/well.  Steroid metabolites were chloroform-extracted from
culture medium and resolved by thin layer chromatography.  Chromatogram is a
representative of three separate assays, each performed in triplicate using keratinocytes
isolated from a different individual. P5 = pregnenolone, P4 = progesterone, 17OHP5 =
17-hydroxypregnenolone, 17OHP4 = 17-hydroxyprogesterone.
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4.2.4 Progesterone metabolism by radiometric assay
The results of the radiometric assay to measure [3H] progesterone metabolism by
primary human keratinocytes after 24 h are shown in Figure 4.7.  The major products
migrated with  Rf values that matched 17-OH progesterone (32.9 ± 2.5 % conversion)
and cortisol (28.5 ± 1.9 % conversion).  Production of cortisol from progesterone was
confirmed by co-migration of progesterone metabolites with an authentic [1,2,6,7-3H]
cortisol standard (Figure 4.7 B).  The metabolites 11-deoxycortisol and cortisone were
not observed at the 24 h time point, however a small peak that migrated to a Rf value
matching pregnenolone was detected.  This would be consistent with reverse 3βHSD
activity, causing progesterone to be reduced to pregnenolone.
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Figure 4.7 Progesterone metabolism by primary human keratinocytes.
Primary human keratinocytes (at a density of 2.5x105 cells/well in 12 well plates) were
incubated for 24 h with fresh serum free medium containing 0.037 MBq (11.0 pmol) of
[3H] progesterone in a total volume of 1 ml/well. Steroid metabolites were chloroform-
extracted from culture medium and resolved by thin layer chromatography.  (A)
Progesterone metabolism by primary keratinocytes (B) Co-migration of progesterone
metabolite with cortisol authentic standard (labelled F).  Chromatogram is a
representative of three separate assays, each performed in triplicate using keratinocytes
isolated from a different individual. P4 = progesterone, 17OHP4 = 17-
hydroxyprogesterone, F = cortisol, E = cortisone.
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4.2.5 Cortisol metabolism by radiometric assay
Cortisol metabolism was assessed over 24 h using [3H] cortisol and TLC.  The results,
as illustrated in Figure 4.8, showed that primary keratinocytes were also capable of
metabolising cortisol into a product that co-migrated with cortisone.  Over 70% of the
cortisol available to the keratinocytes was oxidised to cortisone within 24 h (Table 1).
This suggests that primary human keratinocytes possess 11βHSD activity and are able
to inactivate cortisol to cortisone.  It could also indicate a suboptimal NADP+/NADPH
ER ratio in cells cultured in a serum free environment, which would favour the
metabolism of cortisol to cortisone.
In conclusion, the radiometric data demonstrates that primary human keratinocytes are
able to metabolise pregnenolone, progesterone and cortisol.  Pregnenolone was
metabolised to products that were indicative of progesterone, 17-OH pregnenolone and
17-OH progesterone.  Progesterone was metabolised to a product that co-migrated with
a cortisol authentic standard and cortisol was metabolised to a product matching
cortisone Rf migration.
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Figure 4.8 Cortisol metabolism by primary human keratinocytes.
Primary human keratinocytes (at a density of 2.5x105 cells/well in 12 well plates) were
incubated for 24 h with fresh serum free medium containing 0.037 MBq (13.7 pmol) of
[3H] cortisol in a total volume of 1 ml/well. Steroid metabolites were chloroform-
extracted from culture medium and resolved by thin layer chromatography.
Representative chromatogram for three separate assays, each performed in triplicate
using keratinocytes isolated from a different individual.  F = cortisol, E = cortisone.
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4.2.6 LC-MS analysis of keratinocyte steroid synthesis
To confirm the formation of cortisol from progesterone, cell culture medium from
keratinocytes incubated with progesterone (1 µM; 24 h) was analysed by LC-MS
(Figure 4.9).  In the absence of cells (i.e. in blank wells), the concentration of
progesterone recovered after 24 h was 192.5 ± 23.0 nM, indicating an extraction
efficiency of 19.3% relative to the total amount of progesterone added (since 192.5 nM
is equivalent to 19.3% of the total 1 µM of progesterone added).  In contrast, in the
presence of cells, the concentration of progesterone detected after 24 h fell to 102.7 ±
7.8 nM.  Concomitantly, 104.0 ± 33.6 nM cortisol was measured in the culture medium.
In addition, pregnenolone became detectable in the culture medium at a concentration of
19.6 ± 4.4 nM.  The presence of  pregnenolone could reflect de novo synthesis.
Alternatively, it could reflect the reduction of progesterone to pregnenolone via 3βHSD
as previously observed in immortalised HaCaT keratinocytes (Slominski et al., 2002).
The LC-MS and radiometric analysis both demonstrated that progesterone could be
metabolised to cortisol.  To investigate the process, time courses of pregnenolone,
progesterone and cortisol metabolism were analysed by LC-MS.  When 1 µM
pregnenolone was added to primary keratinocytes it was rapidly metabolised between 0
– 10 min but little metabolism was observed after 10 min (Figure 4.10).  There was
however, a large degree of variation in the distribution of the level of cortisol detected
at t = 0, ranging from 120 nM to 420 nM, possibly due to poor extraction efficiency or
low number of experimental replicates.  This experiment would need to be repeated to
confirm this rapid rate of pregnenolone metabolism at early time points.  There was no
change in progesterone or cortisol levels over this pregnenolone metabolism time
course.
The data illustrated in Figure 4.11 showed that progesterone was metabolised by
primary keratinocytes over a 240 min (four h) period, however, a concurrent increase in
cortisol levels was not observed during this time course.  Interestingly, there was a trend
suggesting that treating keratinocytes with progesterone could promote progesterone
synthesis, since there was an increase in progesterone detected above the baseline
between 10 min and 30 min which returned to basal levels at 60 min.  Progesterone was
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steadily metabolised thereafter (from 60 min to 240 min) although a corresponding
increase in cortisol was not detected.  This may be because the time course was not
sufficiently long enough for cortisol to be generated from progesterone as observed with
other 24 h experiments.  Future experiments should be conducted over a longer time
course, and should include the measurement of other progesterone metabolites such as
17-OH progesterone and 11-deoxycortisol.
Cortisol metabolism was also measured over a 4 h (240 min) time course.  Addition of 1
µM cortisol also appeared to induce a rapid peak in cortisol production, since the level
of cortisol increased above time 0 at 10 min (Figure 4.12).  The amount of cortisol
detected then returned to basal (time 0 levels) and did not appear to change from 30 min
to 240 min.  There was no change in pregnenolone or progesterone levels over the
cortisol time course.
LC-MS was also used to determine the efficiency of inhibition of 3βHSD and CYP17
activity by T and K.  Although radiometric assay demonstrated almost complete
inhibition of 3βHSD and CYP17 activity by T and K, LC-MS did not demonstrate the
same efficiency.  Table 4.1 displays the LC-MS results of pregnenolone detected in the
culture medium of primary keratinocytes treated with T and K and 1 µM pregnenolone
versus pregnenolone-treated cells.  The data showed that the relative capabilities of the
inhibitors to prevent further pregnenolone metabolism was as little as 7.81%.
LC-MS analysis was performed to analyse steroid synthesis by primary keratinocytes
incubated with 25-OH cholesterol, TNFα and/or dex in the presence or absence of T
and K over 24 h.  This was to corroborate the pregnenolone RIA results and to provide a
broader understanding of pregnenolone, progesterone, cortisol and cortisone synthesis
by primary human keratinocytes.  Unfortunately, there appeared to be a high level of
sample degradation as indicated by the relative levels of progesterone and pregnenolone
in the no cell control samples (Table 4.2).  However, despite sample degradation, some
progesterone and cortisol was detected in cells treated with the five compounds, T and
K, TNFα, dex and 25-OH cholesterol (cortisol 3.7 ± 2.6 nM, progesterone 3.6 ± 4.6
nM; pregnenolone was not detected).  This was the only treatment where cortisol and
progesterone were detected above basal/quantification limits.  The result correlates with
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the RIA data which also showed that the highest production of steroid (pregnenolone)
synthesis was with the same five compounds, T and K, TNFα , dex and 25-OH
cholesterol treatment (Figure 4.4).
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Figure 4.9 LC-MS analysis of progesterone metabolism by primary human
keratinocytes.
LC-MS trace of cortisol peak detected from the culture medium of primary human
keratinocytes treated with 1 µM progesterone for 24 h. The result is a representative
trace of two separate experiments from keratinocytes isolated a single skin biopsy.  P4 =
progesterone, F = cortisol, E = cortisone.
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Figure 4.10 Time course of pregnenolone metabolism analysed by LC-MS.
Primary keratinocytes were treated with 1 µM pregnenolone. Steroids were extracted
from culture medium after 0, 10, 30, 60, 120, 180 and 240 min and analysed by LC-MS
for cortisol, progesterone and pregnenolone. The data represents a single experiment,
taken from keratinocytes (isolated from one biopsy) treated in triplicate for each
treatment and analysed by LC-MS (mean ± S.D).
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Figure 4.11 Time course of progesterone metabolism analysed by LC-MS.
Primary keratinocytes were treated with 1 µM progesterone. Steroids were extracted
from culture medium after 0, 10, 30, 60, 120, 180 and 240 min and analysed by LC-MS
for cortisol, progesterone and pregnenolone. The data represents a single experiment,
taken from keratinocytes (isolated from one biopsy) treated in triplicate for each
treatment and analysed by LC-MS (mean ± S.D).
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Figure 4.12 Time course of cortisol metabolism analysed by LC-MS.
Primary keratinocytes were treated with 1 µM cortisol. Steroids were extracted from
culture medium after 0, 10, 30, 60, 120, 180 and 240 min and analysed by LC-MS for
cortisol, progesterone and pregnenolone. The data represents a single experiment, taken
from keratinocytes (isolated from one biopsy) treated in triplicate for each treatment and
analysed by LC-MS (mean ± S.D).
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Cell-free
controls
Untreated
cells
T and K T,  K and
pregnenolone
  247.7 1.6 < 0.4 19.6
  253.6 1.8 < 0.4 22.6
  329.7 Traces < 0.4 22.8
Average 277.0 1.7 < 0.4 21.7
SD 45.8 0.1 - 1.8
Table 4.1 Pregnenolone (nM) concentration determined by LC-MS to assess
relative efficiency of T and K to inhibit pregnenolone metabolism.
The data was generated from a single LC-MS run of triplicate samples for each
condition.
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Cell-free controls Cortisol Progesterone Pregnenolone
Untreated 0.00 0.21 (±0.17) 1.43 (±0.47)
Pregnenolone 0.05 (±0.00) 0.00 (±0.00) 92.37 (±27.46)
Progesterone 0.11 (±0.14) 0.10 (±0.17) 0.00
T, K, TNFα , dex and 25-OH
cholesterol
0.00 0.64 (±0.61) 0.00
Cells Cortisol Progesterone Pregnenolone
Untreated 0.30 (±0.22) 0.97 (±0.68) 0.00
Pregnenolone 0.10 (±0.17) 0.00 1.30 (±0.90)
Progesterone 0.52 (±0.91) 2.08 (±2.67) 3.35 (±3.02)
T and K 0.08 (±0.13) 0.50 (±0.51) 0.00
T, K, TNFα , dex and 25-OH
cholesterol
3.67 (±2.61) 3.58 (±4.58) 0.00
Table 4.2 Sample degradation affected LC-MS steroid analysis.
Primary human keratinocytes were incubated for 24 h with or without the following;
progesterone (1 µM), pregnenolone (1µM), T (100 µM), K (10 µM), dex (1 µM), 25-
OH cholesterol (5 µM), TNFα (50 ng/ml).  Steroids from cell media were extracted and
analysed (after more than three months storage at –80°C) by LC-MS, steroid
concentrations are displayed in nM.  The data represent average steroid concentration
(nM ± S.D.) from a single LC-MS analysis of three separate samples per condition.
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4.2.7 Keratinocyte cortisol synthesis detected by ELISA
A highly sensitive cortisol ELISA was utilised to quantify the production of cortisol by
primary human keratinocytes and to determine which medium condition was optimal
for cortisol synthesis.  Figure 4.13 shows that different types of keratinocyte culture
media affected the ability of the cells to synthesise cortisol.  Culturing keratinocytes in
EpiLife medium (without supplements) provided the highest cortisol levels detected by
ELISA.  Interestingly little or no cortisol was detected in cells that had been incubated
in RM+ culture medium (without supplements) or DMEM.  These experiments
demonstrated that primary keratinocytes (2x105 cell/ml in 12-well plates) grown in
EpiLife released 1.0 ± 0.2 nM cortisol over a 24 h period. The ELISA data demonstrate
that primary human keratinocytes are able to synthesise cortisol without any exogenous
stimulation.  The basal level of cortisol synthesis was dependent upon culture
conditions, with EpiLife keratinocyte culture medium providing the best conditions for
the synthesis of the steroid.  The complete formula of EpiLife is not publicly available
so it is not possible to determine if there is a compound within the medium that is
promoting cortisol synthesis.
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Figure 4.13 Optimisation of culture media for cortisol analysis by ELISA.
Primary human keratinocytes (2x105 cell/ml in 12-well plates) were cultured for 24 h in
different culture.  Cortisol levels from the culture media were then analysed by ELISA.
The percentage increase in cortisol detection relative to cell-free controls for each
condition was calculated.  The results represents two separate experiments of primary
keratinocytes isolated from a single biopsy, each measured in duplicate (mean ±S.D.).
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4.3 Discussion
In the experiments described  in this chapter, the ability of primary human keratinocytes
to synthesise steroids de novo from cholesterol and produce cortisol was investigated.
This pathway has not previously been reported in keratinocytes.
RIA demonstrated that primary keratinocytes were capable of producing pregnenolone,
the first committing step of steroid synthesis.  Previous research had detected
CYP11A1, FDX and FDXR in whole skin by RT-PCR and western blotting,
complementing the findings in this chapter (Slominski et al., 2004).  The pregnenolone
RIA results in this chapter suggest that there is a functionally active P450 side chain
cleavage system in primary keratinocytes.  Although pregnenolone synthesis has not
been previously reported in whole cell primary keratinocytes, steroid synthesis has been
detected by RIA in SEB-1 sebocytes (Thiboutot et al., 2003).  Enzymes required for
steroid synthesis were also identified in the hair follicle and cortisol was detected in
spent medium of cultured hair follicles and dermal fibroblasts (Ito et al., 2005;
Slominski et al., 2006).  In addition metabolism of 7-dehydrocholesterol to 7-
dehydropregnenolone via CYP11A1 has been detected in mitochondria isolated from
skin cells (Slominski et al., 2009).
Although radiometric assay demonstrated that T and K were effective 3βHSD and
CYP17 inhibitors, LC-MS data suggested that there was not a complete inhibition of
pregnenolone metabolism by T and K.  LC-MS demonstrated that the inhibitors were as
little as 7% effective.  This difference could be due to the amount of substrate used for
the two assays, where only 90 pmol pregnenolone was used for radiometric assay
whereas 1 µM (3 mmol) pregnenolone was used for LC-MS.
The RIA data generated some interesting findings since it showed that the addition of
25-OH cholesterol did not promote pregnenolone synthesis.  In classic endocrine
systems, this compound increases pregnenolone synthesis at least three fold (Dyson et
al., 2008).  This is because 25-OH cholesterol is more soluble than cholesterol and can
bypass StAR transport, circumventing the rate determining step of steroidogenesis and
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providing an abundant source of substrate to P45011A1.  However, in keratinocytes no
significant increase in steroidogenesis was detected when cells were treated with 25-OH
cholesterol in the presence of T and K compared to keratinocytes only treated with T
and K.  This suggests that there could be an alternative rate determining step of steroid
synthesis in primary human keratinocytes, such as cofactor availability and rodox
potential.
The only compound that was able to independently promote pregnenolone synthesis
above the level attained with T and K was dex.  This was a serendipitous finding since
dex was originally used to see whether there was a negative feedback mechanism
present in keratinocytes similar to the HPA axis, where cortisol can suppress CRH
activity to inhibit further steroid synthesis (Miller and O'Callaghan, 2002).  However,
there is evidence in the literature suggesting that GC can promote steroid synthesis.  For
example, Wistar rat Leydig cells treated with metyrapone to induce corticosterone
deficiency showed impaired testosterone production which could be rescued with the
addition of corticosterone (Parthasarathy and Balasubramanian, 2008).  In addition,
production of progesterone by immortalised human granulosa cells was at least four
fold higher in dex treated cells (Sasson et al., 2001).  This study showed that forskolin
upregulated StAR and FDXR expression in immortalised human granulosa cells.
Forskolin plus dex caused a significantly greater induction of steroid synthesis without
further upregulation of StAR or FDXR.  The authors did not discuss a mechanism by
which dex enhanced steroid synthesis without further upregulation of key steroidogenic
regulating proteins (Sasson et al., 2001).  This is indicative of potential alternative
mechanism for dex induced steroid synthesis by immortalised granulosa cells.
Radiometric analysis demonstrated that primary human keratinocytes could metabolise
pregnenolone, forming compounds that migrated with a pattern matching 17OH
progesterone, 17OH pregnenolone and progesterone.  The enzyme responsible for
converting pregnenolone into progesterone is 3βHSD (Berliner et al., 1962).  Although
this study is the first to report oxidation of pregnenolone to progesterone in primary
cultures of human keratinocytes, 3βHSD enzyme activity has previously been reported
in cultured keratinocytes demonstrated by the metabolism of DHEA to androstenedione
(Milewich et al., 1988).  The study by Milewich also treated primary human
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keratinocytes with [3H] pregnenolone but did not observe any metabolic activity.  This
could be due to the high concentration of [3H] pregnenolone chosen or to limited
sensitivity of the equipment used to measure the metabolites.  Reverse (but not forward)
3βHSD activity, converting progesterone to pregnenolone was also identified in HaCaT
immortalised keratinocytes (Slominski et al., 2002).  Therefore this unusual reverse
3βHSD activity that was observed in HaCaT cells has also been detected in cultured
primary keratinocytes as described in this chapter.
The presence of 17-hydroxy derivatives of pregnenolone and progesterone and
functional inhibition of 17-hydroxy derivative synthesis by ketoconazole suggests that
CYP17 is active in primary keratinocytes.  One previous study has shown that CYP17
protein is present in skin, including the epidermis, and was found to be functionally
active in SEB-1 sebocyte cells (Thiboutot et al., 2003).  CYP17 can also convert 17-
hydroxypregnenolone and 17-hydroxyprogesterone to DHEA and androstenedione
respectively.  Although DHEA and androstenedione metabolism has been described by
Milewich, synthesis of androgens from 17OH progesterone or 17OH pregnenolone was
not demonstrated by the results presented here or in previous reported studies of skin
steroidogenesis (Milewich et al., 1988).
Further analysis of steroid metabolism showed that primary human keratinocytes
converted pregnenolone to cortisol, including all obligate steroid intermediates.  This is
in contrast to the study of steroid metabolism in primary keratinocytes by Milewich that
was unable to detect pregnenolone or progesterone metabolism (Milewich et al., 1988).
More recently, the conversion of progesterone to deoxycorticosterone and a number of
additional deoxycorticosterone metabolites was demonstrated in HaCaT keratinocyte
immortalised cells, perhaps because this immortalised cell line has lost some
endogenous steroidogenic pathways (Slominski et al., 2002).  However, cortisol
synthesis from progesterone was not detected in the HaCaT system (Slominski et al.,
2002).  Milewich et al, performed similar TLC analysis of pregnenolone and
progesterone metabolism in keratinocytes with [3H] steroids.  However, neither
pregnenolone nor progesterone metabolism by primary human keratinocytes was
identified in their study (Milewich et al., 1988).  This might be due to the concentration
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of the [3H] steroids affecting the relative sensitivity of the enzyme activity and the
assay.
LC-MS analysis of progesterone metabolism confirmed the production of cortisol by
primary human keratinocytes. In the absence of cells (i.e. in blank wells supplemented
with 1 µM progesterone), the concentration of progesterone recovered after 24 h was
192.5 ± 23.0 nM, indicating an extraction efficiency of 19.2%.  In contrast, in the
presence of cells, the concentration of progesterone detected after 24 h fell to 102.7 ±
7.8 nM, and 104.0 ± 33.6 nM cortisol appeared in the culture medium.  This suggests
that approximately 50% of the available progesterone was metabolised to cortisol.  In
addition, pregnenolone was also detected in the culture medium at a concentration of
19.6 ± 4.4 nM.  The presence of pregnenolone could either reflect de novo synthesis via
StAR/MLN64 & CYP11A1, or the reduction of progesterone to pregnenolone via
3βHSD, which has previously been observed in immortalised HaCaT keratinocytes
(Slominski et al., 2002).  The 3βHSD enzyme requires NAD+ as a cofactor for
pregnenolone to be converted to progesterone, whilst NADH is required for the reverse
reaction.
Further radiometric analysis also demonstrated that primary human keratinocyte can
metabolise cortisol to cortisone.  Inter-conversion of cortisol to cortisone is carried out
by 11βHSD and is a common mechanism in mineralocorticoid sensitive tissues to
prevent illicit occupation of mineralocorticoid receptors by cortisol (Monder, 1991;
Tomlinson and Stewart, 2001; Tomlinson et al., 2004).  11βHSD1 activity has been
observed in whole skin, epidermis, sweat gland ducts and dermal fibroblasts (Hammami
and Siiteri, 1991; Hsia and Hao, 1966; Kenouch et al., 1994; Malkinson et al., 1959).
However, 11βHSD1 activity is reported to be low in the epidermis in comparison with
sweat gland ducts (Kenouch et al., 1994).  The results presented in the radiometric assay
demonstrate that keratinocytes possess the ability to inactivate cortisol.  Potentially this
would enable them to achieve a balance between the anti-inflammatory and pro-
differentiation properties of cortisol and the necessity for cell proliferation.  The high
proportion (approximately 70%) of cortisol that was metabolised to cortisone
potentially indicates that NADP+ was abundantly available for 11βHSD1.  Similar to
3βHSD, 11βHSD1 require NADP+/NADPH as cofactors.  When NADP+ is abundant,
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conversion of cortisol to cortisone is favoured.  Alternatively, the cortisol metabolism
could be due to 11βHSD2 activity that has been shown to be induced in primary
keratinocytes treated with dex (Stojadinovic et al., 2007).  Further experiments are
required to determine 11βHSD1 and 11βHSD2 activity respectively.
Keratinocyte culture medium influenced the ability of cells to synthesise cortisol.  The
differences in the culture media and their effect on keratinocyte cortisol synthesis
remain to be defined.  This is mainly because the composition of commercially
available keratinocyte culture media is not publicly available.  However, the level of
cortisol detected by ELISA from cells (2x105 cell/ml in 12-well plates) without any
exogenous stimulation was 1.0 ± 0.2 nM when cultured in EpiLife medium over 24 h.
This confirms that primary human keratinocytes can synthesise cortisol.  Although this
concentration of cortisol is a fraction of systemic levels, which range between 200 –
500 nM for total cortisol and 1-10 nM for free cortisol, it is of physiological relevance
since between 1 – 10 nM cortisol is sufficient to activate glucocorticoid receptors
(Charmandari et al., 2008; Dong et al., 2006).  In addition, the actual levels of cortisol
synthesised by primary keratinocytes maybe as high as 5 nM when taking into account
the 70% oxidation of cortisol to cortisone as observed by radiometric assay.  Cortisol
production by keratinocytes is unlikely to make a significant impact on systemic
cortisol levels since cortisol is negligible in serum from adrenalectomised mice (del Mar
Grasa et al., 2007).  However, it is likely to be important for cutaneous biology as the
glucocorticoid receptor has been shown to be critical to maintain barrier competency
and promotes normal keratinocyte differentiation (Bayo et al., 2008).  In addition, the
epidermis is avascular so may require a localised cortisol supply to maintain the skin
barrier.
The combined analysis of RIA, radiometric assay and LC-MS suggest that the redox
potential of cultured primary keratinocytes favours NADP+ and NADH availability
rather than NADPH and NAD+.  This is for a number of reasons; firstly RIA data did
not increase with 25-OH cholesterol, suggesting an alternative rate determining step of
steroid synthesis other than StAR-mediated cholesterol transport across mitochondrial
membranes.  An alternative rate determining step could involve the availability of the
NADPH co-substrate required for the synthesis of pregnenolone from cholesterol.
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Secondly, radiometric data of [3H]cortisol metabolism showed that approximately 70%
of cortisol was metabolised to cortisone.  The cortisol to cortisone shuttle is a reversible
reaction mediated by 11βHSD1.  The direction of the reaction is regulated by the
availability of the NADPH co-substrate, so when NADPH is abundant, the enzyme
favours cortisone to cortisol conversion and when NADP+ is abundant, cortisol
metabolism to cortisone is favoured. Thus HSB11B1 activity could act as a sensor for
NADPH redox potential of the endoplasmic reticulum (ER).  Thirdly, putative
progesterone metabolism to pregnenolone was identified by radiometric assay and LC-
MS in primary human keratinocytes.  Although 3βHSD is not generally regarded as a
bi-directional enzyme, this reverse activity, generating pregnenolone from progesterone,
has been described in HaCaT keratinocytes (Slominski et al., 2002).  Since NAD+ is
required for the reaction to proceed in the direction of pregnenolone to progesterone
synthesis, NADH would need to be abundant to the enzyme in order for the reverse
reaction to occur.  Finally, dex was able to promote pregnenolone synthesis.  Dex has
been shown to increase luminal NADPH availability (Piccirella et al., 2006).  In
addition, in reconstituted systems, cortisol has been shown to increase NADPH redox
potential, whereas cortisone promotes NADP+ redox potential (Piccirella et al., 2006).
Previous expression analysis of regulators of steroid synthesis in normal versus diseased
epidermis demonstrated a disruption to the expression pattern of steroidogenic
regulators, indicating dysregulated steroidogenesis in these hyperproliferative disorders
(Chapter 3).  Thus it is likely that disorders such as psoriasis and atopic dermatitis that
are treated with cortisol analogues, have a disrupted local steroidogenesis pathway.
Unfortunately it has not been possible to obtain keratinocytes isolated from psoriatic or
atopic dermatitis skin to assess this hypothesis.
In summary, this chapter has demonstrated that primary human keratinocytes are
capable of synthesising and metabolising pregnenolone, progesterone and cortisol.  The
levels of cortisol synthesised by primary keratinocytes without exogenous stimulation
would be sufficient to activate glucocorticoid receptors.  There is also evidence to
suggest that the rate determining step of steroid synthesis in cultured keratinocytes
could be regulated by cofactor availability rather than cholesterol transport.
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Chapter 5.  Investigating the function of
dexamethasone in primary human keratinocytes
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5.1 Introduction
Despite the widespread use of GC for skin conditions such as psoriasis and atopic
dermatitis, there is surprisingly limited analysis of the molecular function of cortisol in
skin.  The most common side-effect of prolonged GC treatment is skin atrophy
(Stojadinovic et al., 2007).  This effect of cortisol is also evident in patients with
Cushing’s syndrome who present with wafer-thin skin.  Cushing’s syndrome patients
and patients who require chronic GC therapy also have increased incidence of bone
fractures (Horsch et al., 2007).  Moreover, some studies have found a correlation with
bone density and skin thickness and the risk of osteoporosis (Cagle et al., 2007).
High doses of GC have been shown to inhibit osteoblast (MBA-15.4 mouse bone
marrow stromal cells and MG-63) cell proliferation, and therefore decrease bone
density, through activation of DUSP1.  This leads to inhibition of the mitogen activated
protein kinase ERK1/2 (Horsch et al., 2007).  DUSP1 is a dual phosphatase that
dephosphorylates and deactivates ERK1/2 activity at p42/44.  Dex has been shown to
promote DUSP1 transcription in primary human keratinocytes but the mechanism of
GC mediated-skin atrophy has yet to be elucidated (Stojadinovic et al., 2007).
In contrast to inducing skin atrophy, cortisol has also been shown to protect specific
types of cells from apoptosis, which has partly been attributed to the effect of cortisol
on cellular redox potential in neurones (Du et al., 2009).  Recently, dex was also shown
to protect primary human keratinocytes from apoptosis by promoting anti-apoptotic and
suppressing pro-apoptotic gene transcription (Stojadinovic et al., 2007).  The anti-
apoptotic nature of cortisol in skin was also demonstrated in GR knock out mice.  Mice
with GR-/- knockout had increased keratinocyte apoptosis throughout the layers of the
epidermis together with hyperproliferation, decreased keratinocyte differentiation and
barrier formation (Bayo et al., 2008).  Therefore, as in neuronal cells, cortisol could also
influence cellular redox potential in keratinocytes as part of a protective mechanism to
prevent apoptosis.
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Cortisol has been shown to promote cellular redox potential by increasing G6PDH and
H6PDH activity to increase the availability of NADPH in rat hepatocytes and adipose
cells (Piccirella et al., 2006).  In addition, cortisol was able to increase NADPH even in
the oxidative environment of the ER, making NADPH available to enzymes such as
11βHSD1 (Piccirella et al., 2006).  All enzymes involved in steroidogenesis are
dependent upon cofactors to deliver or receive electrons for the catalysis of steroids
(Agarwal and Auchus, 2005; Sherbet et al., 2007).  Depending on the steroid enzyme,
these cofactors are NADPH or NAD+ and their abundance determines the oxidative or
reductive capacity of the cell (i.e. the redox potential) (Agarwal and Auchus, 2005;
Sherbet et al., 2007).  NADPH are NAD+ are more abundant than steroid precursors by
several orders of magnitude and are required for many metabolic processes (Agarwal
and Auchus, 2005; Sherbet et al., 2007).  Therefore the redox potential of the cell is
regarded as a critical driver of steroid synthesis and subtle changes in cofactor
availability can dramatically alter the steroidogenic potential of a cell (Agarwal and
Auchus, 2005; Sherbet et al., 2007).  This suggests that cortisol could enhance steroid
synthesis by influencing cellular redox potential.  Indeed, cortisol has been shown to
promote steroidogenesis in Leydig and granulosa cells, which in granulosa cells, was
independent of StAR, or steroid enzyme expression (Parthasarathy and
Balasubramanian, 2008; Sasson et al., 2001).
The aim of this chapter was to investigate mechanisms of GC induced skin thinning by
examining DUSP1 and pERK1/2 expression in keratinocytes after incubation with dex.
Cell proliferation was measured by MTT assay.  Cellular redox potential was measured
by MTT and NADP+/NADPH cycling assay.  Cell viability was assessed using a trypan
blue cell counting assay.  Annexin V and PI labelling flow cytometry was used to
investigate the influence of dex on cell cycle, apoptosis and cell death in primary human
keratinocytes.
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5.2 Results
5.2.1 Effect of dex on DUSP1 expression and ERK1/2
Dex (1 µM) induced DUSP1 expression over time in primary human keratinocytes
(Figure 5.1).  The protein expression increased from 3 h, peaking at 5 h then returned to
basal levels at 7 h.  This suggests that dex was able to activate DUSP1 expression which
could have the ability to suppress MAPK activity.
Dex was able to rapidly decrease phospho-ERK1/2 (pERK1/2) after 30 min whilst total
ERK1/2 expression remained constant (Figure 5.2).  However, pERK1/2 increased after
30 min suggesting that induction of DUSP1 expression between 1 and 5 h was not
responsible for the rapid alteration in pERK1/2 activity.  In addition, phosphorylation of
MEK, the upstream regulator of pERK1/2 remained unchanged by dex treatment
(Figure 5.2).
DUSP1 is also able to influence other members of the MAPK pathway that regulate cell
proliferation.  Therefore a simple MTT assay was employed to assess keratinocyte cell
proliferation in the presence of MAPK inhibitors (MEKi, JNKi, p38i) to determine if
one MAPK pathway was predominant in regulating cell proliferation of primary human
keratinocytes (Figure 5.3).  All three MAPK inhibitors significantly reduced the MTT
readout from primary human keratinocytes suggesting either all three MAPK are
required for keratinocyte proliferation, although the inhibitors are not entirely specific
or demonstrate cross-talk between the pathways.  The most effective inhibitor was
pJNKi, however it is worth noting that the cells appeared highly necrotic upon visual
inspection implying some toxicity of the inhibitor.  Rather unexpectedly, dex
significantly increased the MTT readout.
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Figure 5.1 Western blot analysis of DUSP1 expression (0 – 7 h) in primary
keratinocytes incubated with 1 µM dex.
Upper blot: DUSP1 protein detection, lower blot: β-actin loading control.  Images are
representative of three separate experiments.
0 h 1 h 2 h 3 h 4 h 5 h 6 h 7 h
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166
A.
B.
C.
Figure 5.2 Western blot analysis of pMEK, pERK1/2 and total ERK1/2 expression
over time in primary keratinocytes treated with 1 µM dex.
(A) pMEK, (B) pERK1/2, (C) total ERK1/2 expression.  Images are representative of
three separate experiments.
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Figure 5.3 MTT assay of primary human keratinocytes treated for 72 h with
MAPK inhibitors or dex.
Keratinocytes were incubated with 1 µM dex or MAPK inhibitors; p38i (SB203580 1
µM), JNKi (SP600125 10 µM), MEKi (U0126 10µM).  The data represent the mean+/-
S.E.M of three separate experiments.  Statistical differences were obtained using one-
way ANOVA followed by Tukey’s multiple comparisons test where appropriate, *
P<0.05, ** P<0.01, *** P<0.001.
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5.2.2 Effect of dex on MTT reductive capacity of primary keratinocytes
The MTT assay is primarily used as an indicator of cell proliferation but the assay
actually measures the reductive capacity of cells (for more information see Methods
2.11) (Bernas and Dobrucki, 2002).  There are a number of factors that could influence
an increase in MTT assay readout including increased cell proliferation, increased
cellular redox capacity or decreased cell death.
Dex was able to induce a small but significant (approximately 1.3-fold) increase in
MTT readout of primary human keratinocytes cultured in RM+ keratinocyte medium
without serum (or cortisol) for 72 h.  The effect of dex appeared to be dose-dependent,
with maximal response occurring between 0.01 – 1 µM (Figure 5.4).  The MTT readout
between these doses was significantly higher than untreated or vehicle controls.  In
addition, there was a trend for reduced MTT readout (though not significantly) at the
highest concentration of dex (100 µM).  The keratinocyte response to dex decreased
towards untreated levels at 0.001 µM.  Since dex was used at 1 µM for pregnenolone
RIA and provided maximal MTT response in the primary keratinocytes, 1 µM dex was
chosen for all subsequent experiments.
Increased MTT signal following incubation with dex was unexpected since the MTT
assay is primarily used to measure cell proliferation and dex is regarded as an inhibitor
of keratinocyte proliferation (Stojadinovic et al., 2007).  Visual inspection of cell
morphology of dex treated keratinocytes showed that proliferating cells appeared to
form smaller and in tighter colonies compared to untreated or vehicle control
keratinocytes (Figure 5.7).  There was not a noticeable visual difference in
differentiating keratinocytes that are reported as having a larger, flatter morphology.
However, more aggregates of apoptotic/necrotic cells were observed in untreated and
vehicle control cells.  Thus dex could influence MTT readout by maintaining cell
viability, even in serum-free conditions.
The effect of serum on cultured primary human keratinocytes with and without dex was
also investigated by MTT assay (Figure 5.5).  Low serum culture conditions are
reported to inhibit cell cycle (Cooper, 2003).  Therefore as expected there was a
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sequential increase in MTT readout with increasing serum conditions, 0 % (v/v),  ≤ 1%
(v/v) and < 10% (v/v).  Dex also significantly increased MTT readout detected from the
keratinocytes at each of the different serum concentrations.  Since serum also contains
cortisol, all experiments were consequently performed in serum-free medium.
The effect of dex on keratinocyte MTT assay was inhibited by the GR inhibitor RU486
(Figure 5.6).  Cells incubated with RU486 for 72 h had an MTT readout similar to
untreated keratinocytes.  Moreover, the inhibitor completely blocked the effect of dex
since the combined treatments also matched basal levels.  Therefore dex is likely to be
exerting its effects on keratinocytes via the GR in this instance.
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Figure 5.4 MTT assay concentration-response of primary keratinocytes incubated
with dex.
Primary human keratinocytes were incubated with dex (1x10-9 M – 1x10-4 M) in serum-
free and cortisol-free keratinocyte culture medium for 72 h. Statistical differences were
obtained using one-way ANOVA followed by Tukey’s multiple comparisons test where
appropriate, * P<0.05.
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Figure 5.5 MTT assay of primary keratinocytes cultured in different
concentrations of serum with or without dex.
Primary human keratinocytes were incubated for 72 h in serum-free medium (SFM),
1% serum or 10% serum in the absence or presence of 1µM dex.  The data represent the
mean +/- S.E.M of three separate experiments.  Statistical differences were obtained
using one-way ANOVA followed by Tukey’s multiple comparisons test where
appropriate, *** P<0.001.
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Figure 5.6 MTT assay of primary human keratinocytes incubated with dex and/or
RU486 for 72 h.
Keratinocytes were incubated with 1 µM dex and/or 1 µM RU486.  The data represent
the mean +/- S.E.M of three separate experiments.  Statistical differences were obtained
using one-way ANOVA followed by Tukey’s multiple comparisons test where
appropriate, *** P<0.001 versus untreated; # # # P<0.001 versus dex.
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Figure 5.7 Morphological effects of dex on primary human keratinocytes.
(A) Untreated, (B) vehicle control, (C) dex 1 µM incubated for 72 h in RM+ culture
medium without serum.  Proliferating cells (example colonies are highlighted with a red
outline) formed tighter colonies when treated with dex.  Arrow depicts
apoptotic/necrotic cell cluster.  Images are representative of at least three separate
experiments.
A. Untreated B. Vehicle control
C. Dex
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5.2.3 Effect of dex on keratinocyte cell viability
Primary human keratinocytes were also analysed for cell viability since this could also
explain the changes in MTT readout.  A trypan blue cell counting assay was used to
determine the number of viable keratinocytes (Figure 5.8).  Cell number was
significantly increased (over two-fold) in keratinocytes incubated with dex compared to
untreated or vehicle control samples.  There was no significant difference between the
number of viable cells in untreated and vehicle control samples, suggesting that the
solvent (methanol) that dex was dissolved in did not influence keratinocyte viability.
However, the data does not indicate whether increased cell viability was due to an up
regulation of cell proliferation or inhibition of cell death.
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Figure 5.8 Trypan blue cell viability assay of primary human keratinocytes
incubated with dex for 72 h.
Keratinocytes were incubated with 1 µM dex.  The data represent the total number of
viable cells in a T75 flask counted using a haemocytometer, mean +/- S.E.M of three
separate experiments.  Statistical differences were obtained using one-way ANOVA
followed by Tukey’s multiple comparisons test where appropriate, *** P<0.001.
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5.2.4 Effect of dex on live, early apoptotic and dead keratinocytes
To determine whether increased cell viability and MTT readout were due to changes in
keratinocyte proliferation or cell death, cells were assessed using annexin V and PI
FACS analysis.  Figure 5.9 is an example of the controls and gates used to determine
the subdivision of live, early apoptotic, dead cells and cell debris that had been detected
by annexin V and PI labelling.  U.V. light was used as a positive control for cell death.
The controls showed a clear difference in the distribution of subpopulations, however
there was some autofluoresence detected during analysis, thus the division between
subpopulations was not as discrete as expected.
Figure 5.10 displays the results of live cells determined from annexin V and PI FACS
analysis.  There was no significant difference between any of the treatments except
U.V. exposure, which induced a 50% decrease in cell viability.  Neither dex nor RU486
affected the number of viable cells using this technique of analysis.  In addition there
was no significant difference in early apoptosis between any of the treatments except for
U.V. exposure, where annexin V positive cells increased more than 2 fold (Figure 5.10).
Moreover, there was no significant difference between dead (PI positive and annexin V
positive) cells for any of the treatments, although there was a trend for an increased cell
death in U.V. exposed cells (Figure 5.11).  Finally there was no significant difference in
the amount of cell debris or total number of dead cells (cell debris and dead cells
combined) between in any of the treatments.  Therefore, in contrast to the trypan blue
cell viability assay, annexin V FACS analysis did not detect a difference in live, early
apoptotic, dead cells or cell debris in primary keratinocytes treated with dex and/or
RU486.
An alternative to increased cell viability or decreased cell death that could account for
the higher trypan blue reading would be a change in cell cycle.  Annexin V/PI FACS
analysis only accounts for a proportion of the cells within a given sample.  However,
changes in cell cycle can lead to an increase in cell number without necessarily altering
the proportion of proliferating cells versus apoptotic or dead cells.  To account for this,
cell cycle was analysed using PI labelling (Figure 5.12).  However, no difference in cell
cycle was detected with the different treatments, except for U.V. exposed keratinocytes
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that arrested in G2M phase of the cell cycle (Figure 5.13). One limitation of PI cell cycle
analysis is that it does not account for cell stasis, where the cell stops cycling but is still
metabolically active with an unchanged cell cycle profile.  Further analysis using
bromodeoxyuridine (BrdU) labelling would be required to measure cell stasis.
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Figure 5.9 Example of gated plots used for analysing cell viability, apoptosis and
death.
(A) Total non-labelled cell population, (B) Annexin V labelled cells display apoptotic
cells in Q4, (C) PI labelled cells display cell debris in Q1 and dead cells in Q2, (D) U.V.
treated cells were used as a positive control for cell death.  Left-hand plots depict total
cell population, right-hand plots display gates used for subdividing cells from live,
apoptotic, dead and cell debris.
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Figure 5.10 Flow cytometry analysis of cell viability and apoptosis following
treatment with dex and/or RU486.
FACS analysis results of (A) PI and annexin V negative (live) cells,  (B) annexin V
positive (early apoptotic) cells.  Dex 1 µM,  RU486 1 µM, U.V. 20 mJ U.V.B. at 0.2
mV/cm2.  Data represents the mean ± SEM, n=3. Statistical differences were obtained
using one-way ANOVA followed by Tukey’s multiple comparisons test where
appropriate, * P<0.05, ** P<0.01, ***P<0.001.
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Figure 5.11 Flow cytometry analysis of cell debris and dead cells following
treatment with dex and/or RU486.
FACS analysis results of (A) PI positive cell debris, (B) PI positive and annexin V
positive (dead cells), (C) combined population of PI positive only (cell debris) and PI
positive and annexin V positive (dead cells). Dex 1 µM, RU486 1µM, 20 mJ U.V.B. at
0.2 mV/cm2.  Data represents the mean ± SEM, n=3. Statistical differences were
obtained using one-way ANOVA followed by Tukey’s multiple comparisons test where
appropriate.
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 Treatment Live cells Early
apoptotic
cells
Dead cells Cell debris Early
apoptotic &
dead cells
Untreated 76.3 +/- 4.6 9.7 +/- 8.7 12.2 +/- 5.3 2.9 +/-1.0 21.9 +/-14.0
Vehicle control 76.3 +/- 3.5 3.3 +/- 1.8 11.4 +/- 3.6 1.4 +/- 0.8 14.7 +/- 5.4
Dex 70.8 +/- 7.2 3.6 +/- 2.7 12.8 +/- 6.0 1.6 +/- 0.9 16.4 +/- 8.7
RU486 72.1 +/- 6.9 3.2 +/- 2.2 14.4 +/- 7.0 2.2 +/- 1.3 17.6 +/- 9.2
Dex and RU486 73.0 +/- 6.0 3.5 +/- 2.5 12.8 +/- 5.4 2.1 +/- 1.5 16.3 +/- 7.9
U.V. 40.0 +/- 14.9 8.4 +/- 5.7 34.5 +/- 13.3 4.0 +/- 3.1 42.9 +/- 12.2
Table 5.1 Summary of annexin V/PI flow cytometry data.
The table displays the percentage of live (annexin V and PI negative), early apoptotic
(annexin V positive, PI negative), dead (annexin V and PI positive) cells and cell debris
(PI positive, distinguished by side scatter distribution) of primary human keratinocytes
treated with or without dex and RU486.  Dex 1 µM, RU486 1µM, 20 mJ U.V.B. at 0.2
mV/cm2. Data represents the % mean ± SEM, n=3.
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Figure 5.12 Example of gated graphs used for analysing cell cycle.
The total population was gated (P1) then live cells were gated (P2) and an area
histogram was generated to determine the percentage of cells in sub G1 (P3), G1 (P4), S
(P5) and G2M (P6) phases of the cell cycle.
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Figure 5.13 Area parameter histograms representing cell cycle analysis of primary
keratinocytes treated with dex and/or RU486 for 72 h.
(A) untreated cells, (B) vehicle control, (C) dex, (D) RU486, (E) dex and RU486, (F)
U.V. exposed cells.  Dex 1µM, RU486 1µM, 20 mJ U.V.B. at 0.2 mV/cm2.  Histograms
are representative of two separate experiments.
A.
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5.2.5 Effect of dex on NADPH redox potential of keratinocytes
An alternative explanation for changes in MTT readout and pregnenolone synthesis
(Section 4.3.2) could be through dex mediated changes in cellular redox potential.  The
influence of dex on cellular redox potential was further investigated by measuring
NADP+/NADPH ratio using a cell cycling assay.  The cell cycling assay in Figure 5.14
demonstrated a trend for an increase of total ratio of NADPH relative to NADP+ in
primary human keratinocytes treated with dex for 72 h.  However, the statistical
analysis did not classify this difference as significant.  Therefore it is currently
inconclusive as to whether dex can influence total cellular NADPH availability in
keratinocytes although the trend of the data lies in favour of this possibility.
Since dex appeared to improve cell viability in a serum-free media, the RIA data was
also recalculated relative to total protein concentration to determine whether the
observed increase of pregnenolone output by dex was due to changes in cell viability/
cell number.  Figure 5.15 demonstrated that dex was able to induce significantly higher
pregnenolone synthesis by primary human keratinocytes even when normalised to total
cell protein.  This suggests that the effects of dex on keratinocyte steroidogenic capacity
was not just due to an increase in cell number.
In summary, dex has been shown to induce DUSP1 expression after 3 h and decrease
pERK1/2 after 30 min.  Unexpectedly, dex significantly enhanced MTT measured
reductase capacity of untreated primary keratinocytes whereas MAPK inhibitors
significantly reduced this activity.  Dex treated keratinocytes were then analysed for cell
viability, apoptosis, necrosis and influence on NADPH availability.  No significant
difference was detected in live cells, early apoptotic or dead cells by FACS analysis.
There was also no difference in cell cycle. However, there was an increase in the
number of viable cells tested by trypan blue assay.  In addition, there was a trend for
dex to enhance total NADPH levels, a shift that may explain the increase in
pregnenolone synthesis induced by dex in primary human keratinocytes.
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Figure 5.14 Quantification of NADPH relative to NADP+ in primary human
keratinocytes treated with dex.
Cells were incubated for 72 h with dex (1 µM), results are expressed as a ratio of
NADPH relative to NADP+.  The data represents a two experiments (mean ±S.D.).
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Figure 5.15 Pregnenolone synthesis by primary human keratinocytes normalised
to total protein concentration.
Pregnenolone was detected by RIA from culture media of primary human keratinocytes
after 24 h.  T: 100 µM trilostane, K: 10 µM ketoconazole, dex: 1 µM dexamethasone,
25-OH: 5 µM 25-hydroxycholesterol.  The data represents a single experiment, taken
from keratinocytes treated in triplicate wells for each treatment and analysed in
duplicate by RIA. Statistical differences were obtained using one-way ANOVA
followed by Tukey’s multiple comparisons test where appropriate (mean ± S.D., *P
<0.05, **P<0.01).
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5.3 Discussion
Dex gradually increased DUSP1 expression which peaked at 5 h and decreased after 7
h.  This DUSP1 expression time course corresponds with dex-induced DUSP1
transcription detected between 1 and 4 h by microarray in primary human keratinocytes
(Stojadinovic et al., 2007).  In addition, DUSP1 expression was maximal after 5 h in
MBA-15.4 and MG-63 osteoblasts and this was associated with a decreased level of
pERK1/2 at this time point (Horsch et al., 2007).  However, the same response was not
observed in primary human keratinocytes where dex rapidly reduced pERK1/2 after 30
min but appeared to have no effect at 5 h.  This suggests there was not the same
prolonged suppression of pERK1/2 in keratinocytes relative to osteoblasts, although
further time points would be required to confirm this finding.
The absence of prolonged pERK1/2 dephosphorylation suggests that in this culture
system, dex might not be inhibiting cell proliferation.  Although deactivation of other
MAPK such as JNK and p38 might provide an alternative target for DUSP1 mediated
inhibition of cell division, the MTT assay, FACS analysis and visual inspection of cell
morphology did not identify a suppression of keratinocyte proliferation by dex.
In contrast, dex actually increased the MTT signal in both a concentration-dependent
and GR-dependent manner in primary human keratinocytes.  Although the MTT assay
is classically used to assess cell proliferation it in fact measures cellular reductase
activity.  The MTT reaction was thought to be specific to the mitochondria but MTT
reduction has recently been reported to localise to other organelles in the cell in addition
to the mitochondria (Bernas and Dobrucki, 2002).  Therefore there are a number of
factors that could contribute to increased MTT signal including cell proliferation,
decreased cell death or increased cellular redox potential.
Dex is regarded as an inhibitor of cell proliferation since it is used to suppress
hyperproliferative skin disorders.  Therefore, increased MTT signal by dex treatment
was unexpected.  Indeed, dex (1x10-7M) was reported to induce a small but significant
decrease in cell proliferation in primary human keratinocytes over 72 h (Stojadinovic et
al., 2007).  However, surprisingly the same study demonstrated that dex did not reduce
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the transcription of genes associated with proliferation but rather induced those
associated with differentiation (Stojadinovic et al., 2007).  Differing cell culture
conditions could account for the disparity between these results.  Keratinocytes in this
study were cultured in high calcium medium (supported with 3T3 fibroblasts prior to
the assay) whereas keratinocytes in the Stojadinovik study were cultured in low calcium
keratinocyte defined serum-free (and 3T3 fibroblast-free) medium.  Primary human
keratinocytes cultured in keratinocyte defined medium have been reported to have
slower growth rate/expansion time, poorer adhesion, increased granulation and higher
batch to batch variation with respect to keratinocytes grown in high calcium with 3T3
cells (Daniels et al., 1996).  Therefore the difference in culture conditions could have a
profound effect on cell proliferation assays.
Serum levels of culture medium also increased the MTT response of keratinocytes since
low or no serum can inhibit the cell cycle (Cooper, 2003).  Serum contains steroids, so
all steroid analysis in this study was performed in the absence of serum.  However, the
data shows that serum can significantly alter the MTT signal, suggesting an increase in
cell proliferation, redox potential and/or decrease in cell death.  If redox potential is
dysregulated by an absence of serum, it implies that conditions could be suboptimal for
maximal steroidogenesis of keratinocytes in culture.  Interestingly, the addition of dex
was able to promote a further MTT response at each of the serum concentrations used,
implying dex had a role beyond the serum effect alone.
Dex has been shown to promote granulosa cell viability by preventing apoptosis in a
serum-free environment, so the increase in MTT signal could be due to protection from
apoptosis (Sasson et al., 2001).  Dex can also inhibit apoptosis in keratinocytes exposed
to U.V. light (Stojadinovic et al., 2007).  Therefore, the increased MTT signal could be
due to increase in cell viability by preventing cell death.  The trypan blue assay
demonstrated that with no serum, dex could enhance keratinocyte cell viability.  This
matched the previous observations of keratinocyte morphology in cell culture with and
without dex treatment and the MTT data.
In contrast, annexin V FACS analysis that was utilised to identify whether a difference
in cell viability was due to changes in live, apoptotic or dead cells, failed to determine a
189
difference in dex treatment from untreated cells.  Analysis of live, dead and apoptotic
cells by flow cytometry did not demonstrate a significant difference between untreated,
dex and/or RU486 treated cells.  This could be because the assay was not sensitive
enough to detect a difference between treatments.  Alternatively annexin V may not
have been the optimum marker for apoptotic cells in this instance.  This is because
during apoptosis there is a lag phase between phosphatidylserine (PS) positivity that is
detected by annexin V and PI positivity (Krysko et al., 2008).  Therefore a late
apoptotic cell can appear positive for both annexin V and PI.  In addition, some necrotic
cells have been reported to be PI negative whilst externalising PS that would provide a
false-positive signal of an early apoptotic cell (Krysko et al., 2008).  Thus either the
time point or the marker of apoptosis would need to be optimised if FACS were to be
used for further analysis.  However, since there was no significant difference between
samples with apoptotic and dead cells combined, the data suggests that there was no
change in overall cell death with dex treatment.  Alternatively, due to the mechanics of
FACS, only single cells are selected for analysis and cell aggregates are rejected.
Primary keratinocytes commonly form aggregates upon trypsinisation, therefore a
subpopulation of cell aggregates may have been disregarded which could provide
essential information that could account for the differences between treatments.
An alternate method for analysing apoptosis is a terminal deoxynucleotidyl transferase
dUTP nick end labelling (TUNEL) assay that measures DNA fragmentation as a result
of the apoptotic signalling cascade.  This assay can be performed in vitro without the
use of trypsinisation and measures late rather than early stages of apoptosis.  Therefore,
future work to determine whether dex can protect keratinocytes from apoptosis should
use TUNEL assay, since it will circumvent some of the limitations of FACS analysis.
The anti-apoptotic effects of dex on neuronal cells have been partly attributed to the
treatments influence on cellular redox potential of the cells (Du et al., 2009).  Changes
in reduction capacity could also account for elevated MTT signal with dex treatment.
Further analysis of cellular redox potential was investigated by NADP+/NADPH cell
cycling assay.  Although the data did not reach significance (probably due to the low n
number), there was a trend for increased amount of total NADPH in keratinocytes
treated with dex.  This suggests that dex could have the potential to increase NADPH
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availability, an essential cofactor for many steroidogenic enzymes including CYP11A1
that regulates pregnenolone synthesis.  Previous research has also demonstrated that dex
and cortisol can promote NAPDH production even in an oxidative environment
(Piccirella et al., 2006). Therefore, since cellular redox is an essential driver of
steroidogenesis (Agarwal and Auchus, 2005; Sherbet et al., 2007), the potential effect of
dex on redox potential could account for its potency for induction of steroidogenesis.
Overall, the data shows that dex could induce DUSP1 expression though a
corresponding decrease in proliferation was not detected.  The MTT assay and trypan
blue assay imply that dex can enhance cell viability and mitochondrial reduction
capacity of primary keratinocytes. Further analysis by FACS did not highlight a
difference in proliferation, early apoptosis, dead cells or cell debris, potentially due to
limitations of FACS analysis.  Alternatively, the analysis could be correct and dex does
not influence cell viability, although this conclusion does not correspond with visual
observations, trypan blue assay or previous publications highlighting the ability of dex
and the GR to protect keratinocytes from apoptosis (Bayo et al., 2008; Stojadinovic et
al., 2007).
The NADP+/NADPH cycling assay showed a trend for increased total NADPH upon
dex treatment that may account for the changes in MTT signal observed.  Moreover,
changes in cellular redox potential in response to dex could account for the augmented
level of pregnenolone synthesis described in chapter 4.  However, this data does not
determine whether dex can promote other factors that are required for pregnenolone
synthesis such as CYP11A1 expression so further experiments are needed to examine
this possibility.
Finally the chapter also highlights that culture conditions were suboptimal for steroid
analysis since the absence of serum greatly affected the MTT response.  Therefore the
majority of steroid synthesis measured in previous chapters probably represents StAR
independent basal level steroidogenesis that is restricted by the redox potential of the
cultured cells.
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Chapter 6. Discussion and future research
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6.1 Discussion
The research presented in this thesis demonstrates that primary human keratinocytes are
capable of de novo synthesis of cortisol and intermediate steroids.  Androgen and
oestrogen metabolism have previously been identified in primary human keratinocytes
and progesterone metabolism to corticosterone was described in immortalised HaCaT
keratinocytes (Milewich et al., 1988; Slominski et al., 2002).  However the synthesis of
cortisol by primary human keratinocytes has not been previously published.
Local steroid synthesis has been identified in many non-classical endocrine cells
including pancreatic cells, retinal pigment epithelium, chondrocytes, astrocytes, the hair
follicle and sebocytes (Chen et al., 2006; Ito et al., 2005; Karri et al., 2007; Morales et
al., 2008; Takeuchi et al., 2007; Zmijewski et al., 2007).  Therefore the phenomenon of
steroid (and cortisol synthesis) is not restricted to endocrine glands. It is likely that
locally produced cortisol acts in an autocrine or paracrine fashion since levels
corticosterone are negligible in the serum of adrenalectomised rodents (del Mar Grasa et
al., 2007).  However, the function for local cortisol production remains to be defined,
particularly whether it serves a purpose that is independent of the adrenal supply.
Major regulators of steroidogenesis that are regarded as indicators of steroidogenic
potential were also identified in the epidermis.  StAR that regulates acute steroid
production was localised specifically to the basal keratinocyte layer of the epidermis.
This complements previous research that has also identified StAR in the basal layer of
the epidermis (Tiala et al., 2007).  In addition, StAR mRNA was detected in cultured
primary keratinocytes, although StAR protein was not observed by western blot
analysis.  Using immunofluoresence cytochemistry the expression of StAR was shown
to decrease with time in culture.  Previous research also attempted to identify StAR in
cultured primary human keratinocytes but serendipitously identified MLN64 rather than
StAR when using an antibody to StAR (Slominski et al., 2004).
The loss of StAR expression in tissue culture suggests that acute steroidogenesis is
disrupted in cultured primary keratinocytes.  Moreover, 25OH cholesterol that can
bypass StAR to circumvent the rate determining step of steroidogenesis, failed to
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promote pregnenolone production.  However, keratinocytes still retained some
steroidogenic ability that was likely to be StAR-independent.
The necessity for StAR-independent steroidogenesis is exemplified by comparing
patients suffering from CAH and LCAH.  LCAH occurs due to loss of StAR function
and therefore loss of acute steroidogenesis.  Patients with LCAH have low levels of
circulating cortisol but are able to survive for several months without steroid treatment
(Miller, 2007).  It is the secondary response to the build-up of lipids in the adrenals that
causes complete ablation of steroidogenesis that would be fatal without GC treatment
(Caron et al., 1997; Miller, 2007).  Patients with severe CAH that commonly manifests
due to loss of CYP21 activity have no ability to synthesise cortisol and do not survive
without immediate GC treatment (Miller, 2007).  A similar difference in viability was
observed in mice where StAR-/- mice survived for up to 16 days without treatment
whereas GR-/- mice died within hours of birth (Caron et al., 1997; Cole et al., 1995).
This demonstrates that there is a clear difference in function between acute and
background GC turnover.  The steroidogenic potential measured in primary
keratinocytes is likely to represent low-level StAR-independent steroidogenesis.
The cortisol analogue dex was the only single compound tested that could promote
pregnenolone synthesis in primary human keratinocytes significantly above the basal
T+K level.  In the systemic system, cortisol ultimately suppresses steroidogenesis
through negative feedback of the HPA axis.  Therefore the ability of dex to promote
pregnenolone synthesis was unexpected.  However, there is evidence that cortisol can
promote rather than suppress steroid synthesis in other cell types.  Dex promoted
progesterone synthesis by 8- or 4- fold in HO-23 granulosa cells incubated with
forskolin at 37 or 32°C respectively (Sasson et al., 2001).  This dex-mediated promotion
of progesterone synthesis was independent of StAR and FDXR expression levels
(Sasson et al., 2001).  Furthermore, lack of cortisol was associated with decreased
testosterone synthesis in Leydig cells (Parthasarathy and Balasubramanian, 2008).  Thus
dex and cortisol have been shown to promote steroidogenesis in other systems as well
as primary human keratinocytes.
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The absence of StAR, lack of steroidogenic response to 25OH cholesterol and the
ability of dex to promote pregnenolone suggests that there could be an alternative rate
determining step to steroid production in cultured primary keratinocytes.  Changes in
cellular redox potential may represent an alternative mechanism, since this dictates the
level of cofactor available for steroidogenic enzymes (Agarwal and Auchus, 2005;
Sherbet et al., 2007).  Subtle changes in cellular redox that can be tolerated by cells can
have a large impact on the cells steroidogenic capabilities, hence redox potential has
been described as the driver of steroidogenesis (Agarwal and Auchus, 2005; Sherbet et
al., 2007).  The MTT assays detected a significant increase in mitochondrial reductase
capacity of primary keratinocytes treated with dex. Moreover, there was a trend for
increased total cellular NADPH relative to NADP+.  Cortisol has also been shown to
induce NADPH production in microsomes, suggesting that cortisol can influence ER
redox potential (Piccirella et al., 2006).  In addition cortisol can promote G6PDH and
H6PD activity to increase the availability of cytosolic and ER-localised NADPH.
Finally dex was shown to act in a biphasic manner where low concentrations of dex
protected neuronal cells from apoptosis by regulating redox potential, whereas high
concentrations of dex had the opposite effect (Du et al., 2009).  Therefore, although
further investigations are required, there is evidence to suggest that dex could promote
steroidogenesis in primary human keratinocytes by influencing cofactor availability.
Collectively the data suggests that the act of culturing primary keratinocytes creates a
suboptimal environment for maintaining the steroidogenic potential of the cell.  This is
for several reasons.  Firstly, normal primary keratinocytes express markers of
hyperproliferation (K6 and K16) that are absent in normal epidermis but present in skin
diseases including psoriasis and atopic dermatitis (Leigh et al., 1993).  StAR expression
was absent in these hyperproliferative conditions but StAR was detected in normal
epidermis.  This suggests that isolated normal keratinocytes acquire a phenotype that in
some aspects is similar to hyperproliferative keratinocytes.  Secondly, in order to
measure steroidogenesis cells must be in a steroid-free environment.  Primary
keratinocytes are routinely cultured with cortisol and serum (or pituitary extract for
serum-free culture media).  Removing these components affects cell proliferation,
viability and redox potential that could contribute to limiting steroidogenic capabilities.
Thirdly, the ratio between cells that would reside in the basal, spinous, granular and
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corneum layers is skewed in cultures relative to physiological ratios, where basal and
spinous keratinocytes are encouraged to expand but few corneocytes are detected in
culture.  Organotypic keratinocyte cultures have also been reported to exhibit
desquamation that is more representative of psoriatic rather than normal skin (Vicanova
et al., 1996).  Fourthly, the oxygen gradient that has been shown to regulate
keratinocyte proliferation and differentiation is disrupted in cell culture (Horikoshi et
al., 1986; Ngo et al., 2007).  The ambient oxygen environment in which cells are
cultured does not represent the physiological oxygen gradient across the epidermis,
which could stress the keratinocytes.  However culturing keratinocytes at low (2%)
oxygen was still unable to maintain/upregulate StAR protein expression by western blot
analysis.  Finally, the calcium gradient that regulates keratinocyte differentiation is
disrupted in cell culture, since cells are incubated in a homogeneous calcium
environment.  Homogenously low calcium levels throughout the epidermis are detected
in hyperproliferative conditions such as atopic dermatitis (Proksch et al., 2008).
Calcium signalling is a critical in coordinating cell viability, apoptosis and can affect
steroidogenic potential (Yamazaki et al., 1995).  All these components will limit the
ability of normal primary human keratinocytes to synthesise steroids.
In light of the above observations, compounds that prevent apoptosis and regulate
cellular redox potential might create a better environment for measuring steroid
production in keratinocytes.  Therefore an alternative target for manipulation is the
TSPO protein.  TSPO was identified throughout the epidermis, is present in
keratinocyte culture and has been directly associated with regulating apoptosis and
coordinating cholesterol transport for steroid synthesis (Veenman et al., 2007).
Compounds that act on TSPO such as PK1115 might also enhance steroid production in
primary human keratinocytes.
Regulators of steroidogenesis were shown to be disrupted in hyperproliferative skin
disorders.  This suggest that local steroid synthesis could be disrupted in skin conditions
such as psoriasis and atopic dermatitis.  Down regulation of StAR in psoriatic skin was
previously linked to CCHCR1 located on the major psoriasis susceptibility locus
PSORS1 (Tiala et al., 2007).  DAX1 was localised to the nucleus rather than cytoplasm
of atopic dermatitis and psoriatic (non-lesional only) skin.  Since DAX1 is a nuclear
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receptor that inhibits the transcription of StAR, this change in location could account for
decreased StAR expression.  In addition, NADP+/NADPH ratio has been found to be
aberrant in psoriatic skin suggesting that cofactor availability for steroid synthesis could
be limited in this condition (Hammar, 1975).  Therefore the results from this thesis
suggest that there could be a novel endocrine component influencing the pathogenesis
of atopic dermatitis and psoriasis that requires further investigation.
Cortisol analogues such as dex are one of the most widely prescribed treatments for
hyperproliferative skin disorders but have the major side effect of inducing skin atrophy
with chronic use.  Dex was shown to induce DUSP1 expression, a protein that can
suppress MAPK activity to inhibit cell proliferation.  The DUSP1 pathway has been
implicated in GC-mediated bone weakening by inhibiting ERK1/2 MAPK activity and
cell proliferation of immortalised osteoblasts (Horsch et al., 2007).  The activation of
DUSP1 by dex in keratinocytes suggests that a similar pathway could be the cause of
skin atrophy by GC treatment.  However, inhibition of MAPK activity or cell division
was not detected under the culture conditions.  This is in contrast with an in vivo
embryonic mouse model where GR-/- knockout led to increased keratinocyte
proliferation by up regulating ERK1/2 MAPK activity (Bayo et al., 2008).
Although a decrease in keratinocyte apoptosis was not detected when keratinocytes
were treated with dex, an increase in cell viability was observed.  Recently dex has been
shown to protect primary human keratinocytes from apoptosis when exposed to U.V.
light (Stojadinovic et al., 2007).  Moreover, the epidermis from GR-/- mouse embryos
were shown to have elevated epidermal apoptosis (Bayo et al., 2008).  This
phenomenon of protection from cell death by GC has been observed in many other cell
types including mammary gland epithelial cells, endometrium, hepatocytes, ovarian
follicular cells, fibroblasts and neuronal cells (Du et al., 2009; Viegas et al., 2008).  It
appears to be concentration dependent (where high levels of dex can induce cell death),
tissue specific and has been described as a novel anti-inflammatory component of GC
(Du et al., 2009; Viegas et al., 2008).  In addition increased apoptosis is a hallmark of
hyperproliferative skin disorders that are treated with GC (Iizuka et al., 2004;
Trautmann et al., 2001).  Therefore the anti-apoptotic nature of GC action suggests that
localised cortisol production could function to protect cells from apoptosis.
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Ultimately the research in this thesis demonstrates that primary human keratinocytes are
capable of de novo cortisol synthesis, that dex (an analogue of cortisol) can promote
further pregnenolone production and that this response is potentially due to the
influence of dex on redox potential.  It remains to be shown whether dex alters
keratinocyte proliferation and differentiation, or protects cells from apoptosis, however
these actions of dex have been demonstrated in other studies (Bayo et al., 2008;
Stojadinovic et al., 2007).  In addition, steroidogenic regulators were identified in the
epidermis but their expression was dysregulated in hyperproliferative skin diseases.
This suggests that acute steroid production could be ablated in these conditions.  Many
hallmarks of hyperproliferative keratinocytes are detected in normal keratinocytes when
they are isolated and cultured in vitro, including the down regulation of StAR
expression.  Therefore steroidogenesis measured in this thesis is likely to be StAR-
independent.
The function of local de novo cortisol synthesis remains to be defined, however from
these data and the published literature, I hypothesise that localised de novo cortisol
synthesis acts by a feedback mechanism to regulate cellular redox and prevent
keratinocyte death.  Local cortisol synthesis could increase NADPH and NAD+
availability that in turn promotes steroid synthesis.  The local production of cortisol
could also act on Bcl-2 proteins to prevent MPTP opening and maintain the cholesterol
transport function of TSPO for steroidogenesis rather than the apoptotic role of the
protein.
The system suggests that an apoptotic or necrotic cell would be incapable of
synthesising cortisol.  Whilst apoptosis is considered a form of cell death that does not
release inflammatory signals, an increasing number of reports have associated apoptosis
with inflammation (Schwarz, 2000).  This model would imply that an apoptotic cell
loses its anti-inflammatory signal rather than releases an inflammatory signal.  The local
production of cortisol of a healthy cell would inhibit infiltration of immune cells to
protect the tissue from inflammation. Whilst each of the components of the system have
been described individually in many cell types, coordination of the system has not been
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reported.  In addition the nature of this system to act as a sensor and signal of tissue
health would require steroid production to act locally and not systemically.
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B.
Figure 6.1 Hypothesis for the function of de novo cortisol synthesis to prevent
keratinocyte inflammation and premature cell death.
(A) Normal keratinocytes synthesise cortisol that acts as a local signal to prevent
inflammation.  Production of cortisol is regulated by, and able to regulate cellular redox
potential that, via TSPO maintains MPTP in a conformation that would facilitate further
steroid synthesis and prevent the induction of cell death.  (B) Loss of cortisol through
uncoupled redox potential causes the release of Bcl-2 that leads to MPTP and TSPO to
induce cell death and prevents TSPO-mediated steroid synthesis.  Although not depicted
here, StAR could promote acute steroid synthesis in cells that require a boosted system
(e.g. stem cells and proliferating keratinocytes) to protect the cells from oxidative stress
and prevent premature apoptosis.
Cortisol
Redox
Steroid synthesisTSPO
Inflammation
Bcl-2
MPTPCell death
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6.2 Future Research
This thesis has identified the de novo cortisol synthesis pathway in normal primary
human keratinocytes.  However, there are two fundamental elements that need to be
addressed in order to demonstrate the physiological relevance of this research.  Firstly,
local production of cortisol needs to be shown to have functional relevance in addition
to the systemic cortisol supply.  Secondly, a different model that can overcome the
limitations of steroidogenesis in cultured keratinocytes needs to be identified.
A collaboration with Professor Rod Flower (Barts and The London, London, U.K.) has
been organised to provide an animal model to separate local from systemic GC supply
as follows: Adrenalectomised rats (to remove systemic corticosterone) or sham operated
as controls will have local steroid production or corticosterone response blocked by
daily topical application of (a) T and K or (b) GR inhibitor RU486 to one ear of the
animal for 72h.  The other ear will be treated with a vehicle control.  This time point
was chosen since changes in keratinocyte biology in response to dex were observed
after 72h (Stojadinovic et al., 2007).  Rats will be housed in separate cages to prevent
grooming that could remove or redistribute the treatment to other parts of the body.
Skin sections of rat ears will be compared by measures of (a) hematoxylin and eosin for
histology, (b) Ki67 for proliferation, (c) filaggrin, involucrin and loricrin for
differentiation, (d) TUNEL assay for apoptosis, (e) JC-1 for mitochondrial membrane
potential, (f) TSPO expression and localisation, (g) oil red-O analysis for identifying
lipid accumulation, (h) histochemistry of GR location for assessing RU486 inhibition,
(i) CRH, CRH receptor and ACTH to determine if there is an upregulation of local
expression as would be expected with a block in GC feedback.  In addition the rat
serum will be analysed for corticosterone to validation of complete adrenalectomy.
These analyses should help identify the function for local GC synthesis, whether it
regulates cell viability, proliferation, differentiation apoptosis and cellular redox
potential.
In addition, MALDI imaging is a new technique that can measure small molecules
including steroids in situ.  Therefore a complete steroid profile together with
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localisation can be generated from whole tissue using this technique. This method of
analysis will also overcome limitations that the cell culturing process appears to have on
steroidogenesis.  MALDI imaging will be employed to measure the in situ localisation
of steroids in the rat skin (from sham operated and adrenalectomised animals) to
confirm local production relative to the systemic supply and whether trilostane and
ketoconazole have effectively blocked the pathway.  The technique will also be used on
organotypic models of keratinocytes (also treated with or without RU486 or T and K) to
identify whether in vitro levels of steroidogenesis are equivalent to in situ levels.
Finally freshly isolated psoriatic and atopic dermatitis will also be analysed using this
method to identify whether there is a decrease of local cortisol levels relative to normal
skin.
These experiments could therefore address the hypothesis that local de novo cortisol
synthesis is required to maintain the epidermal barrier, where ablation of the system
leads to premature apoptosis, poor differentiation, immune cell infiltration and
hyperproliferation.  Many tissues that are not regarded as steroidogenic glands have
been found to have steroidogenic potential, this research may eventually be translated to
other tissues and conditions where cortisol provides a potent therapy.
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